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 Oral administration is one of the most common and preferred route of 
drug delivery due to easy administration, manufacturing flexibility and cost-
effectiveness. However, the bioavailability and clinical efficacy of oral dosage 
forms can be hampered by the poor aqueous solubility and dissolution of their 
drug content, especially for those drugs listed under the Biopharmaceutical 
Classification System (BCS) Class II. Enhancing the solubility of poorly 
water-soluble drugs is an important challenge encountered by pharmaceutical 
companies. In formulation, the amorphization of crystalline compounds via 
formulation of solid dispersions using mesoporous carriers and 
transglycosylated food additives have been applied to enhance the dissolution 
rate and aqueous solubility of poorly water-soluble drugs. 
 This thesis focuses on formulating amorphous solid dispersions to 
enhance the biopharmaceutical properties of two antimalarial drugs widely 
used in artemisinin-based combination therapies (ACTs): artemisinin (ART) 
and mefloquine (MFQ). Since ART is a vital component in ACTs, priority has 
been given to the formulation of ART solid dispersions. All the carriers were 
preliminarily tested with ART to identify suitable excipients and to optimize 
storage conditions. The carrier that exhibited a superior performance in 
improving the biopharmaceutical properties with adequate storage stability 
was then used to formulate the solid dispersion of MFQ and followed by 
combination of ART/MFQ. 
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 Solid dispersions of ART were prepared by using porous activated 
carbon (AC), mesoporous silica (SBA-15), α-glucosyl hesperidin (Hsp-G) and 
α-glucosyl stevioside (Stevia-G) via co-spray drying. The characterization of 
the powder samples entailed analysis of surface area and pore volume analyzer 
(BET), thermogravimetric analysis (TGA), differential scanning calorimetry 
(DSC), powder X-ray diffractometry (PXRD), scanning electron microscopy 
(SEM) and transmission electron microscopy (TEM). The drug release profiles 
were investigated by using flow-through cell (USP IV) and in vitro dissolution 
tester (USP II). The physicochemical stability of the samples was investigated 
for 6-months under various storage conditions: desiccators (25 °C/18% RH), 
Activ-vial
®
 (25 °C), open pan (25 °C/75% RH), Activ-vial
® 
(40 °C) and open 
pan (40 °C/75% RH). In addition, the biocompatibility of SBA-15 was 
investigated by in vitro cytotoxicity study using Caco-2 cells after 24-hours 
incubation. 
 The formulated amorphous samples exhibited an enhanced dissolution 
rate and supersaturation as compared with untreated drugs. Interestingly, ART 
formulated with the functionalized food additives showed an initial burst with 
approximately 100% of drug release within 5 min. Although ART formulated 
with mesoporous materials showed slower dissolution as compared with ART 
formulated with functionalized food additives, the dissolution rate is 
nonetheless superior to that of untreated drugs. On the other hand, AC/ART 
was unable to provide acceptable chemical stability during storage periods. 
Meanwhile, ART formulated with SBA-15 and food additives exhibited better 
storage stability for 6-months, except under extreme conditions of 40 ºC or 
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75% RH. Moreover, the results of cytotoxicity with more than 90% of cell 
survival rate indicated good biocompatibility of SBA-15 and ART/SBA-15 
formulations. Additionally, SBA-15 exhibited better drug loading capacity as 
compared with food additives. The drug loading of SBA-15 reached as high as 
50 wt% with retention of the amorphous drug form whereas only 9.1 wt% 
drug loading for Hsp-G and Stevia-G. Thereafter, SBA-15 with superior 
performance compared with other carriers as regards drug loading, drug 
release and stability was chosen as the carrier to formulate solid dispersions of 
ART and MFQ. Moderate storage conditions such as desiccators (25 °C/18% 
RH) and Activ-vial
®
 (25 °C) were used for stability tests, in which formulation 
with SBA-15 was expected to have good physicochemical stability. 
 In conclusion, this work has demonstrated the potential applications of 
mesoporous materials and functionalized food additives in amorphization and 
stabilization of poorly water-soluble antimalarial drugs (ART and MFQ) 
through spray drying. This study could provide a practical reference in 
evaluating the in vitro drug behaviors and in elucidating the physicochemical 
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Chapter 1 Introduction 
1.1 Research Background 
 Oral administration is one of the most common and preferred routes of 
drug delivery due to easy administration, manufacturing flexibility and cost-
effectiveness (Bobe et al., 2011, Savjani et al., 2012, Saharan et al., 2009). 
However, the bioavailability and clinical efficacy of oral dosage forms are 
mainly hampered by their poor aqueous solubility and dissolution, especially 
for those active pharmaceutical ingredients (APIs) listed under the 
Biopharmaceutical Classification System (BCS) class II (Skolnik et al., 2010, 
Heng et al., 2010, Shono et al., 2010). The solubility of BCS class II drugs in 
gastric and intestinal fluids plays a vital role in determining their 
bioavailability and therapeutic effects, since these drugs have a good 
absorption and permeation across the intestinal lumen (Ahuja et al., 2007, 
Uchiyama et al., 2010a). The administrated APIs need to be dissolved in the 
gastrointestinal tract in order to be absorbed across the intestinal mucosa and 
reach the circulatory system. Limited solubility of APIs may result in 
insufficient and variable absorption, which will lead to unacceptable 
bioavailability and inadequate clinical efficacy (Limnell et al., 2011a). 
  Contemporary approaches to drug discovery and development have 
caused an increase in the number of poorly water-soluble drug candidates in 
the past few decades (Lipinski et al., 1997, Van Speybroeck et al., 2009). In 
today’s market, approximately 40% of the drugs listed under the U.S. 
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Pharmacopoeia and 50% of the new chemical entities (NCEs) suffer from poor 
bioavailability due to low aqueous solubility, since the solubility is a deciding 
factor for in vivo absorption (Ahuja et al., 2007, Shen et al., 2010). The 
extremely low water-solubility of drugs often necessitate the application of 
high doses of APIs in order to achieve a desired therapeutic plasma 
concentration (Tozuka et al., 2011), which may concomitantly lead to side 
effects such as gastric discomfort, nausea, vomiting and dizziness (Shen et al., 
2010). Endeavors to enhance the solubility of these therapeutic agents are 
associated with rapid drug absorption, which eventually improves the 
bioavailability and reduces clinically relevant doses (Sugano et al., 2007, 
Sigfridsson et al., 2009, Van Eerdenbrugh et al., 2010). 
 Numerous pharmaceutical formulation techniques have been employed 
to overcome the delivery barriers of BCS class II drugs, including 
modification of the crystal forms (Singh et al., 2010, Lim et al., 2012), 
complexation (ElShaboury, 1990, Cserháti et al., 1996, Jiang et al., 2012b, 
Pitha et al., 1986, Sigurðoardóttir and Loftsson, 1995), solubilization by 
surfactants (Bajaj et al., 2011, Singh et al., 2010), micro- and nano-sizing (da 
Costa et al., 2012, Gupta and Sehrawat, 2011, Rasenack et al., 2003), 
nanoemulsions (Kotta et al., 2012), co-crystallization (Shiraki et al., 2008), 
polymeric micellations (Kutty and Feng, 2013), liposomes (Chen et al., 2009) 
and co-solvency (Singh et al., 2010, Vemula et al., 2010). To date, however, 
the number of simple and effective oral formulations of BCS class II drugs 
developed using the above techniques that have achieved marketed 
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applications is limited. Therefore, it is essential to explore new types of 
formulation approaches with market values.  
 Among these techniques, more attention is given to amorphization to 
circumvent the problem of poor aqueous solubility and slow dissolution rate of 
water-insoluble drugs (Paudel et al., 2013). The amorphous forms possesses 
improved wettability (Liu et al., 2010b) and reduced particle size (Gupta and 
Sehrawat, 2011), which increases the total surface area per unit volume of 
drug particles exposed to the dissolution medium compared with the 
corresponding crystalline forms (Sharma and Jain, 2011). Furthermore, the 
active sites of drug molecules which would strongly interact with each other in 
a crystalline structure would be exposed to the environment in amorphous 
particles. Therefore, the binding energy between molecules in amorphous 
particles is relatively weak, necessitating minimum energy to break them. This 
confers upon the amorphous form a higher solubility and dissolution rate than 
the crystalline form (Yoshioka and Aso, 2007). 
 Unfortunately, amorphization may lead to poor physicochemical 
stability of the drug molecules over the designated shelf-life. This can affect 
the biopharmaceutical properties and the performance of the amorphous drugs, 
especially during the administration, processing and storage periods (Zhang et 
al., 2009a). In drug development, physical and chemical stability is a vital 
factor that determines the success of any drug candidate and is influenced by 
factors such as molecular mobility, particle size, temperature, humidity and 
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pH. Therefore, formulating dosage form with an acceptable shelf-life is a 
major challenge faced during amorphization process. 
 The confinement of drugs in mesoporous carriers via spray drying is 
considered as one of the most effective techniques to enhance the 
supersaturation and physical stability of poorly water-soluble drugs. Pore size, 
pore topology and surface interactions are the most important parameters that 
can change the thermodynamics and crystallization kinetics of amorphous 
drugs to improve their physical stability (Rengarajan et al., 2008). For 
example, it is feasible to form amorphous drugs if the ratio of pore diameter to 
the molecular size of an API is not more than 20 (Sliwinska-Bartkowiak et al., 
2001) and the re-crystallization of amorphous particles can be completely 
suppressed if the pore diameter of a carrier is lower than a certain critical pore 
diameter (Prasad and Lele, 1994). In addition, immobilization of drug 
molecules on the surface of pore walls due to a strong interaction (hydrogen 
bonds) between drug molecules and pore walls can lower the crystallization 
kinetics of amorphous drugs (Arndt et al., 1997).  
 Since Vallet-Regi et al. (2000) used MCM-41 as a novel drug delivery 
system, there has been growing interest in employing mesoporous materials 
especially mesoporous silica in drug delivery systems. Statistics show that 
over 3400 research papers related to mesoporous and drug delivery have been 
published in the Web of Science up to 2014, thereby illustrating the 
importance of the mesoporous materials in medical applications. Kinnari et al. 
(2011) compared the performance of different mesoporous silicon (between 
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thermally oxidized and thermally carbonized) and non-ordered mesoporous 
silica (between Syloid AL-1 and Syloid AL-244) as drug carriers for a 
hydrophobic drug, itraconazole. The effect of surface chemistries, pore 
volumes, surface areas and particle sizes of the mesoporous carriers on the 
degree of drug loading, dissolution behavior and physicochemical stability of 
itraconazole was investigated. Furthermore, Limnell et al. (2011b) performed 
a similar study using ordered and non-ordered mesoporous silica to evaluate 
the loading efficiency and the rate of drug release of indomethacin by 
comparing three drug loading methods: immersion, rotavapor and fluid bed 
loading. The results showed that the drug release properties of the delivery 
system were affected by the pore size and particle size of mesoporous silica. 
Moreover, surface modification of mesoporous materials played a significant 
role in altering the mechanism of drug release. Zeng et al. (2005) reported 
organic modification of MCM-41 with aminopropyl groups via solvothermal 
process for controlling drug delivery of aspirin. The release properties of this 
delivery system were found to be a function of the quantity of aminopropyl 
groups on the pore walls and of the ordered structure of mesoporous materials. 
 Among the diverse mesoporous materials, SBA-15 synthesized by 
non-ionic polymer surfactants has attracted much attention as a drug delivery 
matrix for both rapid and controlled release (Rahmat et al., 2010, Limnell et 
al., 2011a). The growing interest in this material for drug delivery is mainly 
due to its important features such as uniform pore size distribution, tunable 
pore diameter, thick pore walls, large pore volume and specific surface area 
enriched with silanol groups (Van Speybroeck et al., 2009, Mellaerts et al., 
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2010). The ordered mesoporous structures of SBA-15 that can be adjusted in 
the range of 5−30 nm allow encapsulation and release of larger drug molecules 
in a more reproducible and predictable manner compared with microporous 
materials, which can only adsorb small molecules up to 2 nm (Rahmat et al., 
2010). Moreover, the large pore volumes (0.8–1.3 cm3/g) and specific surface 
areas (600–1000 m2/g) of SBA-15 are essential for drug delivery as these 
features enable stronger adsorption with greater drug loading (Van 
Speybroeck et al., 2009, Limnell et al., 2011a). It has been reported that the 
drug loading of SBA-15 can reach up to 50% (w/w) with the drug particles 
remaining in an amorphous form (Shen et al., 2010, Shen et al., 2011). The 
higher payload of drug is critical to minimize the wastage of matrix and to 
reduce the size of formulations. The silanol functional groups on the surface of 
pore walls of silica are useful in immobilizing the drug molecules through 
hydrogen bonds. Thus, SBA-15 microparticles can potentially provide better 
encapsulation and immobilization of drug molecules and play a profound role 
in providing physical stability to the amorphous drugs.  
 Limnell et al. (2011a) studied ordered mesoporous silica MCM-41 and 
SBA-15 microparticles as devices for the delivery of indomethacin. The 
physicochemical stability of indomethacin-loaded MCM-41 and SBA-15 
samples was investigated after three-months of storage at 30 °C and 56% RH. 
The drug release studies were performed using USP dissolution paddle method 
at pH 1.2 and 6.8, mimicking gastrointestinal fluids. Although the physical 
stability of the samples was found to be satisfactory and rapid drug release 
was observed after storage, some impairment was observed in their chemical 
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stability. Shen et al. (2010) investigated the mesoporous SBA-15 submicron 
particles as a drug delivery system to enhance the dissolution properties and 
physical stability of ibuprofen and evaluated the drug release profile of the 
formulated ibuprofen in powder and tablet forms. No significant difference 
between these two forms was observed and the release profiles exhibited a 
pronounced initial burst release of 100% and outstanding stability when 
subjected to stress test conditions of 40°C/75% RH in open pans for 12-
months. Meanwhile, Van Speybroeck et al. (2009) scrutinized the dissolution 
enhancement of 10 poorly water-soluble compounds using SBA-15. The 
physical stability of the samples was analyzed using differential scanning 
calorimetry (DSC) after being stored at 25°C/52% RH for 6-months. All the 
SBA-15 formulations present in amorphous form showed enhanced 
dissolution compared with their crystalline counterparts. Importantly, the 
enhanced pharmaceutical performance of all the formulations was retained 
during the 6-months storage period. These results suggest that SBA-15 can be 
applied as a promising carrier to enhance the biopharmaceutical properties of a 
variety of poorly soluble drugs.  
 Apart from mesoporous silica, activated carbon is another attractive 
and versatile porous material that can be used as a drug carrier. Activated 
carbon is an industrially available cost-effective porous carrier that can be 
synthesized on a large scale and has been used extensively in drug delivery 
systems, especially for oral administration. Porous carbon has attracted as 
much attention as mesoporous silica, due to its highly ordered structures, large 
pore volume, extended specific surface area, strong adsorption capacity and 
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tunable pore diameters, which are capable of extensive drug loading (Wang et 
al., 2011a, Zhao et al., 2012a, Zhao et al., 2012b). Typically, the conventional 
activated carbon has specific volume and surface area in the range of 0.1–
0.5 cm
3
/g and 10–2000 m2/g, respectively (Hu and Srinivasan, 2001). 
Additionally, activated carbon possesses special features like low density, high 
thermal conductivity, good electrical conductivity, mechanical stability and 
ease of handling (Zhu et al., 2011, Wang et al., 2011b). As compared with 
mesoporous silica, porous carbon is highly tolerant to an aqueous 
environment, more resistant to structural changes by hydrolytic effects and 
chemically stable under non-oxidizing conditions (Zhu et al., 2011). 
Moreover, carbon materials are generally considered as inert substances that 
are safe and nontoxic (Zhao et al., 2012a, Zhao et al., 2012b).  
 Niu et al. (2013) evaluated the applicability of mesoporous carbon as a 
novel drug carrier to enhance the dissolution and bioavailability of fenofibrate 
intended for oral administration. Mesoporous carbon was synthesized by the 
co-assembly of phenol resin, TEOS and Pluronic F127, followed by 
carbonization and silica removal. Fenofibrate was loaded onto mesoporous 
carbon using incipient wetness impregnation and solvent and melting methods. 
Besides enhancing the dissolution rate, mesoporous carbon was found to 
improve the oral bioavailability of the drug without any irritation to the 
intestinal mucosa compared with fenofibrate commercial capsules. Wang et al. 
(2011b) synthesized magnetic Fe-containing mesoporous carbon through 
incipient wetness impregnation method without using any solvent. 
Investigation of the release behavior from the material demonstrated that the 
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release rate of ibuprofen increased with the degree of loading. It is evident that 
there are advantages of activated carbon in various applications compared with 
other porous materials. However, to the best of our knowledge, very few 
studies have reported the improvement of dissolution rate and bioavailability 
of poorly water-soluble drugs using porous carbon as a vehicle.  
 Besides mesoporous materials, formulations of amorphous solid 
dispersions using transglycosylated food additives have recently attracted 
much attention, since these pharmaceutical excipients are relatively safe and 
cost-effective (Uchiyama et al., 2010b, Uchiyama et al., 2010a). Among them, 
α-glucosyl hesperidin (Hsp-G) and α-glucosyl stevioside (Stevia-G) are 
particularly noteworthy as potential drug carriers, considering their high 
solubility augmented by transglycosylation (Kometani et al., 1996, Kometani 
et al., 1999, Kometani et al., 2008). Hsp-G is the transglycosylation product of 
hesperidin (a flavonoid also referred to as vitamin P in citrus fruits), of which 
the solubility is improved by 300 fold (approximately 0.2 kg/L) compared 
with that of the original hesperidin. It is used as a drug carrier due to its unique 
properties such as its superior solubility and the absence of toxicity to Caco-2 
cells (Uchiyama et al., 2010a, Tozuka et al., 2011). Moreover, it has 
significant anti-inflammatory, hypotensive and analgesic effects (Uchiyama et 
al., 2010b). On the other hand, Stevia-G is the transglycosylation product of 
Stevia, (a herb belonging to the Compositea family) (Uchiyama et al., 2010b), 
of which the solubility is estimated to be approximately 3.2 kg/L. Stevia-G has 
been used as a sweetener and sugar substitute for more than 20 years 
[Uchiyama et al., 2010b]. It has also been reported to have the ability to 
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regulate blood glucose levels of rats by enhancing insulin secretion (Chen et 
al., 2005).  
 Numerous studies have been published on the applications of Hsp-G 
and Stevia-G as potential drug carriers with an impressive improvement in 
dissolution rates and supersaturation. For example, Uchiyama et al. (2010b) 
found that treatment of two poorly water-soluble drugs, flurbiprofen and 
probucol, with Hsp-G and Stevia-G contributed to elevated dissolution rates 
(up to 3 fold and 1000 fold respectively compared with the untreated drugs) 
and thereby enhanced bioavailability. Tozuka et al. (2011) investigated the 
application of Hsp-G in nanoparticle formation of glibenclamide by dry 
grinding in a vibrational ball mill. The effectiveness of the ground mixtures 
were analyzed by in vitro and in vivo studies. The formulated 
glibenclamide/Hsp-G nanoparticles exhibited marked improvement in the 
dissolution profile and a significantly higher rate of decline in blood glucose 
levels of rat compared with untreated glibenclamide. Uchiyama et al. (2011b) 
demonstrated the ability of Hsp-G to improve both the dissolution and 
absorption properties of pranlukast hemihydrate (PLH) using high-pressure 
homogenization (HPH) processing without using organic solvent. Compared 
with untreated PLH crystals, HPH-processed PLH/Hsp-G (1:10 w/w) 
exhibited enhancement in the following parameters: a 2.5-fold increment for 
apparent solubility and 3.9-fold for Cmax. 
 Artemisinin (ART), also known as qinghaosu, is a BCS class II drug 
with low solubility and high permeability which used in malarial treatment 
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(Shahzad et al., 2012). This antimalarial drug was selected as the model 
compound for the first part of the research, in which ART was formulated with 
mesoporous materials and with functionalized food additives. To the best of 
our knowledge, there have hitherto been no reports on the application of these 
two types of carriers for antimalarial drugs. Pharmacologically, ART 
possesses the most rapid action against Plasmodium falciparum and 
Plasmodium vivax (Shahzad et al., 2012, Sahoo et al., 2010). It has a 
worldwide demand and is recommended by the World Health Organization, 
due to its low toxicity and high efficiency in attacking malaria parasites, such 
as multidrug resistant and cerebral strains (Ngo Thu et al., 1996, Thu Hoa et 
al., 1997, Ferreira et al., 2013). However, ART suffers from a number of 
drawbacks such as poor solubility and a short half-life. The poor solubility of 
ART in water (48 µg/mL at 37°C) and blood (Shahzad et al., 2012, Ferreira et 
al., 2013, Sahoo et al., 2011b) translates into poor bioavailability despite the 
excellent permeability across intestinal membranes. The short half-life and 
high first pass metabolism of ART may also cause incomplete clearance of 
malaria parasites (Sahoo et al., 2011b). In order to address these problems, 
several techniques have been discovered to improve the performance and the 
efficiency of ART, especially for enhancing the solubility and bioavailability. 
Sahoo and coworkers reported the dissolution enhancement of ART by using 
modified multi-fluid nozzle pilot spray dryers (Sahoo et al., 2011a, Kakran et 
al., 2011), with maltodextrin (Sahoo et al., 2009), polyethylene glycol (PEG) 
and polyvinylpyrrolidone (PVP) as hydrophilic carriers (Sahoo et al., 2010, 
Sahoo et al., 2011b). Van Nijlen et al. (2003) used supercritical fluid 
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technology with PVPK25 as a excipient whereas Wong and Yuen (2001) used 
β-cyclodextrin and γ-cyclodextrin to formulate solid dispersion of ART. All 
these formulations of solid dispersions have shown remarkable results in 
solubility enhancement compared with untreated ART crystals. Even though a 
number of studies have reported the solubility enhancement of ART, based on 
our knowledge, no studies have hitherto been published regarding the 
physicochemical stability of the amorphous solid dispersions of ART.  
 MFQ (IUPAC nomenclature: R, S-erythro-et-2-piperidyl-2, 8-bis 
(trifluoromethyl)-4 quinolinemethanol hydrochloride) is a 4-
quinolinemethanol derivative. It is an orally administrated antimalarial drug, 
which is a highly effective against multidrug-resistant strains of Plasmodium 
species (Rao and Murthy, 2002). It was used as the model drug to co-
formulate solid dispersions with ART and a selected carrier for combination 
therapy in the second part of this study. MFQ is slightly soluble in water 
(1.8 mg/mL) at room temperature and highly lipophilic (log P = 3.9), leading 
to variation in oral absorption. MFQ is a weak base with pKa of 8.6 and 
classified as a BCS class II or IV drug because of its low solubility and the 
lack of permeability data (Strauch et al., 2011, Lindenberg et al., 2004). Yadav 
et al. (2010) investigated the effects of co-crystallization on the 
physicochemical properties of MFQ. Different types of co-crystals exhibited 
augmented dissolution rate and supersaturation with adequate physical 
stability for 6-months of storage at 30 °C/65% RH. du Plessis et al. (2014) 
reported an improved therapeutic index with decreased toxicity and unchanged 
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in vivo bioavailability by incorporating MFQ with a lipid-based drug delivery 
system using Pheroid vesicles. 
 Both the drugs are BCS class II antimalarial drugs widely used in 
artemisinin-based combination therapies (ACTs). ART, despite its short half-
life, possesses a rapid action, which is vital to the initial anti-parasite effect 
against Plasmodium whereas MFQ, despite its slow action, possesses a long 
half-life, which is vital to preventing recurrence and resistance against the 
antimalarial drugs (White, 2004). ART has been combined with naphthoquine 
as a product called ARCO
®
 whereas MFQ has been combined with artesunate 
as a product called Artequin™. However, no single commercial products 
contain the combination of ART and MFQ. 
 To the best of our knowledge, only a very limited number of reports on 
the in vitro dissolution and solubility enhancement of antimalarial drugs have 
been published. In addition, no study on these aspects of ACTs using 
mesoporous carriers has been reported. More details on ACTs will be provided 
in Section 2.2. 
 All the solid dispersions of ART and MFQ were formulated via spray 
drying due to the advantages of this technique compared with other drug 
loading techniques. Spray drying is a single-stage process that produces solid 
dispersions in a dry and powdered form. The use of spray drying therefore 
reduces the mass and energy consumption by minimizing secondary 
manufacturing steps such as micronization and milling (Boersen, 1990, Ameri 
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and Maa, 2006). More details about the applications and important features of 
spray dying will be provided in Section 2.7.2.3. 
1.2 Hypothesis and Research Objectives  
 It is hypothesized that both the mesoporous carriers and functionalized 
food additives are able to amorphize the crystalline ART and MFQ by 
encapsulating them during co-spray drying. The amorphization with a 
reduction in particles size is expected to enhance the drug release profile of the 
drugs. In addition, these carriers are also expected to confer acceptable 
physicochemical stability to the amorphous forms. 
 This thesis focuses on formulating amorphous solid dispersions to 
enhance the biopharmaceutical properties of two widely used antimalarial 
drugs for ACTs. The amorphization of these drugs was achieved by 
encapsulating the drug particles in porous and/or biocompatible carriers via 
co-spray drying. The excipients used include two mesoporous carriers 
(activated carbon and SBA-15) and two functionalized food additives (Hsp-G 
and Stevia-G). Since ART and ART derivatives are vital components in 
ACTs, priority has been given to the formulation of ART solid dispersions. 
The carriers were first tested with ART to identify suitable excipients and 
optimal storage conditions. This was followed by the formulation of solid 
dispersions of the ART/MFQ drug combination. The objectives of this 
research are as follows: 
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I. To formulate amorphous solid dispersions of ART and ART/MFQ 
combination drugs and to identify suitable carriers for dosage forms.  
II. To enhance the biopharmaceutical properties such as aqueous 
solubility, dissolution rate and physicochemical stability of the 
formulated solid dispersions. 
III. To develop a suitable method and identify optimal storage conditions 
to stabilize the amorphous solid dispersions of ART and MFQ.  
IV. To elucidate the physicochemical properties of the formulated solid 
dispersions. 
1.3 Organization of Thesis 
 This thesis comprises of nine chapters. Chapter 1 provides a brief 
introduction and research background of formulation of solid dispersions for 
oral drug delivery systems, especially on improving the dissolution rate of 
poorly water-soluble drug via nano-confinement by using mesoporous carriers 
and via encapsulation into functionalized food additives. Therein, the 
objective of our research work is defined.  
 Chapter 2 can be separated into 2 sections; the first section outlines a 
brief literature review about malaria including life cycle of malaria parasites, 
complications of malaria, current challenges in malaria treatments and ACTs. 
The second section outlines the current challenges in drug development and oral 
delivery systems. It also includes recent approaches to enhance the dissolution 
rate of poorly water-soluble drug such as micronization, inclusion 
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complexation, solubilization by surfactants and modification of the crystal 
forms; and formulation strategies including hot-melt extrusion, 
lypophillization and supercritical fluid and spray drying.  
 Chapter 3 describes the material and experimental procedures used in 
this study. The synthesis of mesoporous silica via hydrolysis is was 
summarized. The formulation methods including spray drying, physical 
mixture, cryo- and ball-milling employed to generate solid amorphous forms 
were outlined. It also includes different types of characterization procedures, 
in vitro drug release, physicochemical stability evaluation and cytotoxicity 
study. 
 Chapter 4 and Chapter 5 present experimental results and discussion of 
the ability of mesoporous materials as drug carriers to enhance the solubility 
and storage stability of ART. Chapter 6 describes the formulation of solid 
dispersions of ART using functionalized food additives as carriers whereas 
Chapter 7 introduces the biopharmaceutical enhancement work of ACTs by 
using SBA-15, ART and MFQ. 
 Conclusions are drawn in Chapter 8 to summarize all the important 
results presented in the preceding chapters and future research work of this 
PhD is recommended in Chapter 9. A list of publications stemming out from 




Chapter 2 Literature Review 
2.1 Malaria 
 Parasitic infections remain one of the major causes of mortality in 
many tropical and subtropical areas around the globe. Among the different 
species of parasites, the parasitic protozoan belonging to the genus 
Plasmodium causes the vector-borne infectious disease, malaria. Malaria is the 
most important parasitic disease and biggest infectious killer of human beings 
(Ridley, 2002). It is a major public health and economic burden in third-world 
countries and has therefore become a tropical disease of the first priority for 
the World Health Organization (WHO) (Ridley, 2002, Snow et al., 2005, Yang 
et al., 2011, Liu et al., 2010a). Malarial infections in human beings are caused 
by five species of the genus Plasmodium; most cases are caused by either 
P. falciparum or P. vivax and the rest of the infections caused by caused by 
P. ovale, P. malariae and P. knowlesi (Trampuz et al., 2003, Kantele and 
Jokiranta, 2011). P. falciparum is the most virulent and lethal form that is 
responsible for the most serious form of the disease and fatal cases, resulting 
in rapid deterioration of the patient’s condition with concomitant development 
of life-threatening complications (De Donno et al., 2012, Guerin et al., 2002). 
Malaria is transmitted in 97 countries inhabited by roughly 3.3 billion people, 
of whom 1.2 billion are from Africa and Southeast Asia. Approximately 500 
million clinical cases and 2–3 million of death cases are reported annually, 
accounting for about 4–5% of total fatalities in the world. More than 81% of 
malaria cases and 91% of malaria deaths occur in Africa, wherein most 
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victims are children under 5 years of age and pregnant women (Yaméogo et 
al., 2012, Wells et al., 2013). The severity of the situation is reflected in the 
estimation that one person (usually a child) dies every 12 s as a consequence 
of this infection (Ajibade and Kolawole, 2008, Marconi et al., 2004). In the 
following sections, symptoms of disease and the treatment methods are 
discussed. 
2.1.1 Life Cycle of Plasmodium Falciparum 
 Malaria is transmitted to humans by the bite of infected female 
Anopheles mosquitoes (the definitive host) while feeding on human blood 
(Cloete et al., 2012). The life cycle of P. falciparum is provided in Figure 2.1. 
 
Figure 2.1 Lifecycle of P. falciparum in the human host and in the Anopheles 




The asexual stage of the cycle begins when microscopic motile infective forms 
of sporozoites in the saliva of the mosquitoes are inoculated into the 
bloodstream of a vertebrate host such as a human. Within days, the sporozoites 
travel through the blood vessels, enter hepatocytes and begin to divide 
asexually into thousands of exoerythrocytic merozoites (tissue schizogony). 
For P. vivax and P. ovale infections, some schizonts may remain dormant as 
hypnozoites in the liver for-weeks to years (depending on the geographic 
origin) before causing clinical relapses that characterize these infections; for 
P. falciparum, no such hypnozoites are produced. Once the merozoites leave 
the liver, they invade erythrocytes and develop into early trophozoites, which 
are ring-shaped, vacuolated and uninucleated. Upon division, the trophozoites 
are called schizonts, consisting of many daughter merozoites (blood 
schizogony). Eventually, infected erythrocytes are lysed, releasing the 
merozoites into the bloodstream, which subsequently invade other 
erythrocytes; thus the infective cycle of schizogony begins anew. The duration 
of each cycle is about 48 hours for P. falciparum, P. vivax and P. ovale, 72 
hours for P. malariae and 24 hours for P. knowlesi (White et al., 2014). In 
non-immune humans, the infection is amplified by about 20-fold each cycle 
(Simpson et al., 2002). After several cycles, some of the merozoites develop 
into the non-multiplying and longer-life sexual form (immature gametocytes), 
which are the precursors of male and female gametes and cause no symptoms, 
but are infective for mosquitoes. These gametocytes are crucial for 
perpetuating the life cycle of the parasite. When a fertilized female mosquito 
bites an infected person, the gametocytes are taken up by it and thereafter 
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reproduce sexually, forming ookinete and then oocyst in the mosquito midgut. 
The oocyst bursts and liberates thousands of infective sporozoites, which 
migrate to the insect's salivary glands to await inoculation of the next 
vertebrate host to initiate another life cycle. The entire cycle can take roughly 
1-month (White et al., 2014, Greenwood et al., 2005). 
2.1.2 Complications of Malaria 
 The clinical symptoms of malaria are primarily due to the rupture of 
schizonts and the destruction of erythrocytes. Illness starts when the number of 
total asexual parasites in the circulation reaches approximately 100 millions. 
Malaria can have a gradual or fulminant course with nonspecific symptoms 
(Murphy and Oldfield, 1996). Usually the symptoms for malaria infections 
appear within 8 to 25 days after the mosquito bite (possibly longer in the case 
of a patient who has taken antimalarial prevention medication). The 
presentation of malaria often resembles those of common viral infections, 
potentially leading to delayed diagnosis. The majority of patients experience 
fever, chills, headaches and diaphoresis; other common symptoms include 
back and muscular pain, dizziness, malaise, myalgia, convulsion, abdominal 
pain, hemoglobin in the urine, nausea, vomiting, jaundice, mild diarrhea and 
dry cough. Clinical assessment also depends on signs such as tachycardia, 
jaundice, pallor, orthostatic hypotension, hepatomegaly and splenomegaly 
(Taylor et al., 2010, Malaria, 2014). 
 Serious complications of malaria may still develop notwithstanding 
clinical responses to initial treatment and eradication of parasitemia, due to 
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delayed cytokine release. Patients with severe malaria should be treated in an 
intensive care unit. Some of the example of the complications in patients with 
severe malaria are hypoglycemia, hypotension and shock, hematologic 
abnormalities (Trampuz et al., 2003) as well as neurologic (Warrell et al., 
1982, Brewster et al., 1990), pulmonary (Gachot et al., 1995) and renal 
(Prakash et al., 1996) complications 
 Though malaria is a major cause of death, for which the number of 
mortalities is as high as that for human immunodeficiency virus (HIV) 
infections, effort and financial resources allocated to the research on malaria is 
much lower compared with that on HIV infections. For example, in 2013, 
malaria-associated deaths totaled up to approximately 1 million whereas HIV-
associated deaths totaled up to 1.5 million. However, the money spent on 
malaria research was $US42 per malaria-associated death compared $US3270 
per HIV/AIDS-associated death. The reason for the scant attention or interest 
devoted to the research on malaria is that the infection is predominantly 
localized in poor countries (Nosten and Brasseur, 2002). In addition, the cost 
of the treatment is another major problem in treating malaria. The complete 
diagnosis and treatment of malaria costs about $US2 to 3 per patient, which 
will be financially untenable for African countries considering that the 
expenditure per person for health is only around $US5 to 7 per year (Nosten 
and Brasseur, 2002). This causes the Africans to depend on self-medication 
through the unregulated private and informal drug sectors. A large portion of 
antimalarial medicines sold in Africa is believed to be substandard medicines 
(i.e. those genuine ones with 80% or less of the listed active ingredient that fail 
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to meet quality specifications) and counterfeit medicines (i.e. those spurious 
ones that are “fraudulently mislabeled with respect to identity and/or source”) 
(Snow et al., 1992, Newton et al., 2011, Cockburn et al., 2005, Bate et al., 
2008) The low quality of drugs and the poor access to public health facilities 
translate into the failure of properly treating malaria and contribute to the 
spread of antimalarial drug resistance; these, in turn, increase morbidity and 
mortality (Newton et al., 2011).  
2.1.3 Emergence of Resistance  
 The emergence and spread of drug-resistant strains of P. falciparum is 
another obstacle in malaria treatment in the 21
st
 century. The first cases of 
drug-resistant malaria were documented during World War II, in which 
patients showed reduced efficacy to the prophylactic antimalarial drug, 
mepacrine (Atebrine). Since then, drug resistance has continued to 
characterize malaria treatment and has currently developed against all classes 
of antimalarial drugs (Sa et al., 2011). Chloroquine is one of the earliest and 
most effective drug discovered in the 1940s to control malaria. However, 
towards the end of the 1960s, treatment failures of chloroquine were reported 
almost simultaneously in South America and Southeast Asia (Western 
Cambodia and the Thailand–Myanmar) and then in Africa in the late 1970s, 
which have caused millions of deaths (Sa et al., 2011, Dondorp et al., 2009, 
Phyo et al., 2012). At present, this drug has become ineffective in most of 
P. falciparum malaria-endemic areas and has been almost removed from 
modern malaria treatment due to the widespread resistance. The resistance to a 
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drug develops through spontaneous genetic mutations, which are a function of 
the number of individual parasites in a given population. For instance, in any 
malaria patient, the probability of resistance-conferring mutations is higher 
when the parasite biomass is the largest during the acute phase of the infection 
(White, 1997). Drug resistance and the relative increase in the probability of 
carrying gametocytes lead to a slower clinical and parasitological recovery, 
anaemia and ultimately an increase in mortality, especially among children 
and pregnant women. Therefore re-treatment, sometimes warranting more 
expensive drugs is required (Ekvall et al., 1998, Trape et al., 1998). 
 Factors that contribute to the development of drug resistance are (1) 
total number of parasites exposed to the drug; (2) concentration of the drug to 
which the parasites are exposed; (3) pharmacokinetic and pharmacodynamic 
properties of the drug; (4) degree of resistance conferred by mutations; (5) 
degree of premunition in the host; (6) exposure of the parasites to other drugs 
for which no resistance has arisen; (7) monotherapy; (8) usage of counterfeit 
drugs; (9) extensive use and misuse of drugs; (10) intensity of transmission; 
and (11) population immunity or population movements (Wernsdorfer, 1994, 
Nosten and Brasseur, 2002). Meanwhile, the consequences of the emerging 
resistance are summarized in Figure 2.2. The length of half-life of antimalarial 
drugs also plays an important role in determining the development of 
resistance. The long half-life of antimalarial drugs, such as mefloquine and 
sulphadoxine-pyrimethamine (SP), are meritorious in affording effective 
single-dose treatment and in preventing infection for weeks. However, this 
feature is also detrimental in exerting drug pressure on the parasites for an 
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undesirably long time even after their concentration has fallen below the 
critical threshold (Watkins et al., 1997). Such overly long exposure to the 
drugs may induce the development of resistance among the parasites (Keating, 
2012). 
 
Figure 2.2 The ‘vicious cycle’ of antimalarial drug resistance (Wernsdorfer, 1994, 
Nosten and Brasseur, 2002). 
2.2 Artemisinin-based Combination Therapies (ACTs) 
 Combination therapies have paved the way in preventing and delaying 
the emergence and spread of drug resistance. The idea of drug combinations is 
not novel since the principle has been used for highly drug-resistant diseases 
such as HIV/AIDS, tuberculosis and cancers (Montaner et al., 1999). For 
malaria, some of the examples of the earliest combination therapies are 




















atovaquone-proguanil, quinine-tetracycline and mefloquine-
pyrimethamine/sulfadoxine (White, 1999b, White and Olliaro, 1996, White, 
1998). Unfortunately, resistance has emerged to all these combinations for the 
following reasons: a lack of activity on the sexual stage of the parasite cycle in 
the host; linked modes of action of compounds that are susceptible to the same 
parasite mutations; existing resistance to one of the compounds; mismatched 
pharmacokinetic properties of the compounds; and the slow action (low 
parasite reduction ratio) on the parasites. 
 Artemisinin-based combination therapies (ACTs) have subsequently 
been proposed and approved as a new approach due to their efficacy and 
ability to lower malaria incidence (some examples of ACTs are presented in 
Table 2.1). ACTs have shorter parasite and fever clearance times compared 
with chloroquine. The addition of artemisinin derivatives to combination 
therapies has shown a remarkable double effect of preventing the emergence 
and spread of drug resistance and of interrupting the transmission of 
P. falciparum (Nosten et al., 2000, White, 1999b, Price, 2000, White, 1999a). 
In the event that some parasites have survived the double actions of the 
therapies, the probability of transmission is still low. Therefore, the combined 
actions of drugs in ACTs result in a faster clinical and parasitological recovery 
(Nosten et al., 1994). ACTs were pioneered in Southeast Asia, the most 
studied and used of which is the combination of artesunate-mefloquine. 
Interestingly, this combination was shown to stop the progression of resistance 
to mefloquine (Brockman et al., 2000). By 2005, 43 countries have adopted 
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ACTs as their first or second line drugs, most of them being in sub-Saharan 
Africa (Table 2.2) (Mutabingwa, 2005, Attaran et al., 2004). 
Table 2.1 Examples of artemisinins (ART derivatives are underlined) and partner 
drugs in ACTs and their half-life (t1/2) (Eastman and Fidock, 2009) 
Antimalarial combination 
drug 
t1/2 of artemisinin 
derivatives  
t1/2 of partner drugs  
Artemether-lumifantrine 
(Coartem)  
~ 3 h 4-5 days 
Artesunate-mefloquine  < 1 h 14-21 days  
Artesunate-amodiaquine  < 1 h 9-18 days  
Dihydroartemisinin-
piperaquine  
45 min ~ 5-weeks 
Artesunate-pyronaridine  < 1 h 16 days  




Table 2.2 Countries that have adopted ACTs as the first or second line drugs 
(Mutabingwa, 2005) 
Continent  Country  First line Second line 
Africa Burundi, Cameroon, Eq. 
Guinea, Gabon, Ghana, 
Madagascar, ST&P, 
Sierra Leone, Liberia, 




Angola, Benin, Comoros, 
Ethiopia, Kenya, Mali, 
Namibia, Niger, Nigeria, 
































































 In order to have a better performance in combating malaria, the 
component drugs in ACT must have certain characteristics (Nosten and 
Brasseur, 2002). However, none of the previous and current combination 
therapies meets all these criteria, except artemether-lumefantrine combination, 
which is the closest. The characteristics of an "ideal" antimalarial combination 
are:- 
i. Modes of action: The modes of action of component drugs on the 
parasite must be unrelated. 
ii. Onset of action and parasite reduction ratio (PRR): At least one rapid-
acting component drug must be used in the combination and exhibit 
the highest possible parasite reduction ratio of no less than 10
4
. 
iii. Pharmacological profile: The co-administration of the drugs must not 
result in detrimental drug-drug interactions. 
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iv. Duration of treatment: The total duration of the dosing regimen must 
be sufficiently short for patients’ adherence, i.e. it must at most be only 
3-day long. 
v. Elimination half-life and duration of action: One of the components 
must be present in the circulation after the 2 cycles of exposure to the 
fast-acting drug, i.e. the elimination half-life of the partner drug must 
be longer than that of the fast-acting one. 
vi. Toxicological profile: The tolerability must be good with reasonably 
acceptable toxicity. 
vii. Spectrum of action: The combination must have pharmacological 
activity against all stages of the parasite, including gametocytes. 
viii. Dosage formulation: The relative proportions of the drugs in 
combination must be fixed, i.e. formulated in the same tablet. 
ix. Economic consideration: The therapeutic regime must be financially 
viable for all patients. 
 Artemisinin and its derivatives have a rapid parasite clearance rate 
(Adjuik et al., 2004). Despite its short half-life, it is vital to the initial anti-
parasite effect against Plasmodium. The gametocytocidal effect of 
artemisinins on the parasite in the early developmental stages reduces the 
viability of gametocytes, thereby controlling the overall malaria transmission 
and lowering the infectivity of mosquitoes. Treating early cases of 
uncomplicated malaria with rapidly acting artemisinins is able to thwart the 
progression to severe cases and reduce mortality rates (Barnes and White, 
2005, Adjuik et al., 2004). Complementing this, the partner drug(s) should 
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have a slow action with a long half-life, which is vital to the prevention of 
recurrence and resistance to the antimalarial drugs.  
 Though artemisinin is the parent compound and economical to produce 
from the plant Artemisia annua, more attention has been given to its 
derivatives produced from bio-synthesis such as artemether, artesunate and 
dihydroartemisinin. Artemisinin derivatives are preferred as a potent 
antimalarial in ACTs over artemisinin itself due to the poor aqueous solubility 
and the resultant poor oral bioavailability of artemisinin (Lapenna et al., 
2009). Artemisinin has not been widely deployed in ACTs, except for 
artemisinin-naphthoquine (ARCO
®
), which is the only available commercial 
oral delivery ACT product that contains artemisinin (Hombhanje et al., 2009, 
Hombhanje and Huang, 2010). Even though antimalarial drugs are 
administrated via oral and intravenous routes, the oral administrations are 
much preferred and most commonly used especially in poor countries due to 
easy administration and cost-effectiveness. Most of the ACT products 
available in the market are manufactured for oral administration. Some of the 
examples of malaria pharmaceutical products classified according to the 
Global Fund Quality Assurance Policy are listed in Table 2.3. Therefore, 
enhancing the solubility of artemisinin (especially oral dosage forms) by using 
cost-effective and simple steps is essential to reduce the overall manufacturing 
cost. In the next section of literature review, more details will be provided on 
these aspects: oral drug delivery, Biopharmaceutical Classification Systems, 
the mechanism and principle of dissolution, solubility enhancement, examples 
of drug loading methods and available porous carriers. 
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Table 2.3 List of ACT products classified according their dose and dosage forms and 
manufacturers (Anonymous, 2015) 
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 Fixed-dose combination 
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2.3 Oral Drug Delivery 
 Medical drugs can be administered by various routes into the human 
body depending on the desired effects, the therapeutical medications, the type 
and pathophysiology of the disease and the physicochemical properties. Drugs 
can be either delivered directly to the target organ or tissue affected by the 
disease or given systematically to target the infected organ on which it can 
exert its therapeutic effect. Knowledge on the possible methods of drug 
delivery is vital in achieving the best therapeutic benefits from any drug. Oral 
(Agrawal et al., 2014), intravenous (Lalatsa et al., 2015), pulmonary (Patton 
and Byron, 2007), transdermal (Lee et al., 2015), ocular (Ahuja et al., 2015) 
and nasal routes (Illum, 2002) are some routes of administration, each with its 
own advantages and disadvantages, as summarized in the Table 2.4 (excluding 




Table 2.4 Advantages and disadvantages of different routes of drug administration 
Route  Advantages Disadvantages 
Rectal -Affords good absorption – the haemorrhoidal veins 
drain directly into the inferior vena cava, avoiding 
hepatic first-pass metabolism 
-May not be suitable after rectal or anal surgery 




-Affords good absorption, especially for drugs with a 
low oral bioavailability 
-Exhibits rapid onset of action 
-Can have very long duration of action depending on 
formulations, e.g. depot antipsychotics and 
contraceptives 
-Can be formulated as controlled depot release 
-Can be used for most therapeutic molecules 
-May exhibit unpredictable absorption if peripheries 
are poorly perfused 
-Causes pain and bruises and may cause fear amongst 
patients  
-May lead to noncompliance amongst patients out of 
fear  
-May lead to higher risks of infection 
Intravenous -Exhibits dependable and reproducible effects 
-Can be used for drug administration in life 
threatening situations 
-Exhibits rapid onset of action – the entire 
administered dose reaches the systemic circulation 
immediately  
-Affords accurate dose-titration against clinical 
response 
-Affords up to 100% bioavailability 
-Can be used for most therapeutic molecules 
-May be more expensive and labor intensive than other 
routes 
-May lead to distress amongst patients 
-May lead to higher risks of infection 
-May be difficult for patient to self-administer 
-May afford only a short duration of action 
-May cause local reactions e.g. thrombophlebitis and 




Route  Advantages Disadvantages 
Topical/ 
Transdermal 
-Affords easy and non-invasive drug delivery  
-Affords patient satisfaction 
-Results in fewer side-effects due to direct delivery to 
the skin 
-Bypasses first-pass degradation 
-May not be suitable for drugs of high molecular 
weight or that are poorly lipid soluble due to poor 
transdermal absorption 
-May lead to slow absorption, as dependent on skin 
conditions and locations  
-May lead to potential use of the wrong dose (e.g. 
creams) by patients  
Inhalation -Affords rapid absorption due to the huge surface area 
of the respiratory endothelia  
-Allows targeted action lungs with low levels of 
systemic absorption by means of bronchodilators and 
inhaled steroids  
-May yield inconsistent delivery and bioavailability 
due to patient-to-patient variations in techniques of 
using inhalers and the size of drug particles generated  
35 
 
 Oral administration represents the most extensively used mode of drug 
delivery; for instance, more than billions of aspirin tablets are consumed 
worldwide annually (Kermode, 2004). The multifarious merits of this route 
form the rationale underlying the fact that the majority of small drug 
molecules are designed for oral administration. It is by far the most dominant 
and convenient route that offers portability, flexibility and control over dosing 
schedules, simplicity for self-administration and systemic delivery; all 
incorporated in one tablet or capsule along with the non-invasive nature of 
administration (Brayden and O'Mahony, 1998, Park et al., 2011, Goldberg and 
Gomez-Orellana, 2003). In addition, it offers convenience for chronic therapy 
and effectiveness in dealing with specific diseases (Bromberg, 2008, 
Yamanaka and Leong, 2008). From the perspective of the manufacturing 
industry, another merit of the orally administered drugs is their less stringent 
sterility constraints. From the perspective of clinical practice, compared with 
parenteral delivery, oral administration can suppress the risk of disease 
transmission and reduces the overall treatment cost (Gaucher et al., 2010, 
Ruenraroengsak et al., 2010). 
 Despite the numerous benefits, oral drug delivery has its own 
drawbacks. With regard to the gastrointestinal (GI) tract, orally administered 
drugs must survive in the harsh environment, transit through the chemical and 
enzymatic GI liquids, cross the mucous layer and the epithelia before being 
absorbed. This route is therefore limited by the complex interplay between the 
physicochemical properties of the drug and the physiological processes; the 
repercussion is that the bioavailability may be compromised. Bioavailability 
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refers to the extent and rate at which a drug reaches the systemic circulation 
after administration, depending on aqueous solubility, drug permeability, 
dissolution rate, first-pass metabolism, pre-systemic metabolism and 
susceptibility to efflux mechanisms (Savjani et al., 2012). For intravenously 
administered drugs, a bioavailability of 100% can be expected; for those drugs 
otherwise administered, especially orally delivered ones, a poor bioavailability 
is often observed. The undesirably low bioavailability of oral drugs are mainly 
influenced by the low mucosal penetration inherent to the physicochemical 
properties of the drug; restricted drug permeability at specific GI regions; poor 
dissolution rate in intestinal fluids corresponding to a low aqueous solubility; 
gastric emptying and intestinal motility; and drug degradation before 
absorption due to drug instability within the microenvironment of GI tract 
(Ponchel and Irache, 1998). The Biopharmaceutical Classification System 
(BCS) is a scientific framework to classify active pharmaceutical ingredients 
according to their solubility and permeability, which are essential in predicting 
bioavailability (Shugarts and Benet, 2009) (refer in Section 2.4).  
 In addition, the inability of oral drug administration route to deliver 
large therapeutic molecules is also a concern. Considering that the rate of 
absorption depends on the molecular size, macromolecules such as proteins, 
vaccines or nucleic acids encounter intestinal barrier limits more frequently 
than small molecules (Agrawal et al., 2014). Besides, oral drug delivery fails 
to meet advanced therapeutic needs such as targeting. Also, the immediate 
release of certain oral dosage forms has also been found to be associated with 
toxicity and side effects (Goldberg and Gomez-Orellana, 2003).  
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2.4 Biopharmaceutical Classification System (BCS) 
 The Biopharmaceutical Classification System (BCS) was introduced 
by Amidon et al. (1995) to correlate physicochemical properties of the drug to 
absorption and bio-performance after oral administration. It plays a vital role 
in the designing of formulations and in the understanding the physicochemical 
and biopharmaceutical properties of drugs. The BCS divides active substances 
into four classes, i.e. class I to class IV (Figure 2.3). Permeability is measured 
based on the rate of mass transfer of a drug substance across the human 
intestinal membrane; a drug is considered highly permeable when the extent of 
intestinal absorption is more than 90% of the administered dose. Solubility is 
measured based on the rate at which solid drug or drug in a formulation passes 
into solution; a drug is considered highly soluble when the highest strength is 
soluble in less than 250 mL of aqueous media at 37 ºC and pH range of 1.0–
7.5. The volume estimate of aqueous media is derived from typical 
bioequivalence study protocols that prescribe the administration of a drug 
product to fasting human volunteers with about 250 mL of water (Kawabata et 




Figure 2.3 The Biopharmaceutical classification system (BCS) and the techniques to 
overcome limitations of each class (Kawabata et al., 2011). 
 The BCS class II drugs are of specific interest, because the number of 
poorly water-soluble compounds are rapidly increasing in drug discovery and 
approximately 40% of the world’s top oral drugs are classified as BCS class II 
and class IV compounds (Lipinski et al., 1997). Artemisinin (Shahzad et al., 
2012), lumefantrine, mefloquine, pyrimethamine and doxycycline are example 
of APIs that classified under BCS class II and sometime may classified under 
both BCS class II and IV due to lack of permeability data (Lindenberg et al., 
2004). The permeability of BCS class II drugs across the intestinal membranes 
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of the drug in the GI fluids. As a result, a small increase in the dissolution rate 
can result in a drastic increase in the bioavailability (Lobenberg and Amidon, 
2000). As the drug is exposed in the intestine, the dissolution profile will 
influence the concentration profile along the intestines and absorption will 
occur for a much longer time, which can contribute to an improved 
bioavailability (Amidon et al., 1995, Kawabata et al., 2011). Therefore, 
enhancement in solubility and dissolution will translate into an enhancement 
in bioavailability; the challenge remains that how the dissolution rate of BCS 
class II drugs can be augmented. 
2.5 Solubility and Dissolution Rate  
 Solubility is the maximum concentration of a drug that can dissolve in 
a certain quantity of solvent or solution under specific conditions of 
temperature, pH and pressure (Lachman et al., 1986). A solution is said to be 
saturated if its concentration equals the equilibrium concentration, sub-
saturated if its concentration is lower than the equilibrium concentration and 
super-saturated if its concentration exceeds the equilibrium concentration. 
Different classifications of solubility are summarized in Table 2.5 (Savjani et 
al., 2012) and factors affecting the solubility of a drug are summarized in 
Table 2.6. In comparison with solubility, dissolution (Figure 2.4) refers to the 
transfer of molecules or ions from a solid state into a solution, which depends 
on temperature and the relative affinity between molecules of the solid 




Figure 2.4 Scheme of solubilization. 
 Both dissolution and solubility are important parameters that influence 
and determine the bioavailability of dosage forms, especially for orally 
administrated BCS class II drugs. The rate-limiting step to achieve in vivo 
absorption and bioavailability of BCS class II drugs is their solubility and 
dissolution rate since these drugs have rapid diffusion across the gut walls; 
therefore enhancing the solubility will improve the drug absorption and drug 
bioavailability. Solubility is important to accomplish the required 
concentration of a drug in the systemic circulation for acceptable 
pharmacological responses and therapeutic effectiveness (Alavijeh et al., 
2005, Kamble et al., 2014). The drugs need to be dissolved in the 
gastrointestinal tract and present in the form of an aqueous solution at the 
absorption site to be distributed and absorbed across the intestinal mucosa and 
reach the circulatory system (Limnell et al., 2011a). Therefore, poor solubility 
of orally administrated drug has a low saturation solubility which is typically 
correlated with a low dissolution rate causing inadequate and variable 
bioavailability. The application of drugs with insufficient solubility causes 
increase in dosage and frequency of administration to reach the desired 
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therapeutic plasma concentration. High dosage and repeated administration 
may then lead to occurrence of side effects (Daughton and Ruhoy, 2013, 
Savjani et al., 2012). Hence, drugs with poor solubility face many 
development challenges which lead not only to increased developmental cost 
and time but also results in higher risks of failure during discovery, 
formulation development and generic development, since the solubility affects 
both pharmacokinetics and pharmacodynamics properties.  
Table 2.5 Classification of drugs according to their solubility (Takagi et al., 2006) 
Descriptive term Parts of solvent required for 
one part of solute 
Solubility range 
(mg/mL) 
Very soluble  < 1 ≥ 1,000 
Freely soluble  From 1 to 10 100–1,000 
Soluble  From 10 to 30 33–100 
Sparingly soluble  From 30 to 100 10–33 
Slightly soluble  From 100 to 1,000 1–10 
Very slightly soluble  From 1,000 to 10,000 0.1–1 




Table 2.6 Factors affecting the solubility of a drug (Murdande et al., 2010b) 
Factors Remarks 
Nature of solute 
and solvent 
The solubility of substances can be influenced by their 
nature such as their ability to form hydrogen bond, the 
strength of the bonds, polarizability and ionization 
potential. 
Particle size Smaller particle size increases surface-area-to-volume 
ratio, which will result in greater contact and interaction 
with the solvent. Since interactions between the solute 
and the solvent takes place at only the surface of each 
particle, a larger surface area will mean that dissolution 
occurs more rapidly. For very small particle sizes, the 
solubility will be a function of particle dimension, 
resulting in higher equilibrium solubility. 
Molecular size The solubility of the substance is inversely proportional 
to the molecular size. Generally, solubility decreases 
with an increase in molecular weight and molecular size 
since larger molecules are more difficult to be solvated 
by solvent molecules. 
Temperature As temperature rises, more energy will be provided to 
the dissolution process and increase the motion of 
solvent and solute particles. This generally increases the 
solubility. 
Pressure Pressure has no effect on solids and liquid solutes, but 
influences the solubility of gas. An increase in pressure 
increases the solubility of gaseous solutes. 
Polarity Polar solutes will dissolve in polar solvents and non-
polar solutes will dissolve in non-polar solvents. The 
phenomena are due to intermolecular forces such as 
dipole-dipole interactions and van der Waals force. 
Polymorphism Different polymorphs will have different physical 
properties and molecular arrangements. Metastable 
forms will have higher solubility compared with stable 
forms. Generally the range of solubility differences 
between polymorphs is only within 2-3 fold due to 
relatively small differences in free energy. 
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2.6 Solubility Enhancement Techniques  
 According to recent studies, more than one-third of the drugs listed 
under the U.S. Pharmacopoeia and half of the new chemical entities (NCEs) 
developed in the pharmaceutical industry have poor bioavailability because of 
their biopharmaceutical properties such as poor aqueous solubility and 
dissolution (Ahuja et al., 2007, Shen et al., 2010). Enhancing the solubility of 
BCS class II drugs is a major challenge for formulation scientists to a 
successful drug development (Sugano et al., 2007, Sigfridsson et al., 2009, 
Van Eerdenbrugh et al., 2010). Numerous pharmaceutical formulation 
techniques have been reported to overcome the delivery barriers of poorly 
water-soluble drugs; however, the number of simple and effective techniques 
that have achieved marketed applications is limited. Therefore, it is essential 
to explore new types of formulation approaches with market values. Recently, 
more attention has been given to amorphization technique by confining drug 
particles in mesoporous carriers via spray drying to circumvent the poor 
supersaturation and storage stability of poorly water-soluble drugs 
(Rengarajan et al., 2008). There has been growing interest in employing 
mesoporous materials especially mesoporous silica and mesoporous carbon in 
drug delivery systems for both rapid and controlled drug release (Rahmat et 
al., 2010, Limnell et al., 2011a). Common approaches utilized for achieving 
higher drug bioavailability/solubility such as particle size reduction, inclusion 
complexation, modification of the crystal forms and solid dispersions are 
discussed further in this section. 
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2.6.1  Particle Size Reduction  
 According to the modified Noyes-Whitney relationship [equation (a)] 
(Noyes and Whitney, 1897), the dissolution rate of drugs can be related to the 
particle size. Reducing the particles size of a coarse drug powder by applying 
considerable shear forces will increases the surface area per unit volume ratio 
of drugs, which in turn augments the interaction between the drug and the 
solvent, thereby improving the dissolution rate. However, this is not suitable 
for drugs having a high dose number because it does not influence the 
saturation solubility of the drug (Blagden et al., 2007). Examples of particle 
size reduction techniques include micronization (2−5 µm) (Rasenack and 
Muller, 2002) and nanonization (200–500 nm) (Keck and Muller, 2006) using 
hammer mills, rotor stator colloid mills, ball mills, air-jet mills, comminution 
and spray drying. Meanwhile nanosuspensions are produced by 






        (a) 
where, 
M = mass of compound dissolved in time t; D = diffusion coefficient of the 
compound in the medium; S = surface area; h = thickness of the stagnant film 
layer; Cs = saturated solubility of the compound at the particle–media 
interface; and Cb = concentration of compound in the bulk medium. 
 Rasenack et al. (2003) have studied the effect of micronization on a 
poorly water-soluble drug, ECU-01 (a low molecular enzyme-inhibitor with 
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anti-inflammatory properties). The dissolution rate of micronized ECU-01 
(mean particles size = 1 µ) was 93% after 20 min while that of the untreated 
crystals (mean particles size = 20 µ) was only 4% after 20 min. Table 2.7 
shows examples of samples prepared by particle size reduction methods..  
Table 2.7 Examples of samples (solid dispersions) prepared by particle size reduction 
methods 
Drug  Technique References 
Cilostazol Hammer -mill, jet-mill and 
spray-dryer 
(Jinno et al., 2006) 





Wet milling (Bhakay et al., 2011) 
Creatine and  
Ibuprofen 
Rapid Expansion of 
Supercritical Solution (RESS) 
(Hezave et al., 2010) 
and  
(Charoenchaitrakool 
et al., 2000) 
Fenoﬁbrate  Micronization , co-grinding and 
spray drying 
(Vogt et al., 2008a) 
EMD 57033 Co-grinding  (Vogt et al., 2008b) 
Danazol  Aqueous dispersion of 
nanoparticulate danazol, 
danazol-hydroxypropyl-β-
cyclodextrin complex; aqueous 







2.6.2 Inclusion Complexation 
 
 Figure 2.5 Schematic diagram for inclusion complexes using cyclodextrin with 
drug/carrier ratio of (a) 1:1 (w/w) and (b) 1:2 (w/w). 
 Inclusion complexes are another common method to enhance the 
stability, wettability, aqueous solubility, membrane permeability, dissolution 
rate and bioavailability of poorly water-soluble oral or parenteral drugs (Park, 
2006). Inclusion complexes are formed by insertion of the non-polar region of 
a drug molecule (known as the ‘guest’) into the cavity of another group of 
molecules (known as the ‘host’) to form a stable association (ElShaboury, 
1990). The most commonly used complexing ligand is cyclodextrin (CD) 
(Figure 2.5); α-CD, β-CD and γ-CD are three naturally occurring CDs 
(Uekama et al., 1998). Other complexing ligands include apart from caffeine, 
urea, polyethylene glycol, N-methylglucamide. Derivatives of β-cyclodextrin 
such as hydroxypropyl-β-cyclodextrin are widely used in pharmaceutical 
formulations. CDs are non-reducing, crystalline and water-soluble compounds 
made up of sugar molecules, bound together in a donut-shaped ring (cyclic 
oligosacharides) that have a non-polar cavity and a hydrophilic external 
surface (Jiang et al., 2012b, Pitha et al., 1986). The polar exterior of the 
cyclodextrin (due to the presence of hydroxyl groups on the molecule) renders 
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them water-soluble and the hydrophobic cavity provides a microenvironment 
for inclusion of non-polar molecules (which reduces the contact of the 
hydrophobic drug molecules with water) (Uekama et al., 1998). Complexation 
relies on relatively weak forces such as London forces, hydrogen bonding and 
hydrophobic interactions. Slightly water-soluble drugs such as 
phenobarbitone, diazepam, prednisolone and spironoiactone have been found 
to form inclusion complexes with β-CD in different molar ratios. These drugs 
that are produced in the tablet dosage form with spray dried lactose exhibit 
better mechanical properties and enhanced dissolution rate of up to 6-10 fold 
(ElShaboury, 1990). Various technologies are applied for the preparation of 





Table 2.8 Examples of samples (solid dispersions) prepared by inclusion 
complexation 
Carrier Drug Approaches  References 
Hydroxypropyl -β- CD  Ketorolac Kneading method (Nagarsenker et 
al., 2000) 
β- CD Meloxicam  Milling (Bandarkar and 
Vavia, 2011) 
β - CD  Scutellarin  Lyophilization/ 
Freeze drying 
technique 
(Cao et al., 
2005) 
2- 






(Lee and Lee, 
1995) 
β- CD Carvedilol  Microwave 
irradiation 
(Wen et al., 
2004) 







(Ozeki et al., 
2012) 
β- CD Artemisinin Spray drying (Balducci et al., 
2013, Sahoo et 
al., 2009) 
β- CD Naringenin  Solvent 
evaporation 
method 




Piroxicam Freeze drying 
and the spray 
drying 
(Bouchal et al., 
2014) 
β- CD Diosmin  Kneading 
technique 






 Co-solvency or solvent blending (Figure 2.6) is a process in which the 
solubility of a poorly water-soluble drug is improved by changing the polarity 
of water by adding one or more water-miscible solvents. The mixture thus 
formed, in which the drug has a good solubility, is known as co-solvents 
(Strickley, 2004). Co-solvency is a suitable approach for highly crystalline and 
lipophilic drugs that have a high solubility in a solvent mixture. The system 
works by reducing the interfacial tension between the aqueous solution and the 
hydrophobic solute. Co-solvency is one of the most widely used techniques for 
the oral and parenteral routes because it is simple to produce and evaluate; 
ethanol, glycerin, sorbitol, polyoxyethylene glycols, PEG 300 and propylene 
glycol are the most frequently used low-toxicity co-solvents (Table 2.9) 
(Yalkowsky and Rubino, 1985, Pan et al., 2001). 
 




Table 2.9 Examples of samples (solid dispersions) prepared by co-solvency 








Polyethylene Glycol 400, 
polyethylene Glycol 8000, 
propylene glycol, glycerol, ethanol 




Famotidine  Liquid co-solvent: ethanol and 
polyethylene glycol 400 
(Matsuda et al., 
2011) 
Risperidone Transcutol (Shakeel et al., 
2014) 
Daidzein  Propylene glycol (Zeng et al., 
2014) 
Rapamycin  Polyethylene Glycol 400/ethanol, 
glycerol/ethanol, propylene glycol, 
glycerol formal, transcutol P 









Polar solvents: methanol, ethanol 
and propanol;  
Less polar solvents: N-methyl 
pyrrolidone, tetraglycol and 
labrasol. 
(Miyako et al., 
2010) 
phenytoin Surfactants: sodium dodecyl 
sulfate, Tween 80; Co-solvents: 
dimethylacetoamide, ethanol, 








Figure 2.7 Schematic diagram for micelle formation and drug encapsulation. 
 Surface active agents (surfactants) are molecules with both a non-polar 
(hydrophobic) region, of which hydrocarbons are a major portion and a polar 
(hydrophilic) region. Depending on their charge characteristics, surfactants 
can be divided into four classes: anionic (i.e. the hydrophilic group is 
negatively charged, e.g. sodium lauryl sulphate and potassium laurate); 
cationic (i.e. the hydrophilic group is positively charged, e.g. cetrimide, 
benzalkonium chloride); zwitterionic (i.e. the molecule is both negatively and 
positively charged, e.g. N-dodecyl-N, N-dimethylbetaine); nonionic (i.e. the 
hydrophile carries no charge but derives its water-solubility from highly polar 
groups such as hydroxyl or polyoxyethylene groups, e.g. Spans, Tweens, 
polysorbates, polyoxyethylated castor oil, polyoxyethylated glycerides and 
lauroyl macroglycerides) (Kawakami et al., 2006, Kawakami et al., 2004). 
Surfactants are used to form micelles to improve the solubility and wettability 
of hydrophobic drugs by entrapping the poorly soluble drugs in the 
hydrophobic core (Figure 2.7) and lowering the surface tension between the 
drug and the solvent (Torchilin, 2001, Jones and Leroux, 1999). They can also 
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be used to stabilize drug suspensions and micro-emulsions and increase the 
rate of disintegration of drugs into finer particles (Schreier et al., 2000, Yu et 
al., 1998). The micelles are formed when the surfactant concentration exceeds 
their critical micelle concentration (CMC), which depends upon the surfactant 
itself and the ionic strength of the media (Dutt, 2003). This process, known as 
micellization, is a widely used alternative for the dissolution of poorly soluble 
drugs which generally results in enhanced solubility (Desai et al., 2003, Liu et 
al., 2004, Desai and Park, 2004). Gliclazide, glyburide, glimepiride, glipizide, 
repaglinide, pioglitazone and rosiglitazone are examples of poorly water-
soluble drugs of which the solubility is enhanced by micellar solubilization 
(Seedher and Kanojia, 2008). 
2.6.5 Modification of the Crystal Forms 
 
Figure 2.8 Schematic diagram of crystalline structure in different polymorphs. 
 Modification of the crystalline form of a drug is another method to 
improve the solubility of poorly water-soluble drugs. Polymorphism is the 
ability of a drug substance to exist in more than one crystalline form (Figure 
2.8). Different polymorphs of the same drug will have identical chemical 
properties but may show variations in physical properties such as solubility, 
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melting point, density, texture and stability (Singh et al., 2010, Datta and 
Grant, 2004, Grunenberg et al., 1996). Identifying the desired polymorph of a 
drug before formulation is important to ensure a sufficiently reasonable 
solubility and dissolution rate. It can be done by controlling the crystallization 
process to favor the creation of amorphous or metastable forms of a drug 
possessing higher free energies. Compared with metastable forms and 
amorphous forms, the most stable polymorph has the least amount of free 
energy and, consequently, the lowest solubility. The dissolution rate of 
different solid forms of a given drug, in descending order, is as follows: 
amorphous (highest), metastable and stable (lowest) (Hammond et al., 2007). 
For example, indomethacin normally exists in 2 polymorphs which are α- and 
γ-indomethacin. The γ-indomethacin which is more thermodynamically stable, 
has a lower solubility in water compared with the α-indomethacin, which is in 
a metastable form (Lim et al., 2012). Chloramphenicol palmitate (Aguiar et 
al., 1967), sulfameter (Khalafallah et al., 1974), phenylbutazone (Pandit et al., 
1984), amobarbital (Kato and Kohketsu, 1981), celecoxib (Lu et al., 2006), 
rifaximin (Viscomi et al., 2008) are some examples of drugs thus formulated. 
However, the stability of the amorphous and metastable forms is still a 
problem to address unless stabilizers intended to inhibit crystal growth of the 
stable form are incorporated in the formulation. 
2.6.6 Solid Dispersions 
 Solid dispersion is a a useful pharmaceutical technique to enhance the 
dissolution, aqueous solubility, absorption and therapeutic efficacy of 
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formulated drugs. A solid dispersion refers to a solid containing one or more 
active ingredients in an inert carrier or matrix in a solid state. The matrices 
refer to amorphous or crystalline water-soluble carriers where the hydrophobic 
drugs can be dispersed molecularly or in amorphous or crystalline forms 
depending on drug-carrier interactions and drug loading (Akbuga et al., 1988, 
Okonogi et al., 1997). The concept of solid dispersion was first recognized by 
Sekiguchi and Obi to overcome the poor dissolution or solubility and the low 
bioavailability of lipophilic drugs (Sekiguchi and Obi, 1961). Solid 
dispersions can produce non-molecular level mixing (eutectic) or molecular 
level mixing (solid solution) products. According to the properties of the 
carrier and molecular arrangement of the drug within the carrier matrix, solid 
dispersions can be classified into 6 categories (Table 2.10) which involves 3 
generations (Figure 2.9). Detailed literature reviews about these solid 
dispersions are available in works by Leuner and Dressman (2000) and 
Vasconcelos et al. (2007).  
 The enhancement of the dissolution by solid dispersions is influenced 
by different mechanisms: (1) a reduction in particle size with a resultant 
increase in the total surface area per unit volume of drug particles that is 
exposed to the dissolution medium; (2) an augmented saturation concentration 
around smaller particles compared with larger particles; (3) improved 
wettability of a drug by its direct contact with the hydrophilic matrix; (4) a 
reduction in the lattice energy due to changes in polymorphs or amorphization 
or reduced crystallinity; and (5) an increase in the porosity of drug particles; 
and (6) an elevated solubilizing effect of the carriers. 
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 The selection of carriers for the formulation of solid dispersions is 
critical since it determines the physicochemical properties and stability of the 
drug. The chosen carrier should ideally possess these features: high solubility 
in not only water but also a variety of solvents with rapid dissolution 
properties; ability to enhance the aqueous solubility of the drug; 
biocompatibility, lack of toxicity and pharmacological inertness; thermal 
stability with a low melting point for the melt method; chemical compatibility 
with the drug and only weakly bonded with the drug. Different classes of 
water-soluble carriers such as surfactants, sugars and polymers are employed 
to formulate solid dispersions using techniques including melting (fusion) 
method, solvent method, or fusion solvent-method (Table 2.11). Spray drying, 
a solvent method that is of interest in this research, will be discussed 
extensively in Section 2.7.2.3. Gris-PEG
®
 is a commercially available solid 
dispersion of griseofulvin and polyethylene glycol 8000 (carrier). Other 
carriers such as nanoparticles, microcapsules, microspheres are also widely 




Table 2.10 Classification of solid dispersion subtypes according to the physical form 
of the drug and the carrier 
Type Solid 
Dispersion 






















































Table 2.11 Types of water-soluble excipients employed as carriers to formulate solid 
dispersions 
Carriers API Preparation of 
solid dispersion 
References 
Poloxamers Desloratadine Melting method/ 
fusion method 




Rofecoxib Melting method/ 
fusion method 























Felodipine Physical mixing 
and hot melt 
mixing 























et al., 2013) 












 Despite the promising dissolution enhancement and simplicity of solid 
dispersion techniques, challenges in formulation methods and manufacturing, 
problems associated with the reproducibility of physicochemical properties, 
poor predictability of solid dispersion behavior, stability and scale-up have 
limited the solid dispersions from achieving commercial market values 
(Serajuddin, 1999, Dahlberg et al., 2008, Leuner and Dressman, 2000). Solid 
dispersions are thermodynamically less stable and tend to re-crystallize due to 
mechanical stress during the processing period and temperature and humidity 
stress during the storage period (Pokharkar et al., 2006, Vasanthavada et al., 
2004, Vasconcelos et al., 2007). Most of the hygroscopic carriers tend to 
absorb moisture from humid surroundings. The resultant alteration in the 
molecular mobility of drug particles may promote re-crystallization and phase 
separation, thereby hampering storage stability of amorphous and metastable 
crystalline pharmaceuticals, potentially resulting in decreased solubility and 
dissolution rate with aging (Sharma and Jain, 2011, Johari et al., 2005, 
Vasconcelos et al., 2007). In view of this, formulating solid dispersions by 
confining drug particles in mesoporous carriers present a better solution for 
the poor stability of the amorphous forms. Some details of nano-confinement 
have been discussed in introduction (Section 1.1); and more detailed literature 
regarding mesoporous materials especially mesoporous silica will be provide 
in next section 
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2.6.6.1 Mesoporous materials 
 Mesoporous materials are highly porous solids characterized by a 
uniform pore shape and a narrow pore size distribution. According to the 
IUPAC classification, porous materials can be classified into three main 
categories, depending on their pore size: pores with a diameter smaller than 2 
nm are referred to as micropores, those between 2–50 nm as mesopores and 
those larger than 50 nm as macropores (Sing et al., 1985). The term of 
nanopore is also sometimes used to describe mesopores.  
 Ordered mesoporous materials possess outstanding properties 
compared with other porous materials, including: (1) high surface area, high 
porosity and high pore volume; (2) well-defined pore sizes and shapes with a 
narrow pore-size distribution; (3) adjustable pore size in the range of 2−30 
nm; (4) highly ordered pore structures at the nanometer level; (5) presence of 
micropores in the amorphous walls; (6) diversity of structures, wall 
compositions and pore shapes; (7) high thermal and hydrothermal stability; (8) 
availability of different controllable regular morphologies on scales ranging 
from nanometers to micrometers (Zhao et al., 2012, Charnay et al., 2004, 
Kapoor et al., 2009, Vinu et al., 2005).  
  The discovery of MCM-41 (M41S family), the first mesoporous 
material, in 1992 by Mobil scientists heralded the beginning of ordered-
mesoporous-material synthesis and application (Kresge et al., 1992, Wan and 
Zhao, 2007). Since then, mesoporous materials have attracted research interest 
and much progress has been accomplished in aspects such as elucidating the 
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formation mechanism, synthesizing mesoporous materials with large pore 
sizes (up to 30 nm) and generating mesoporous materials in different 
structures (lamellar, cubic and 2D- and 3D-hexagonal phases) (Figure 2.10) 
and forms (films, fibers, spheres and monoliths) (Hartmann, 2005, Stein, 2003, 
Meynen et al., 2009). To date, the ordered mesoporous materials and their 
synthesis methods have become a ‘hot’ research area in the discipline of 
material science worldwide. 
 
Figure 2.10 Structures for first synthesized mesoporous materials (M41S family) 
 Mesoporous materials have practical application in areas such as 
adsorption, separation, purification of gas and liquid, catalysis and also been 
used as semiconductors, optics components, sensors, materials for 
environmental protection and so on (Xu et al., 2009, Igarashi et al., 2007, 
Perez-Quintanilla et al., 2006, Bhatnagar and Sillanpaa, 2010). With specific 
regard to drug delivery, mesoporous materials have also offered much 
promising potential (Manzano and Vallet-Regi, 2010, Wang, 2009). For 
example, improved dissolution of poorly soluble drugs either rapid release or 
sustained release of active pharmaceutical ingredients (APIs) through the 
encapsulation of drug particles into nano-sized carriers.  
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 The successful development of a mesoporous drug carrier involves the 
production of the porous material, the design of the appropriate surface 
chemistry and the characterization of the properties of the carrier and the drug 
loaded in the pores. There are several types of mesoporous materials are 
available, such as mesoporous carbon, polymers and various metal oxides 
(Ahola et al., 2000, Kortesuo et al., 2000, Unger et al., 1983). Among them, 
silicon-based materias sucha as porous silicon (PSi) and porous silica are the 
most studied mesoporous materials in drug delivery applications. More 
literature of the applications of mesoporous carriers in dissolution 
enhancement is provided in Table 2.12. The characteristics of porous silica 
render it suitable for different purposes: its relatively inert nature makes it a 
perfect host for guest species and its structural features afford improved 
molecular accessibility and rapid mass transport (Zhao et al., 1998, Ambrogi 
et al., 2007, Heikkila et al., 2007, Charnay et al., 2004).  
2.6.6.1.1 Mesoporous silica  
The first mesoporous silica was synthesized with amphiphilic triblock 
copolymers in 1998 by Zhao et al (Zhao et al., 1998). These materials are 
named SBA-X (Santa Barbara Amorphous) where X is a number denoting a 
specific pore structure and surfactant, e.g. SBA-15 has hexagonally ordered 
cylindrical pores synthesized with P123 as a surfactant while SBA-16 has 
spherical pores arranged in a body-centred cubic structure synthesized with 
F127. Other families of mesoporous silica are MSU (Bagshaw et al., 1995), 
KIT (Ryoo et al., 1996) and FDU (Yu et al., 2000) which are synthesized 
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under various conditions with different surfactants. Among these mesoporous 
silica, the SBA-series has attracted considerable interest for various 
applications, chief amongst which is the most extensively studied SBA-15, 
which is the subject of attention in this thesis (Zhao et al., 1998). In the 
following sections are summarized more details of SBA-15 including 
syntheses, structures, formation mechanisms and applications. 
2.6.6.1.1.1 Santa Barbara Amorphous-15 (SBA-15) 
 SBA-15 is a mesoporous silica (SiO2) characterized by hexagonally 
arranged cylindrical pores, with the pore size being tuneable between 4–26 nm 
and the length of the pores ranging from approximately 200 nm to several 
microns (Zhao et al., 1998, Zhang et al., 2004). Around each mesopore is a 
microporous network called the corona (Impéror-Clerc et al., 2000, Ryoo et 
al., 2000), which originates from trapped hydrophilic chains of the surfactants 
(Kruk et al., 2000, Ruthstein et al., 2003). This network underlies the 
interconnection of the mesopores with each other, affording its hexagonal 
structure (Figure 2.11) and high surface area of SBA-15.  
 
Figure 2.11 The structure of mesoporous silica SBA-15 (to the left) and its replica in 




The meritorious features of SBA-15 render it ideal for a diverse array 
of applications. Its narrow pore size distribution makes it a suitable candidate 
as molecular sieves and as templates for producing nanoparticles and other 
mesoporous structures. Its large specific surface area (500–1000 m2/g) 
contributes to its being an ideal substrate for catalysts and mesoreactors where 
chemical reactions take place in the pores. Besides that, by proper 
functionalization of the silica walls, catalytic reactions can be realized at the 
surfaces. Examples of the usage of SBA-15 as a host for catalysts are: 
incorporation of Ti for hydrogen storage and photovoltaic applications (Das et 
al., 2010), addition of FeW for hydrotreating heavy gas oil and storage of 
methanol (Boahene et al., 2011). Furthermore, SBA-15 can be used as a 
template for anode or cathode materials for batteries (Procházka et al., 2009, 
Xi et al., 2005). SBA-15 is also exploited in solar cell applications, both as a 
template for incorporation of titanium or cobalt nanoparticles (Lachheb et al., 
2011, Ding et al., 2005) and as a scattering layer for improving the cell 
efficiency (Yang and Zheng, 2012). 
With specific regard to dosage form design, mesoporous silica has 
been shown to be an excellent carrier for poorly water soluble drugs (Slowing 
et al., 2008). The delivery of such drugs by means of mesoporous silica can 
resolve many problems associated with these molecules. In general, for poorly 
soluble drugs, an enhanced release rate can be achieved either by reducing the 
drug particle size or by changing in the physical state of loaded drugs (meta-
stable or amorphous forms) via confining the drugs into mesopores (Salonen 
et al., 2008). In the latter, the use of mesoporous silica not only augments the 
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release rate but also efficiently stabilizes the state of the drug. In addition, 
SBA-15 with large specific surface areas and total pore volumes provides a 
high capacity to absorb drug molecules into their pore structures, thereby 
achieving a high extent of drug loading. The high applicability of this method 
to a wide variety of poorly soluble drugs (Van Speybroeck et al., 2009) also 
means that it is conveniently unnecessary to tune the carrier according to the 
properties of the drug, provided that the drug is chemically compatible with 
the carrier. Other potential benefits of the carrier are as follows: ensuring a 
sustained release resulting from attachment of molecules onto the surface and 
diffusion limitations; potentially protecting drug molecules from enzymatic 
degradation prior to release since the pores are inaccessible to enzymes; and 
ease of practical use (the loading of the carrier is uncomplicated, at least on a 




2.6.6.1.1.2 Syntheses of Mesoporous Silica 
 
Figure 2.12 Possible synthesis pathway for the synthesis of hexagonal silica 
 The core principle of synthesis of all the mesoporous materials is 
almost the same. It involves a sol–gel process (Figure 2.12), in which 
surfactants or other species are used as templates in the presence of an acidic 
or basic synthesis medium. The nature of the templates may be cationic, 
anionic, neutral, multiple charges, multiple alkyl chains and polymer 
surfactants while the temperatures may vary from room temperature to 
approximately 150 ºC. The structures and compositions of materials are also 
extended, including silica-based materials: FSM-16, SBA-1, SBA-2, SBA-6, 
SBA-8, SBA-11, SBA-12, SBA-16, FDU-n, disordered HMS, MSU-n, KIT-1 
and so on.  
 There are four main steps in the preparation of SBA-15. The first step 
is the synthesis of the mesoporous structure using a block copolymer and a 
silica precursor. The surfactants are added to a homogeneous, acidic solution 
containing distilled water and HCl. In some cases, the addition of surfactants 
may be preceded by that of swelling agents. For SBA-15, the triblock 
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copolymer P123 is used as the surfactant. The P123 forms spherical micelles 
in the solution. Upon addition of silica precursor, it penetrates into the core of 
the micelles due to their hydrophobic properties. The hydrolyzed precursors 
then diffuse into the corona and adsorb onto the P123, followed by 
polymerization beginning in the core/corona interface and subsequently in the 
corona. The polymerization in the core/corona region is simultaneous with 
respect to the elongation of the micelles whereas the polymerization in the 
pure corona is associated with the precipitation of flocs. When the silica 
precursor is polymerized on the PEO chains, the water content in this area is 
decreased. This changes the polarity resulting in a reduced curvature of the 
micelle and hence, the micelles, now elongated from spheres to cylinders, 
arrange themselves in a hexagonal pattern while the silica walls are built. 
 The second step is the hydrothermal treatment at a higher temperature 
after the formation of SBA-15. Through hydrothermal treatment, the 
properties of the final products such as pore size, micropore volume and 
surface area can be tuned. After the establishment of the hexagonal structure, 
the PEO chains are trapped into the silica network (Ruthstein et al., 2003, 
Galarneau et al., 2001), which subsequently are the source from which the 
micropores in the final product are formed. With increasing temperature, the 
PEO chains becomes more hydrophobic and retract from the silica wall and 
migrate into the more hydrophobic core of the micelles. The results of this are 
threefold: an increased pore size, reduced microporosity and surface area and 
reduced shrinkage of the silica walls upon calcination. The effect of 
hydrothermal treatment is illustrated in Figure 2.13. By increasing the 
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hydrothermal treatment temperature from 35 to 130 ˚C, it is possible to 
increase the mesopore size by several nanometers. Significant changes are 
observed above 60 ˚C (Galarneau et al., 2001). wherethe microporosity and 
surface area are decreased. At 130 ˚C, no micropores remain and all surface 
originates from the mesopores. The unit cell parameter is however nearly 
constant for calcinated samples with hydrothermal treatment temperature 
above 60 ˚C; therefore, during the increase of mesopore size, the wall 
thickness decreases, the wall becomes denser and the microporosity is lost 
(Galarneau et al., 2001, Impéror-Clerc et al., 2000). A similar effect, but not as 
pronounced, is observed by prolonging the hydrothermal treatment time. 
 
Figure 2.13 The effect of the hydrothermal treatment. 
 Filtration and washing the samples are the third step followed by the 
fourth and final step is the removal of the surfactants most often done by 
calcination. Calcination is the most common way to remove the surfactants 
from SBA-15. During the process, which is performed in air, the material is 
heated to 550 ˚C and this temperature is held for 5 h before the material is 
cooled down to room temperature. Most of the surfactants decompose between 
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150–250 ˚C and at this stage the hexagonal structure retains its size. Above 
300 ˚C water is released and the rest of the polymers are combusted and the 
hexagonal framework is decreased probably due to condensation in the 
framework and closure of micropores (Kleitz et al., 2003). During the 
shrinkage of the hexagonal structure, the mesopore volume is decreased but 




Table 2.12 The application of mesoporous carriers in dissolution enhancement of poorly water-soluble drugs reported in literature. The BET 

















Morphology  Drug Loading 
(wt%) 
BCS References 





















(Hu et al., 
2012b) 
1028 27 0.73 – – Fenofibrate 20.0 (Van 
Speybroeck et 
al., 2010a) 










1063 26 0.72 <38.0 – Ibuprofen 11.7 (Heikkilä et 
al., 2007) 
850 34 0.62 10.0– 
50.0 
Spheres  Ibuprofen 2.5– 37.1 (Charnay et al., 
2004) 
920 34 0.78 <125.0 Irregular 
clusters 

























629 73 0.83 – Fibrous- rod-
like sub-
particles 


























(Zhao et al., 
2012a) 


















625 69 1.07 ∼50.0 Rod-like 
particle 
Ibuprofen 102.0 (Heikkilä et 
al., 2007) 








Itraconazole 19.1 (Vialpando et 
al., 2011) 
844 73 0.85 0.2– 1.0 Randomly 
oriented 
building 


















































































0.5– 1.0 Spheres  Ibuprofen 21.3– 
24.3 
(Xu et al., 
2009) 
Syloid 244 311 190 1.42 2.5– 3.7 Irregular 
clusters 
Indomethacin 28.9 (Limnell et al., 
2011b) 
Syloid AL- 1 683 32 0.13 6.5– 8.1 Spheres Itraconazole 21.0/ 
25.1 




311 190 1.42 2.5– 3.7 Spheres Itraconazole 21.9/ 
32.8 


































(Song et al., 
2005) 
SBA-16 541 43 0.34 2.0– 3.0 Spheres  Carvedilol 25.0 (Hu et al., 
2012b) 
















(Salonen et al., 
2005) 











(Limnell et al., 
2007) 
282 110 0.86 <38.0 – Ibuprofen 41.5 (Heikkilä et 
al., 2007) 




Itraconazole 11.3 (Kinnari et al., 
2011) 




















Morphology  Drug Loading 
(wt%) 
BCS References 
TOPSi 321 88 0.54 13.6 Irregular 
shape with 
sharp edges 

























(Wang et al., 
2010) 




Itraconazole 11.2 (Kinnari et al., 
2011) 
TOPSi 222 85.3 0.62 <38.0 – Ibuprofen 36.5 (Limnell et al., 
2007) 







































– – Ibuprofen 18.0– 
30.0 




















Morphology  Drug Loading 
(wt%) 
BCS References 
NFM-1 793 26 0.40 10.2 Rod -type Atazanavir 28.2 II (Xia et al., 
2012) 
AMS-6 847 43 0.80 9.4 Spheres Atazanavir 31.5 (Xia et al., 
2012) 








364 20–30 0.20 0.3 Cotton-like 
spheres 












(Zhao et al., 
2012c) 
TUD-1 453 46 0.57 <38.0 – Ibuprofen 49.5 (Heikkilä et 
al., 2007) 
COK- 2 445 -
652 









2.7 Methods of Preparation of Solid Dispersions  
  Solid dispersions can be formulated through thermal and solvent 
methods. The former includes fusion method, solvent evaporation and hot-
melt extrusion whereas the latter includes supercritical fluid technology, 
lypophillization and spray drying. Provided in the following section are a short 
summary of the fusion method, hot-melt extrusion, supercritical fluid method 
and lypophillization and detailed explanations of spray drying, i.e. the 
technique of interest in this study. 
2.7.1 Thermal Methods  
2.7.1.1 Fusion/Melting Method  
 The fusion method entails the dissolution of drugs in molten carriers in 
rubbery state by direct heating for incorporation into the matrix. Processes 
such as ice bath agitation, spreading on plates placed over dry ice, immersion 
in liquid nitrogen, spraying the hot melt on a cold surface and storage in 
desiccators are used to cool and solidify the melted mixture. The resultant 
sample is crushed, pulverized and sieved (Chiou and Riegelma.S, 1971). The 
combination of sulfathiazole and urea as a matrix was the first solid dispersion 
prepared by the fusion method for pharmaceutical applications. Poly (ethylene 
glycol), poly (vinyl pyrrolidone), mannitol and poloxamers are types of 
matrices commonly used in the fusion method because of their low melting 
point (Sharma and Jain, 2011, Leuner and Dressman, 2000). Several 
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modifications such as hot-melt extrusin, melt agglomeration and Meltrex
TM
 
were introduced to overcome the limitations encountered by this technique. 
2.7.1.2 Hot-Melt Extrusion 
 Hot-melt extrusion is a method similar to the fusion method but there 
is an additional mechanical process applied to the molten mixture of drug, 
carrier and plasticizer under controlled conditions of temperature and shear 
forces. The co-melts are mixed, homogenized using transport screws and 
extruded through a die to form tablets, pellets, sticks and sheets for implants, 
ophthalmic inserts, or oral dosage forms (Crowley et al., 2007, Breitenbach, 
2002). One of the important parameters for hot-melt extrusion technique is the 
operating temperature, which can be determined by the melting points (Tm) of 
drug and of crystalline carrier or glass transition temperature (Tg) of the 
amorphous carrier. Knowledge of the optimal operating temperature is critical 
to not only preventing degradation of the drug during this process but also 
ensuring that the carrier(s) are sufficiently softened (less viscous) so that it can 
flow through the extruder (Forster et al., 2001b). Additives such as surfactants 
(Tween
® 
80) are widely used as plasticizers to decrease the Tm or Tg of carriers 
and the operating temperature to enable the flow of the mixture through the 
extruder (Ghebremeskel et al., 2007). Two categories of carriers widely used 
in hot-melt extrusion are the synthetic polymeric carriers and the carbohydrate 
carriers. Examples of synthetic polymeric carriers include PVP K30, PVPVA 
64 and EudragitR E100 (polymethacrylates) whereas examples of 
carbohydrate carriers include cyclodextrin (CD) derivatives and 
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hydroxypropylmethylcellulose (Forster et al., 2001a, He et al., 2010, Fu et al., 
2010). Although hot-melt extrusion has some disadvantages as a fusion 
method, this technique offers continuous production which is suitable for large 
scale productions (Leuner and Dressman, 2000). 
2.7.2 Solvent Methods 
2.7.2.1 Supercritical Fluid Method 
 Supercritical fluid method is another technique used for formulating 
solid dispersion and for particle size reduction. Supercritical fluid exists as a 
single fluid phase with both liquid and gas physicochemical behaviors: the 
liquid-like characteristic is exploited for the dissolution of the solute whereas 
the gas-like characteristic is exploited for the rapid precipitation of solutes. 
Carbon dioxide is the most common supercritical fluid used because of its low 
supercritical temperature (Tc=31.1°), low supercritical pressure (Pc=73.8 bar), 
inertness, nontoxic and non-flammable nature, cost-effectiveness and 
environmentally friendly properties (recyclable after processing) (Lim et al., 
2012). The relatively low Tc and Pc allow easy processing which is suitable for 
pharmaceutical products (Yasuji et al., 2008). Even nitrous oxide, water, 
methanol, ethanol, ethane and propane are also used as supercritical fluids for 
a variety of applications. There are two categories of supercritical drying in 
which the supercritical fluid plays different roles: as a solvent and as an anti-
solvent (Subramaniam et al., 1997). When the supercritical fluid is used as a 
solvent, the drugs are dissolved in it and the precipitation of drug or solid 
79 
 
dispersion is obtained by reducing the pressure and/or the temperature [known 
as rapid expansion of supercritical solutions (RESS)]. The main disadvantage 
of this method is that both the drug and the carrier have to be soluble in 
supercritical CO2 which may not be invariably feasible for many drug and 
carrier combinations (Matson et al., 1987). Conversely, when the supercritical 
fluid is used as an anti-solvent, a common organic solvent is used to dissolve 
both the drug and the carrier, followed by the saturation of the solution with 
supercritical CO2 to precipitate the drug and the carrier (Sharma and Jain, 
2011, Leuner and Dressman, 2000). In this technique, the drug and carrier 
should not be soluble in the mixture of supercritical fluid and organic solvent; 
and the organic solvent should be miscible with the supercritical fluid. Among 
the methods in which the supercritical fluid serves as an anti-solvent include 
gas antisolvent precipitation (GAS), precipitates by compressed antisolvent 
(PCA), supercritical antisolvent (SAS), aerosol solvent extraction system 
(ASES) and solution enhanced dispersion by supercritical fluids (SEDS) 
(Pasquali et al., 2008). 
2.7.2.2 Lyophilization  
 Lyophilization or freeze-drying is an alternative method to replace the 
drying and solvent evaporation process in order to prepare solid dispersions. In 
this technique, the drug and the carrier are dissolved in a common solvent, 
which is then subjected to freezing and sublimation to produce a lypophilized 
molecular dispersion. It consists of three sequential steps: freezing, primary 
drying and secondary drying. In freezing, samples that consist of the drug, the 
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carrier and the solvent system are solidified (Abdelwahed et al., 2006). The 
frozen solvents are then removed from the sample by sublimation (primary 
drying) and the remaining unfrozen solvents are removed by 
diffusion/desorption (secondary drying) to produce the final product with a 
sufficiently low moisture or solvent content. Lyophilization is advantageous in 
two aspects: the drugs undergo minimal thermal stress during formulation; and 
the risk of phase separation is reduced once the solution is vitrified. The 
disadvantage, however, is that more complex co-solvent systems are required 
due to the low solubility of lipophilic compounds in water. Furthermore, the 
choices of organic solvents to be used in lyophilization are very limited 
because most organic solvents have a low freezing point. Ideal co-solvents for 
lyophilization, therefore, are those with a high vapor pressure for high 
sublimation rate and a high melting point to allow convenient freezing 
(Sharma and Jain, 2011, Leuner and Dressman, 2000). Therefore, organic 
solvents such as tertiary butanol (TBA) and 2-methyl-2-propanol which fulfill 
such criteria are widely used in this process (Van Drooge et al., 2004). 
2.7.2.3 Spray Drying  
 Spray drying is a widely applied and effective technique to convert 
aqueous or organic solutions into dry materials with distinct properties 
required for various applications. The spray dryer was discovered and 
developed in the 1940s to reduce the weight and volume of food products for 
transportation during World War II (Shahidi and Han, 1993, Gouin, 2004). 
Intensive research and development in the last few decades have rendered 
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spray drying a highly competitive and widely applicable technology in the 
pharmaceutical, chemical and food industries. The range of product 
applications produced predominantly by spray drying continues to expand, 
among which are dairy products, detergents and dyes (R. P. Patel et al., 2009). 
 Spray drying is a continuous process in which a fluid feed will be 
transformed into dried particles by spraying the feed into a hot drying medium 
such as air or nitrogen, where the evaporation of the organic solvent or water 
gives rise to solid microparticles (Billon et al., 2000). The feed can be in the 
form of solutions, emulsions or suspensions which contain a drug, a carrier 
and sometimes additives. The final products can be in the form of powders, 
granules or agglomerates, depending on the parameters of the spray dryer and 
the physicochemical properties of the final products (Ré, 2006). Important 
parameters that affect the morphology, yield, physicochemical characteristics 
and amount of residual solvent of the final products include the following: 
feed rate of the solution, flow rate of the atomizing air, inlet temperature and 
flow rate of the drying gas (Dobry et al., 2009, Esposito et al., 2000, Cabral-
Marques and Almeida, 2009, Nekkanti et al., 2009). Detailed correlations of 





Table 2.13 Optimization of the process settings of spray drying 
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 Various types of spray dryers are available for current applications, 
among which are single-stage and two-stage spray dryers, horizontal and 
vertical spray dryers and fluidized spray dryers. Spray dryers are used based 
on the type of applications and the properties of samples; for example, two-
stage spray dryers are used for heat-sensitive samples whereas vertical spray 
dryers are suitable for both fat and non-fat samples (R. P. Patel et al., 2009). 
Spray dryers can be divided into two designs: open-cycle and close-cycle (or 
inert loop). In the open-cycle design, the air used as a heating medium and the 
aqueous solution as a feeding medium are discharged into the atmosphere after 
use; in the close-cycle design, inert gases such as nitrogen are used as a drying 
medium and the organic solvents as a feeding medium is re-cycled after use 
(R. P. Patel et al., 2009, Ré, 2006).  
 The four fundamental steps involved in spray drying are atomization, 
mixing, evaporation and separation (Thybo et al., 2008, Paudel et al., 2013). 
Spray drying starts with the atomization of a liquid feed into a spray of fine 
droplets, which are then mixed with a heated gas stream (typically air or 
nitrogen gas), allowing the liquid to evaporate, leaving behind the dried solids 
of a similar size and shape depending on the form of atomized droplets. The 
drying continues until the desired moisture content is achieved in the sprayed 
particles. Finally, the dried powder is separated from the gas stream and 
collected (Boersen, 1990, Ameri and Maa, 2006).  
 In atomization, the fluid streams will be broken down into fine droplets 
by applying force or pressure to increase the surface area per volume ratio of 
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the streams. The size of the droplets depends on the flow rate, viscosity, solid 
content and surface tension of the feed. Smaller particles will have a larger 
surface-to-volume ratio which affords a better evaporation rate, so that the 
particles can be dried more rapidly and efficiently. Several types of atomizers 
are available for spray drying, such as rotary atomizer, ultrasonic atomizer, 
pressure nozzle and single and two-fluid nozzles (Paudel et al., 2013). 
Choosing the right atomizer is critical to yield products of a high quality and 
with the desired properties such as particle size, shape and density. There are a 
number of aspects that determine the selection of atomizers such as the 
properties of the liquid to be processed and the specifications required for the 
final product. 
 The atomized fluid streams will come across with the heated air from 
the air disperser for evaporation to take place. The mixing and evaporation 
processes must occur immediately after atomization to prevent the droplets 
from sticking on the walls of the dryer. The 3 types of configuration to mix the 
heated air with the atomized droplets are the concurrent configuration (suitable 
for commodity chemicals), the counter-current configuration (suitable for 
products that need heat treatment) and the mixed-flow configuration (suitable 
for thermally stable products).  
 Drying or evaporation is a crucial part of spray drying process because 
it will determine the quality of the final products. Evaporation begins once the 
droplets come into contact with the heated air and continues until the fluid can 
diffuse from the inner part to the surface of the solids. The dimensions of the 
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drying chamber play a crucial role in evaporation of the droplets, by providing 
sufficient contact time between the droplets and hot air to prevent direct 
contact between the droplets and the heated chamber walls. It is substantially 
important to prevent the droplets from coming into contact with and sticking 
to the walls before they have been dried. Once the products are dried into the 
powder form, the fine powder will be collected by using a cyclone separator, 
while the used drying gas and medium is treated to fulfil environmental 
requirements followed by exhaustion of the gas to the atmosphere or, in some 
cases, re-circulated to the system. 
 Spray drying has garnered much attention as it exhibits multifarious 
advantages compared with other conventional methods. Such useful features 
render it a promising technique in formulating various types of products in the 
pharmaceutical, chemical and food industries (Takeuchi et al., 2005, Moretti et 
al., 2001), including heat-resistant and heat-sensitive drugs, organic or non-
organic excipients, water-soluble and water-insoluble drugs and hydrophilic 
and hydrophobic polymers (Ré, 2006). Some of the advantages offered by 
spray drying are:  
i. It has demonstrated reproducibility and reliability under production 
conditions and enabled the possible control of particles size and drug 
release.  
ii. A wide range of spray drying designs is available to meet diverse 
product specifications. Various types of feeds can be dried 
instantaneously into fine, homogeneous and often amorphous powder 
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with a large surface (Sahoo et al., 2009). Feed concentration, nozzle 
feed rate and inlet air temperature of the drying gas play vital roles in 
determining the particles characteristics; thus sample properties can be 
controlled by optimizing these critical parameters (Paudel et al., 2013).  
iii. Feeds with different viscosities such as solutions, slurries, pastes, gels, 
suspensions or melt forms can be spray dried as long as the feeds can 
be pumped (Ré, 2006).  
iv. Spray drying presents as a technique in which different types of 
powder samples can be handled with negligible degradation; for 
instance, heat-sensitive or heat-resistant samples can be spray dried 
with the retention of the properties and quality of the final products. 
The rapid evaporation of liquid from atomized droplets entails only 
low particle temperatures, which minimize heat damage or degradation 
under optimal conditions (Ståhl et al., 2002, Ré, 2006).  
v. In terms of economic considerations, spray drying is able to reduce 
mass and energy consumption because dried final products in micron-
sized powders can be produced within a single processing step and 
additional secondary manufacturing steps such as micronization and 
milling could be minimized (Boersen, 1990, Ameri and Maa, 2006).  
 
 In next section, some of the important formulation techniques that have 
been used to enhance the biopharmaceutical and physicochemical properties 
of various types of antimalarial drugs will be discussed. 
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2.8 Formulations of Antimalarial Drugs  
 Enhancing the bioavailability and therapeutic efficacy of antimalarial 
drugs (especially artemisinin) is a major concern and challenge encountered 
by pharmaceutical industries. Various approaches have therefore been used to 
improve their performance and the efficiency. For example, Lapenna et al. 
(2009) have investigated not only the micellar solubilization capacity of 
sodium dodecyl sulphate (SDS) for artemisinin and curcumin but also the 
potentially useful combination of the surface activity and antioxidant 
properties of the binary system of SDS and octanoyl-6-O-ascorbic acid 
(ASC8) for artemisinin. Quantitative analysis measurements by diffusion-
ordered spectroscopy (DOSY) and 1H-NMR revealed two findings: firstly, the 
solubility of artemisinin and curcumin increased as a function of the 
concentration of SDS; secondly, the incorporation of ASC8 enhanced the 
molecular stability. Gahoi et al. (2012) reported elevated antimalarial activity 
of lumefantrine by nanopowder formulation through wet-milling using DYNO 
MILL with HPMC E3 and Tween 80 as dispersing agents. This formulation 
technique afforded nanoparticles of lumefantrine with a mean size of 251 nm. 
It was found that the nanopowder exhibited an enhanced dissolution rate and 
in vivo antimalarial activity with an IC50 175-fold lower than untreated 
lumefantrine.  
 Balducci et al. (2013) studied the efficiency of formulation of 
microparticles of artemisinin/β-cyclodextrin via co-spray drying in enhancing 
the dissolution rate and bioavailability of oral dosage forms of artemisinin. 
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The co-spray dried microparticles were able to increase the apparent solubility 
of artemisinin by approximately six-fold and its dissolution rate (in 10 min) by 
60% compared with untreated artemisinin. Yang et al. (2009) reported a 
similar study, but, instead of artemisinin and β-cyclodextrin, they used 
artemether and hydroxypropyl-β-cyclodextrin. The results have shown that the 
apparent bioavailability was enhanced by 1.81-fold compared with untreated 
artemether due to an increase in water-solubility. Shahzad et al. (2012) 
evaluated the effectiveness of solid dispersions of artemisinin by three 
different formulation methods: physical mixtures using glass mortar and 
pestle, solid dispersions via solvent evaporation and lyophilization. Samples 
with different drug ratios were prepared with the hydrophilic polymer 
polyvinylpyrrolidone (PVP). The dispersions of artemisinin with PVP improve 
the pharmaceutical properties of ART including solubility and permeability in 
this descending order: lyophilisation > solvent evaporation > physical 
mixtures. The solubility of lyophilized artemisinin, which was found to be 
PVP-dependent, was increased by up to 4-, 5- and 8-fold in water, in PBS and 
in methanol, respectively. 
 Additional examples from the literature regarding the formulation 
techniques are summarized in Table 2.14. Despite the number of studies 
reporting solubility and bioavailability enhancement techniques of antimalarial 
drugs, to the best of our knowledge, there have been very few studies 
regarding the physicochemical stability of antimalarial drugs, especially 
artemisinin. Knowledge of the long-term storage stability of drugs is essential 
in order to understand their performance for long periods and their shelf-life. 
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Therefore, characterization of the physicochemical stability of artemisinin in 
single dosage forms and combination dosage forms are the major aim of this 
study. 




Solubility enhancement techniques  References 
Mefloquine 
 
Co-crystallization by using solution 
crystallization method 
(Yadav et al., 
2010, Shete 
et al., 2013) 
Preparation of microparticles by co-
acervation method using Eudragit E 
(polymer) and sodium hydroxide (precipitant) 





Liposomal delivery systems via film 



















Micellization using Camel Beta-casein (Esmaili et 
al., 2011) 




Formation of solid dispersion by solvent 
evaporation technique using cellulose acetate  
(Wan et al., 
2011) 
Microemulsions using oil, surfactant and co-
surfactant 
(Hu et al., 
2012a) 
Artemisinin Formation of artemisinin-polyethylene glycol 








Solubility enhancement techniques  References 
Formation of microparticles by co-spray 
drying ART with polyethylene glycol (PEG) 
via modified multi-fluid nozzle pilot spray 
drier 
(Sahoo et al., 
2011b) 
Inclusion complex with β-CD by evaporative 




Micronization and formation of solid 
dispersions with PVPK25 and supercritical 
fluid technology 
(Van Nijlen 
et al., 2003) 
Micronization via a Rapid Expansion of 
Supercritical Solutions (RESS) method 
(Yu et al., 
2012a) 
2.9 Latest Outlook of Formulations of Poorly Water-Soluble 
Drugs 
 Although existing sophisticated approaches have circumvented the 
drawbacks of poorly water-soluble drugs and improved the absorption of the 
active substances, these approaches are often inefficient due to inadequate 
drug delivery for most formulations and yet to progress to broad clinical 
application. Numerous new approaches have been proposed from time to time 
to overcome the limitation and inefficiency of currently available drug 
delivery systems. The global market for advanced drug delivery systems 
amounted to $134.3 billion in 2008 and rose to $139 billion in 2009 and to 
$196.4 billion in 2014. Examples of novel drug delivery approaches are 
summarized as follows (Bernkop-Schnurch and Kast, 2001). 
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 Combinations of two or more formulation strategies in a single device 
have become increasingly attractive. For example, mucoadhesive polymers 
chemically bound to an enzymatic inhibitor of peptidases have been 
synthesized to afford and improve oral delivery of peptides and proteins 
(Bernkop-Schnurch and Kast, 2001).  
 Intestinal patches are another novel oral delivery method to address 
shortcomings of poorly-absorbed molecules, such as peptides and proteins. 
These patches with combination of different features into a single drug 
delivery platform possess multiple advantages compared with other polymeric 
systems. Using such patches minimizes the dilution and loss of drugs into 
luminal fluids by creating a reservoir containing an elevated drug 
concentration with unidirectional drug release (Martin and Grove, 2001). 
 Nanotechnology, characterized by the technology of using carriers on 
the nanoscale, is another technique that enhances oral drug delivery and 
overcomes the associated demerits including poor solubility, stability and 
biocompatibility of drugs (Agrawal et al., 2014). Nanotechnology has been 
used to improve oral delivery of anticancer drugs across the gastrointestinal 
barrier by virtue of their extremely small size and their appropriate surface-
coating to escape from the recognition by P-glycoprotein (P-gp) (Wang et al., 
1996). Moreover, oral administration of nanoparticles encapsulated agent 
control the drug releases to slow breakdown of the polymer over a period of 
time such as nanoparticles made of poly (ε-caprolactone) (Carrio et al., 1995, 
Calvo et al., 1996). 
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Chapter 3 Materials and Methods 
3.1 Materials 
 Artemisinin (ART) was obtained from Junda Pharmaceuticals, Co. 
China, Mefloquine hydrochloride (MFQ-HCl) from Provizer Pharma, India 
and activated carbon (Norit Caspf) was obtained from Behn Meyer, Singapore. 
Meanwhile, α-glucosyl hesperidin (Hsp-G) and α-glucosyl stevioside (Stevia-
G) was purchased from Toyo Sugar Refining Co., Ltd. Activ-vial
®
 was 
supplied by CSP technologies, USA. Tri-block copolymer poly (ethylene 
oxide)-poly (propylene oxide)-poly (ethylene oxide), pluronics P123 (EO20-
PO70-EO20, MW: 5800) and tetraethyl orthosilicate (TEOS, 98%) were 
purchased from Sigma-Aldrich. Hydrochloric acid (HCl) was from Kanto 
Chemical Co. Inc., Japan and deionized water was acquired by reverse 
osmosis with a MilliQ system (Millipore, Roma, Italy). All other reagents and 
solvents used in the study were reagent grade and were used without further 
purification.  
3.2 Synthesis of SBA-15 
  Ordered mesoporous silica, SBA-15, was synthesized via a rapid 
condensation process as reported by Shen et al. (2010, 2011). In the typical 
synthesis, Pluronic P123 was used as a template in acidic conditions and 
TEOS as a silica source. 4 g of Pluronic P123 was added to 150 g of an 
aqueous solution of HCl (2N) and stirred for 2 h at 40 ºC to completely 
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dissolve the Pluronic P123. Successively, to this acidic Pluronic P123 
solution, 9 g of TEOS was added under vigorous stirring for 1 min, while 
maintaining the temperature. The hydrolysis of TEOS was then carried out at 
40 ºC without stirring for 2 h. The mixture was transferred to a polypropylene 
bottle and aged in an oven at 100 ºC for 24 h under static conditions. The 
white solid obtained was then recovered through rinsing (deionized water) and 
filtering and then dried at 55 ºC for 12 h. Finally, the resulting white powder 
was heated from room temperature to 550 ºC at a heating rate of 2 ºC/min and 
calcined in air at 550 ºC for 6 h to eliminate the template molecules. 
3.3 Synthesis of non-porous silica 
Typically, 90.8 ml of ethanol was mixed with 15 ml of NH4OH (25 wt.%) 
aqueous solution. 5.2 ml of tetraethoxysilane (TEOS) or a mixture of TEOS 
and (3-aminopropyl)triethoxysilane (APTES) was introduced into the 
ammonia solution under sonication. The reaction was performed at room 
temperature under sonication for 30 min. The resultant solid was recovered by 
centrifugation and washed with ethanol twice to remove unreacted free silica 
precursors. The powder was vacuum dried at room temperature for subsequent 
characterization.  
3.4 Spray Drying  
 The solid dispersions of ART and SBA-15 were formulated by using 
BÜCHI B-290 mini spray dryer (BÜCHI Labortechnik AG, Switzerland) that 
operated in inert loop mode with nitrogen purge flow. The inlet temperature 
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was maintained at 81 °C (slightly higher than the boiling point of ethanol, 
78 °C). The resulting outlet temperature at the aforesaid operating condition 
was approximately 47–53 °C. In order to formulate ART/SBA-15 (1:1 w/w) 
samples , 2 g of ART was dissolved in 200 mL of ethanol (Fisher Scientific 
Ltd., UK), to which 2 g of SBA-15 was subsequently dispersed. The mixture 
was stirred overnight. The fine liquid suspension of SBA-15 and ART was fed 
to the spray dryer via a peristaltic pump at a feed rate of 6.0 mL/min and 
sprayed into the chamber from a nozzle with 406 μm diameter at a pressure of 
0.12-0.15 MPa. Similarly, in order to formulate ART/MFQ/SBA-15 
(1:2:3 w/w/w) samples, 2 g of ART, 4 g of MFQ and 6 g of SBA-15 were 
used. In the case of solid dispersions of ART/Hsp-G (1:10 w/w) and 
ART/Stevia-G (1:10 w/w), 2 g of ART was dissolved in 250 mL of mixture of 
ethanol/water (8:2 v/v), to which 20 g of Hsp-G or Stevia-G was subsequently 
added. The inlet temperature was 120 °C and the outlet temperature was 70–
80 °C. All the samples were dried in desiccators with silica gel under reduced 
pressure for 1 day before characterization. 
3.5 Physical Mixture  
 The physical mixtures (hereafter denoted by P.M.) were prepared by 
thoroughly mixing the components in a turbula mixer (Turbula® T2F) at 
49 rpm for 30 min until a homogeneous mixture was obtained. All the P.M.s 
were characterized immediately after harvesting the samples from the glass 
vessels at the end of the mixing. Meanwhile, physical mixtures of ART/MFQ 
(1:2 w/w) were prepared by using simple mixing using spatula. 
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3.6 Surface Area and Pore Volume Analyzer 
 Nitrogen adsorption-desorption isotherms were measured by using 
Autosorb-6B gas adsorption analyzer (Quantachrome Instruments, Boynton 
Beach, FL) at -196 °C (77 K). Approximately 0.10 g of sample was used for 
each measurement. Prior to adsorption measurements, SBA-15 samples were 
degassed under vacuum at 200 °C while drug-loaded samples were outgassed 
at 40 °C under vacuum for 24 h to remove any residues and absorbed water. 
The temperature applied for the drug-loaded samples was kept low to avoid 
degradation of the drug during pre-treatment. The specific surface areas of the 
samples were assessed using the linear region of the Brunauer-Emmett-Teller 
(BET) plots. The total pore volume was estimated from the amount of N2 
adsorbed at a relative pressure of 0.95 P/Po whereas mesopore size 
distributions were computed from the adsorption branch of N2 adsorption-
desorption isotherms by means of the conventional Barrett-Joyner-Halenda 
(BJH) approach. The primary mesopore volume was calculated with the BJH 
theory and micropore volume by t-plot analysis. 
3.7  Powder X-ray Diffraction (PXRD) 
 The crystallinity of the formulated samples was characterized by 
powder X-ray diffraction (PXRD). The PXRD was performed using a D8-
Advance (Bruker, Madison, WI) X-ray diffractometer in steps of 0.028° using 
monochromatized Cu Kα radiation (λ = 0.1542 nm) as X-ray source and 




 (2θ). The measurement 
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conditions were as follows: target, Cu; filter, Ni; voltage, 40 kV; current, 10 
mA; scanning speed, 2°/min. PXRD holders were used to support samples and 
all the measurements were performed at room temperature. 
3.8 Differential Scanning Calorimetry (DSC) 
 The loaded powder samples were analyzed by using differential 
scanning calorimetry (DSC) to study the thermal behaviour of drug particles in 
the mesoporous silica. The DSC was performed concurrently using a SDT 
2960 simultaneous TGA-DSC thermo-gravimetric analyzer (TA Instrument 
Co.). Samples of 10 mg were weighted directly into open platinum pans in 
each experiment, with an empty platinum pan being the control. Before each 
analysis, the sample pans were washed with ethanol and heated with flame jet 
to remove any residues. The samples were heated from room temperature to 
170 °C under nitrogen purge flow at 100 mL/min with a heating rate of 
10 °C/min. All data handling was performed using the Universal Analysis 
2000 software package ((TA Instrument Co.). 
3.9 Thermogravimetric analysis (TGA) 
 Thermogravimetric (TA instrument, TGA-Q500) analysis was 
conducted with an automatic analyzer to determine the drug loading of co-
spray dried samples. Samples of 10 mg were used in each analysis. Weight 
changes of the samples were measured at the temperature range of 25–800 °C 
with a heating rate of 10 °C/min under a nitrogen purge flow of 40 mL/min. 
The loading of drug in mesoporous silica was determined by the weight loss. 
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3.10 Scanning Electron Microscopy (SEM) 
 The morphology of powder samples was examined by a high 
resolution scanning electron microscope (SEM, JSM-6700F, JEOL, Tokyo, 
Japan) operating at 5 keV in secondary electron imaging (SEI) and lower 
electron image (LEI) modes. Prior to analysis, samples were mounted on 
double-sided adhesive carbon tapes and coated with gold for 1 min in a sputter 
coater (Cressington Sputter Coater 208HR, UK). 
3.11 Transmission Electron Microscopy (TEM) 
 The internal pore structures of SBA-15 and drug-loaded SBA-15 were 
observed by transmission electron microscopy (TEM). High resolution TEM 
images were taken by Tecnai F20 (G
2
) (FEI, Philips Electron Optics, Holland) 
electron microscope at 200 kV. Prior to examination, powdered samples were 
deposited on a copper grid with Formvar carbon film. 
3.12 Karl Fisher Coulometric (KFC) 
 Moisture contents of all formulations were determined using Karl 
Fisher coulometric titration (coulometric titration method, 831 KF 
Coulometer, Metrohm, Metrohm Ltd. Ch-9101 Herisau, Switzerland). Sample 
powders weighing 15 mg were added into a titration vessel containing 
Hydranal
®
-Coulomat AG reagent, following equilibration of the instrument. 
The drift value and the pause time were 20 µg/min and 4 min, respectively. 
Each sample was measured in triplicates (n=3) to ensure reproducibility.  
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3.13 Dissolution Test using Flow-Through Cell (USP IV) 
Flow-through cell apparatus (Erweka Gmbh, D63150, Heusenstamm, 
Germany), representing the USP Apparatus 4 was used to study the dissolution 
rate of formulated samples. This apparatus can be operated as either an open 
loop or a close loop system. The former provides an infinite sink condition by 
a fresh medium continuously pumped through the samples whereas the latter 
provides a finite sink condition. In this research, the open loop system to 
maintain the infinite sink condition was used. 
Although USP IV was initially introduced for slow and sustained 
release, the application of USP IV for immediate release has been approved by 
FDA (Yu, 2012b) and a large number of studies about the application of USP 
IV for rapid and burst release of poorly water soluble drugs have been 
reported (Heng et al., 2008, Nicklasson et al., 1991, Waehling et al., 2011, 
Emara et al., 2009, Emara et al.,2002, Okumu et al., 2008). This wide 
application of USP IV is mainly due to the advantages of this apparatus as 
compared with others. For example, variation in the dissolution profiles of 
USP I and II have been reported, as can be attributed to, firstly, coning or dead 
zones of the apparatus and, secondly, the propensity of nanoparticles to form 
aggregates and floating drug samples (especially crystalline drug particles) on 
the surface of the medium despite the use of wetting agents such sodium lauryl 
sulphate as and sodium dodecyl sulphate (Bhattachar et al., 2002). These 
effects are observed predominantly for those drugs that have poor wettability 
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such as artemisinin. These problems necessitate the application of a USP IV 
apparatus in order to achieve acceptable and reproducible results.  
Compared with other USP dissolution apparatus, the USP IV is specially 
designed to have a small hold-up volume that helps to minimize spreading of 
drug particles to undefined sites of the apparatus. This feature is useful in the 
testing of drug powders, especially those with poor solubility and wettability, 
as spreading results in erratic and highly variable dissolution profiles 
(Langenbucher et al., 1989). The USP IV was found to be less dependent on 
the hydrodynamics and the amount of substance tested in each run, which 
generated a better overall reproducibility of the in vitro dissolution data. Some 
investigators have demonstrated that good in vitro/in vivo correlations can be 
established using the USP IV dissolution testing method (Derendorf et al., 
1983, Aiache et al., 1987, Phillips et al., 1989). Some of the applications of 
USP IV for the investigation of rapid release of poorly water soluble drugs has 
been demonstrated in the studies below:  
I. Bhattachar et al. (2002) studied the dissolution enhancement of Pfizer 
Compound PD198306 by investigating the impact of drug loading into 
a flow-through dissolution cells on dissolution rate. 
II. Sunesen et al. (2005) have used USP IV to study the in vitro/in vivo 
correlations for a poorly soluble drug, danazol. The authors found out 
that the correlations with in vivo release of danazol under fasted and 




III. Heng et al. (2008) have compared the performance of four commonly 
used dissolution tester (the paddle, rotating basket and flow-through 
cell and a dialysis method) to identify a suitable dissolution method for 
cefuroxime axetil. Their results showed the flow-through cell to be 
unequivocally the most robust dissolution method for the 
nanoparticulate system. A substantial variability was found when the 
USP II method was used, probably due to insufficient reproducibility 
of the hydrodynamic conditions in the vessel and due to wetting 
problems caused by the physical nature of cefuroxime axetil.  
IV. Nicklasson et al. (1991) have evaluated the in vitro dissolution of 
phenacetin crystals by comparing the USP IV method with the USP II. 
The USP IV method shows less variation compared with the USP II 
method. The USP IV was also found to generate faster in vitro 
dissolution rates for phenacetin than those found with the USP II 
method, probably caused by steeper concentration gradients at the 
vicinity of the crystals and by the better ability to uniformly wet the 
phenacetin crystals.  
However, some of the limitations of USP IV also cant be overlooked. 
For example, the possibility of the dissolved drug to re-crystallize in the 
sample holder due to the minute amount of dissolution medium passing 
through the drug samples. In addtion, the possibility of the undissolved 
inorganic carrier particles to form a cake (under PTFE membrane filters), 
which can block the flow of dissolution medium as well as the diffusion of the 
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dissolved drugs. Therefore the dissolution test was conducted by using both 
USP II (Section 3.14) and USP IV. 
The equipment was fitted with cells of internal diameter (i.d.) of 
12.0 mm. A glass bead with an i.d. of 6 mm were placed at the bottom of the 
cone to prevent a jet of fluid from back flowing and glass beads with 1 mm i.d 
were placed inside the dissolution chamber to generate a laminar flow. The 
tests were performed in an open loop system to maintain sink condition with 
fresh solvent from the reservoir continuously passing through the cell at 37.0 ± 
0.5 ºC pumped using a peristaltic pump at a rate of 8 mL/min. Different 
amount of samples used in each dissolution test are shown in Table 3.1. Each 
of the samples were mixed or sandwiched with 1 g of glass beads (i.d. 1 mm) 
and placed inside the dissolution chamber. PTFE membrane filters (pore size 
0.45 μm) were placed at the bottom and the top of the dissolution chamber to 
retain the undissolved samples. During the dissolution tests, the fluid passing 
through the cells was collected, the accumulated volume was weighed and the 
exact volume was calculated based on the density of water. Subsequently, 
3 mL aliquots of the dissolution medium were withdrawn from the vessel at 
intervals of 5, 10, 15, 30, 60 and 120 min, filtered over PTFE membrane filters 
(pore size 0.45 μm). The drug concentration was determined by means of high 
performance liquid chromatography (HPLC, Agilent 1100 series). Based on 
the concentration and the volume of the collected samples at different time 
intervals, the exact amount of the dissolved drug was calculated. Drug release 
from the formulated solid dispersions was compared with that from their 
corresponding untreated crystalline drugs and physical mixtures. All 
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experiments were performed in triplicates (n=3) and the results were registered 
as an average with standard deviation. 
Table 3.1 Amounts of samples used for dissolution test under sink condition 












ART 10 10 – – 
Spray dried ART 10 10 – – 
MFQ 20 – 20 – 
ART/MFQ 
(1:2 w/w) 
30 10 20 – 
ART/AC  
(1:1 w/w) 
20 10 – 10 
ART/SBA-15 
(1:1 w/w) 
20 10 – 10 
ART/Hsp-G 
(1:10 w/w) 
110 10 – 100 
ART/Stevia-G 
(1:10 w/w) 
110 10 – 100 
ART/MFQ/SBA-
15 (1:2:3 w/w/w) 
60 10 20 30 
3.14 Dissolution Test using In Vitro Dissolution Tester (USP II)  
 The supersaturation of ART and MFQ was established under non-sink 
condition by using an in vitro dissolution tester, USP II, Agilent 708-DS 
Dissolution Apparatus. The total amount of samples used in this study was 
equivalent to 200 mg of ART and 400 mg of MFQ. Drug release from the 
SBA-15 formulations was compared with that from the corresponding 
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crystalline drugs. The amount of samples used in each dissolution test is 
shown in Table 3.2. Each of the samples was mixed with 800 mg of cornstarch 
and pressed to a tablet (i.d. 13 mm) at a pressure of 75 MPa to characterize the 
drug release profile. The tests were executed in 900 mL of distilled water (D.I 
water) at 37 ± 0.5 ºC with a paddle speed of 100 rpm. Subsequently, 3 mL 
aliquots of the dissolution medium were withdrawn from the vessel at interval 
of 5, 10, 15, 30, 60 and 120 min and replaced by fresh dissolution medium. 
The collected samples were filtered over PTFE membrane filters (pore size 
0.45 μm).  
 In addition, USP II also was used to quantify the dissolution rate 
(under sink condition) of SBA-15 related samples as a comparison and also to 
study the dissolution of samples after 6-months of storage. Tablets of samples 
with an amount equivalent to 50.0 ± 1.0 mg ART and 100.0 ± 1.0 mg MFQ 




Table 3.2 Amounts of samples used for dissolution test under non-sink condition 












ART 200 200 – – 
 




600 200 400 – 
ART/AC 
(1:1 w/w) 
400 200 – 200 
ART/SBA-15 
(1:1 w/w) 
400 200 – 200 
ART/Hsp-G 
(1:10 w/w) 
2200 200 – 2000 
ART/Stevia-G 
(1:10 w/w) 
2200 200 – 2000 
ART/MFQ/SBA-
15 (1:2:3 w/w/w) 
1200 200 400 600 
3.15 Chemical and Physical Stability  
 Physical and chemical stability tests of spray dried solid dispersions at 
controlled temperature and relative humidity (RH) were conducted based on 
the procedures from the International Conference on Harmonization (ICH)-
ICH Q1A (R2). The samples were tested for 3- and 6-months under different 
storage conditions: open pan inside desiccators (25 ºC/18% RH); open pan (25 
ºC/75% RH); open pan (40 ºC/75% RH); Activ-Vial
®
 (25 ºC) and Activ-Vial
®
 
(40 ºC). The Activ-vial
®
 consists of a flip-top closed vial with integrated 
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molecular sieve sleeves that prevent moisture by providing a greater moisture 
adsorptive capacity than ordinary silica gel. The physical stability of all the 
samples was analyzed using PXRD; the chemical stability was investigated 
using HPLC.  
3.16 In vitro cytotoxicity  
The in vitro cytotoxicity tests of the ART, SBA-15 and solid dispersions were 
evaluated by the standard flow-cytometric technique on human colon 
carcinoma (Caco-2) cells. Caco-2 cells were cultured using the Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% phosphate 
buffered saline (PBS) and 1% penicilline-streptomycin solution in 75-cm
2
 
culture flasks. Cells were cultivated in an incubator at 37 ºC with 5% carbon 
dioxide. Prior to each test, the cells were washed with PBS, trypsinized, 
pelleted at 1500 rpm for 5 min and re-suspended in DMEM. The cells were 
seeded in 12 well plates (Costar, IL, USA) at 5×10
5
 cells/well (1 mL) and 
incubated for 24 h. Then, the medium was replaced with sample suspensions 
at different concentrations and incubated for 24 h. After incubation, the wells 
were washed with PBS to remove excess particles and the cells were then 
harvested with trypsin solution. After being centrifuged at 1500 rpm for 5 min, 
the pellets were re-suspended in PBS. In order to distinguish cellular debris 
and living cells in the flow cytometeric analysis, Caco-2 cells were further 
stained with propidium iodide (PI, Becton Dickinson, Franklin Lakes, NJ, 
USA). The dead cells were measured using a FACSCalibur with CellQuest 
software (BD Biosciences, San Jose, CA). The data were derived from a 
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minimum of 10,000 events per sample measurement. Each sample was tested 
in triplicates (n=3). Untreated cells were used as controls. 
3.17 Method of Analysis  
 The concentration of ART was measured by HPLC (Agilent 1100 
series) equipped with Eclipse XDB C18 (150 mm × 4.6 mm (i.d.) × 5 μm) 
(Eka Chemicals AB, Sweden) column (Stringham et al., 2009, Liu et al., 
2010a). The mobile phase consisted of 50% of ultrapure water and 50% 
acetonitrile (HPLC grade). The flow rate was maintained at 1.0 mL/min and 
the UV detector was operated at a wavelength of 210 nm. Drug content was 
determined by calculating the peak area at 9.3 min. For MFQ, the 
concentration of the samples was measured by means of HPLC (Agilent 1100 
series) equipped with Inertsil C8-3 (150 mm × 4.6 mm (i.d.) × 5 μm) (GL 
Sciences Inc., Tokyo, Japan) column (Lai et al., 2007). The mobile phase 
which consisted of MeOH, acetonitrile and 0.05 M KH2PO4 (55:9:35, v/v/v) 
adjusted to pH 3.9 with 0.5% orthophosphoric acid was filtered through a 
0.2 µm nylon filter. The flow rate was maintained at 1.00 mL/min and the UV 
detector was operated at a wavelength of 284 nm. Drug content was 
determined by calculating the peak area at 6.8 min. All the measurements were 
carried out in triplicates (n=3) to ensure replicability. 
3.18 Statistical analysis  
Data were processed using Microsoft Excel 2003 software. Each sample was 
tested in triplicates and the mean ± standard deviation is reported. Two sample 
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comparisons of means were carried out using Student’s t-test analysis and 




Chapter 4 Formulation of Amorphous ART using Activated 
Carbon 
 ART was formulated into solid dispersions by using porous activated 
carbon (AC) to enhance its dissolution rate, supersaturation and 
physicochemical stability. AC was chosen as a drug carrier due its remarkable 
structural properties, biocompatibility and cost-effectiveness. It was expected 
that ART/AC would be able to form amorphous solid dispersions even at 
higher drug loading due to its high specific surface area, large pore volume 
and strong adsorption capacity. Therefore, solid dispersions of ART/AC at 
drug loadings from 25 wt% to 80 wt% were prepared by using co-spray drying 
(Figure 4.1) and their dissolution rate and solubility were investigated. Both 
moderate and stressed conditions were used to study the physicochemical 
stability of the formulated samples. 
 





4.1 Surface Area and Pore Volume after Drug Loading  
 N2 adsorption was conducted to understand the changes in pore 
structures of AC before and after co-spray dying with ART. The N2 
adsorption/desorption isotherms for ART/AC samples with different degrees 
of drug loading are presented in Figure 4.2. The changes in the surface area 
and total pore volume of AC are summarized in Table 4.1. The isotherm of 
AC is similar to the type IV isotherm with a clear hysteresis loop from a 
relative pressure of 0.04 to 1.0, indicating that most of the pores are in the 
mesoporous range. However, the pore size distribution of AC is not uniform 
(Figure 4.3) as compared with other reported activated carbons, such as 
uniform mesoporous carbon spheres (UMCS) and fibrous ordered mesoporous 
carbon (FOMC) (Zhao et al., 2012b). The amount of N2 adsorbed onto AC 
was reduced drastically after co-spray drying with ART. The surface area and 
the total pore volume for the ART/AC (1:3 w/w) sample declined with respect 
to those of the AC-only samples, i.e. from 1364.1 to 478.6 m2/g and from 1.45 
to 0.48 cm3/g, respectively.  
 The significant reduction in N2 adsorption, alongside the decrease in 
the total pore volume and surface area of AC, suggested that most of the pore 
channels of AC were occupied by ART molecules after co-spray drying. The 
large surface area (1364.1 m2/g) and pore volume (1.45 cm3/g) of AC 
contribute to its high encapsulation capacity and drug loading efficiency. This 
is illustrated by the findings that about 90% of the ART used in each 
formulation of solid dispersions was encapsulated in the porous structures of 
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AC and that the final drug loading is close to the designated value (Table 4.2). 





Figure 4.2 N2 adsorption-desorption isotherms of AC before and after co-spray drying 
with ART. 
 
Figure 4.3 Pore size distribution of AC. 
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Table 4.1 Pore volume and surface area of AC before and after co-spray drying with 
ART 








AC  1364.1 ± 64.0 1.45 ± 0.23 
ART/AC (1:3 w/w) 478.6 ± 40.5 0.48 ± 0.16 
ART/AC (1:1 w/w) 24.4 ± 30.8 0.05 ± 0.04 
ART/AC (2:1 w/w) 25.6 ± 13.9 0.08 ± 0.02 
ART/AC (3:1 w/w) 19.8 ± 9.7 0.07 ± 0.02 
ART/AC (4:1 w/w) 15.5 ± 12.8 0.05 ± 0.01 
Data represent mean ± S.D., n=3 
Table 4.2 Drug loading of ART in AC 






ART/AC (1:3 w/w) 25 23.6 ± 0.9 94.4 ± 3.6 
ART/AC (1:1 w/w) 50 45.0 ± 2.8 90.0 ± 5.6 
ART/AC (2:1 w/w) 67 64.9 ± 0.8  96.9 ± 1.2 
ART/AC (3:1 w/w) 75 72.6 ± 1.0 96.8 ± 1.3 
ART/AC (4:1 w/w) 80 79.6 ± 0.5 99.5 ± 0.6 
Data represent mean ± S.D., n=3 
4.2 Thermal Analysis 
 The thermal behavior of untreated ART and co-spray dried ART/AC at 
different weight ratios was analyzed by using DSC (Figure 4.4). The DSC 
curve of untreated ART is found to have an intense endothermic peak at 
153.4 °C, with an enthalpy of fusion of 73.0 J/g (Table 4.3), similar to that 
reported by Kakran et al. (2011). In comparison, for drug-loaded samples, the 
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DSC curves are found to have endothermic peaks with a decreased intensity, 
each with a lower corresponding temperature. Amongst the drug-loaded 
samples, the ART/AC (2:1 w/w), ART/AC (3:1 w/w) and ART/AC (4:1 w/w) 
exhibited lower heat of fusion and their endothermic peaks are at 144.2, 147.3 
and 149.4 °C, respectively, In addition, combination of two endothermic peaks 
can be observed for both the ART/AC (3:1 w/w) and ART/AC (4:1 w/w) 
samples which might be due to the presence of different polymorphs of ART. 
This is in good agreement with the results reported by Chan et al. (1997), 
whereby two types of polymorphs (orthorhombic and triclinic) have been 
observed. On the other hand, the ART/AC (1:3 w/w) and ART/AC (1:1 w/w) 
samples did not exhibited observable endothermic peaks. 
 The intense endothermic melting peak of ART at 153.4 °C shows the 
crystalline nature of the untreated ART. Since the heat of fusion is 
proportional to the crystallinity of the solid dispersions (Sahoo et al., 2011b), 
the decrease in endothermic peak intensity and heat of fusion of the drug-
loaded samples indicates the reduction in crystallinity of ART upon its 
encapsulation into the pores of AC. The shift of endothermic peak 
temperatures of co-spray dried samples to lower values may be attributed to 
the interaction between ART and AC as proposed by Zhao et al. (2012a) and 
Shen et al.(2011). The absence of endothermic melting peak for ART/AC 
(1:3 w/w) and ART/AC (1:1 w/w) samples suggest that the ART adsorbed 
onto AC lacked crystalline structure and were hence in amorphous form. The 
amorphization of ART in the ART/AC samples could be attributed to the 
nano-confinement of ART in the pore of AC and rapid evaporation of organic 
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solvent during co-spray drying. During co-spray drying, the AC particles 
allow entrapment of the dissolved ART within the pores of AC through 
capillary condensation. This prevents the nucleation and growth of large ART 
crystals. The spray dried ART particles will remain in amorphous form in the 
confined pores of AC after the organic solvent was removed. 
 
Figure 4.4 DSC curves of (a) untreated ART crystals, (b) ART/AC (4:1 w/w), (c) 








Table 4.3 Melting temperatures (Tm) and heat of fusion (ΔHf) of untreated ART and 








Untreated ART 153.4 ±2.8 73.0 ± 5.8 - 
ART/AC (1:3 w/w) - - - 
ART/AC (1:1 w/w) - - - 
ART/AC (2:1 w/w) 144.2 ± 1.2 6.1 ± 1.6 8.6 ± 2.4 
ART/AC (3:1 w/w) 147.3 ± 1.1 9.8 ± 0.8 13.8 ± 1.6 
ART/AC (4:1 w/w) 149.4 ± 0.8 17.9 ± 4.5 24.6 ± 6.5 
%Crystallinity was calculated based on the equation reported by Khanfar et al. (2013) 
Data represent mean ± S.D., n=3. 
4.3 Solid State 
 Figure 4.5 displays the PXRD patterns of ART and solid dispersions of 
ART/AC with different extents of drug loading. As anticipated, the untreated 
ART exhibited a highly crystalline nature with intense PXRD peaks. The 
untreated ART crystals show numerous distinct sharp peaks at 2θ values of 
7.3°, 11.8°, 14.7° and 22.1°, indicating that the bulk ART is present in the 
orthorhombic crystal form (Kakran et al., 2011). In addition, ART that spray 
dried without AC retained the X-ray diffraction characteristic peaks as 
crystalline ART, even though the intensity of the peaks was decreased. This 
indicates, although the degree of crystallinity of ART decreased after spray 
drying, the polymorphic conversion and amorphization may not be feasible 
without presence of carriers. This signifies the role of AC as a carrier in 
amorphization of ART via co-spray drying. 
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 The co-spray dried ART/AC samples showed less intense X-ray 
diffraction peaks compared with the untreated ART crystals. The intensity of 
the PXRD peaks decreases as both the drug loading and the crystallinity of 
ART decreased from ART/AC (4:1 w/w) to ART/AC (1:3 w/w). The flat 
PXRD pattern of ART/AC (1:3 w/w) and the weak diffraction peak of 
ART/AC (1:1 w/w) indicate that most of the ART entrapped in the pore 
structures are in the X-ray amorphous form. The presence of a small amount 
of crystals in ART/AC (1:1 w/w) could be detected by PXRD but not by DSC. 
The PXRD patterns of the other three solid dispersions (ART/AC > 1:1 w/w) 
are similar to that of untreated ART, especially the characteristic peak at 
11.8°. This demonstrates the presence of partially crystalline ART in ART/AC 





Figure 4.5 PXRD patterns of (a) ART/AC (1:3 w/w), (b) ART/AC (1:1 w/w), (c) 
ART/AC (2:1 w/w),(d) ART/AC (3:1 w/w), (e) ART/AC (4:1 w/w), (f) spray dried 
ART and (g) untreated ART crystals. 
4.4 Morphology 
 The morphologies of all the unprocessed and processed samples were 
characterized by using SEM images as shown in Figure 4.6. Apparently, the 
crystalline nature of untreated ART could be seen clearly from Figure 4.6(a) 
and the crystalline form of ART did not change after co-spray dried without 
any excipients [Figure 4.6(b)]. Figure 4.6(a) and (b) also show the 
orthorhombic forms with prism and rod-like sub-particles of ART. The 
particle size of the spray dried ART (0.5–10 μm) is 100 times smaller than the 
untreated ART crystals (50–1000 μm). In this regard, Sahoo et al. (2010) have 
reported the reduction in particles size of ART to the range of 1−5 µm by 
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using a modified multi-fluid nozzle pilot spray dryer. However, the inlet 
temperature used in their study was 140 ºC, which is significantly higher than 
that used in the present work (81ºC). Figure 4.6(c) depicts the irregular shape 
with rough surfaces and sharp edges of AC. Such rough surfaces might be due 
to the presence of porous structures on the surface of AC. Mesoporous carbons 
with different structures have been reported in the literature. For example, 
Zhao et al. (2012a) have studied two types of mesoporous carbons, uniform 
mesoporous carbon spheres (UMCS) and fibrous ordered mesoporous carbon 
(FOMC) and found that the former has uniform and spherical structures 
whereas FOMC has fibrous structures. 
 Figure 4.6(d)-(h) illustrate the morphology of ART/AC solid 
dispersions with different extents of drug loading. When the ratio of ART/AC 
is below 1:1 w/w, as for ART/AC (1:3 w/w) [Figure 4.6(d)] and ART/AC 
(1:1 w/w) [Figure 4.6(e)], the morphology is similar to that of AC with sharp 
edges and rough surfaces, as most ART molecules were entrapped inside AC 
pores. In comparison, when the ratio of ART/AC increased to 2:1 w/w or 
above, as for ART/AC (2:1 w/w), ART/AC (3:1 w/w) and ART/AC (4:1 w/w) 
[Figure 4.6(f)-(h)], the morphologies were changed significantly. Additional 
particles with smooth edges were observed on the surface. With such extents 
of drug loading, the amount of ART exceeded the capacity of total pore 
volume of AC, thus part of ART remained on the external surface of AC to 
form surface particles after being co-spray dried.  
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 Further inferences could be drawn by examining the morphology in 
SEM images. Firstly, the particle size of ART formed on the surface of AC 
was much smaller than that of raw and spray dried ART. During co-spray 
drying, the atomization of ART solution was affected by the presence of AC 
particles. The moving inorganic AC particles prevent the formation of large 
ART crystals. Secondly, the prism and rod-like structures of ART are not 
found in all of the four solid dispersions with AC, which could be attributed to 
the amorphization and decrease in the crystallinity of ART. This is in contrast 
to the observations of Sahoo et al. (2010) who reported the formation of solid 
dispersion of ART by using PVP and PEG as hydrophilic carriers via co-spray 
drying. The morphology of the formulated solid dispersions showed that PVP 
and PEG did not mix homogeneously with ART, resulting in free ART 
particles which were observed in the solid dispersions even at higher contents 




Figure 4.6 SEM images of (a) untreated ART, (b) spray dried ART crystal, (c) AC, 
(d) ART/AC (1:3 w/w), (e) ART/AC (1:1 w/w), (f) ART/AC (2:1 w/w), (g) ART/AC 




4.5 Dissolution Rate under Sink Condition 
 In vitro drug release studies of co-spray dried ART/AC samples were 
performed in order to demonstrate the significance of AC in improving the 
dissolution kinetics of ART. This dissolution study was performed using 
distilled water instead of simulated gastrointestinal fluids since ART is a 
neutral compound whose dissolution is not pH-dependent (Hoa et al., 1996). 
Figure 4.7 shows the in vitro dissolution profile of untreated ART and 
ART/AC solid dispersions with different drug loadings. Untreated ART 
crystals have a very poor dissolution rate in water, as indicated by a meager 
26.7% of drug release of ART after 30 min. Furthermore, the dissolution rate 
of untreated ART was consistently low throughout the experiment and only 
56.7% of the ART was dissolved after 120 min. Relative to untreated ART 
crystals, the physical mixtures of ART and AC are also found to have a poor 
drug release profile: only 26.9% and 41.5% of ART dissolved from P.M.-
ART/AC (1:1 w/w) and P.M.-ART/AC (2:1 w/w), respectively, at the end of 
the dissolution test after 2 h. Physically mixing ART with AC appears to 
decrease the dissolution of the crystalline drug. This decrease might be due to 
the strong adsorption capacity of AC, which able to re-adsorb the dissolved 
ART. On the other hand, for the spray dried ART, the dissolution was 
observed to be 52.9% (p < 0.05) and 61.9% in 30 and 120 min, respectively. 
Similarly, the co-spray dried samples also [except ART/AC (1:3 w/w)] 
exhibited an improved dissolution rate compared with the untreated ART and 
with the physical mixtures. For the spray dried ART/AC samples, within the 
first 30 min, dissolution was observed to be approximately 61.7% (p < 0.05), 
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74.6% (p < 0.05), 82.1% (p < 0.05) and 87.5% (p < 0.05) of ART for ART/AC 
(1:1 w/w), ART/AC (2:1 w/w), ART/AC (3:1 w/w) and ART/AC (4:1 w/w), 
respectively, before equilibrium was attained. However, ART/AC (1:3 w/w) 
sample show very poor results throughout the dissolution process with 
approximately 15% of ART was dissolved. Similar type of study has been 
conducted by Wang et al. (2011a) whereby dissolution enhancement of 
ibuprofen by using ordered mesoporous carbon via solvent evaporation was 
reported and all the drug-loaded samples reach 60–70% drug release in one 
hour.  
 The dissolution improvement in spray dried ART can be attributed to 
the particle size reduction as suggested by the Noyes-Whitney equation 
(Noyes and Whitney, 1897). The SEM images in Figure 4.6 indicate that the 
particle size of ART was reduced significantly after being spray dried, 
resulting in augmented specific surface areas exposed to dissolution medium 
compared with their crystalline counterpart. This confirms the significance of 
particle size reduction on dissolution enhancement, as observed with other 
reported studies (Zhang et al., 2009b, Brion et al., 2009).  
 Several reasons underlie the dissolution enhancement of ART/AC solid 
dispersions compared with the untreated ART samples. Firstly, the rapid 
dissolution of ART from the solid dispersion with a lower extent of drug 
loading (ART/AC < 1:1 w/w) is contributed by the amorphous state of ART 
entrapped inside the porous structures as revealed by PXRD and DSC. The 
amorphous form of pharmaceutically active materials represents the most 
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energetic solid state, which provides the greatest advantage in terms of 
bioavailability and solubility (Hancock and Zografi, 1997). It has also been 
reported that the amorphization of drugs increases the molecular motion and 
reduces the binding energy of drug particles, subsequently resulting in the 
increases in dissolution rate (Zhao et al., 2012a). Secondly, in solid 
dispersions with a higher extent of drug loading (ART/AC > 1:1 w/w), ART 
will be in partially crystalline form, which distributed in two phases; ART 
entrapped in AC pore structures and ART remained on external surface. These 
partially crystalline ART particles are highly dispersed with reduced in 
crystallinity and particle size. Simultaneous decrease in crystallinity and 
particles size can remarkably enhance the dissolution rate of ART due to the 
increase in solubility and surface area of the particles in contact with the 
dissolution medium. 
 Although all the solid dispersions, except ART/AC (1:3 w/w), 
exhibited enhanced dissolution rate compared with the raw ART and physical 
mixtures, the total amount of drug dissolved at the end of the dissolution test 
still leaves room for improvement. The release of ART from solid dispersions 
achieved equilibrium after 30 min, with the systems failed to reach a 100% of 
drug release after 120 min. The total amount of ART dissolved before the 
attainment of equilibrium decreases with increasing amounts of AC in the 
solid dispersions. For example, about 90% of ART dissolved from the 
ART/AC (4:1 w/w), whereas only 15% and 60% ART dissolved from the 
ART/AC (1:3 w/w) and ART/AC (1:1 w/w) samples, respectively. Therefore, 
it can be deduced that the presence of AC might affect the total release of 
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ART prior to the equilibrium. The explanation for this lies in the large surface 
area and strong adsorption capacity of AC, onto which the dissolved drugs 
could re-adsorbed.  
 
Figure 4.7 Dissolution profiles (sink condition) of (a) ART/AC (1:3 w/w), (b) P.M.-
ART/AC (1:1 w/w), (c) P.M.-ART/AC (2:1 w/w), (d) untreated ART crystal, (e) 
spray dried ART, (f) ART/AC (1:1 w/w), (g) ART/AC (2:1 w/w), (h) ART/AC 
(3:1 w/w) and (i) ART/AC (4:1 w/w). n=3, p < 0.05 versus free ART. 
4.6 Supersaturation under Non-Sink Condition 
 Dissolution profiles of ART/AC were examined under non-sink 
conditions to evaluate the supersaturation of ART. Figure 4.8 illustrates the in 
vitro dissolution profile (under non-sink condition) of untreated ART and 
ART/AC solid dispersions with different extents of drug loading. The amount 
of ART/AC used is equivalent to 200 mg of ART. The obtained 
supersaturation of ART (48.4 µg/mL) is almost similar to the reported 
literature value: 48 µg/mL (aqueous solubility of ART at 37 °C) (Ferreira et 
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al., 2013). The co-spray dried ART/AC dispersions enhanced the 
supersaturation of ART compared with the untreated ART. The ART/AC 
samples could achieve an apparent solubility of approximately 86–95 µg/mL 
(p < 0.05). 
 The amorphization and decrease in crystallinity and particle size of 
ART are the main factors for the enhancement of supersaturation of treated 
ART compared with that of the untreated ART. It has been reported that 
amorphous APIs are remarkably more soluble than their crystalline 
counterparts (Hancock and Parks, 2000). The improved supersaturation of 
amorphous APIs is due to the higher free energy and greater molecular motion 
of solids in the amorphous form compared with those in the crystalline form, 
which have undesirably higher lattice energy and lower solvation energy (Van 
den Mooter, 2012, Murdande et al., 2010a). This difference translates into the 
fact that no additional energy is required to solvate or hydrate the amorphous 
ART. In addition, the reduction in particle size also contributes to the 
solubility enhancement of ART. The particle size of all the four solid 
dispersions of ART/AC is much smaller than the untreated ART crystals. The 
amorphous ART which undergoes reduction in particles size will have a 
reduced radius of curvature that can contribute to improved supersaturation 
compared with the crystalline counterpart. The relationship between the 
particles size and supersaturation of amorphous solids is illustrated by the 




Figure 4.8 ART dissolution profiles using equivalent of 200 mg of untreated ART 
and formulated ART under sink conditions using USP II. n=3, p < 0.05 versus free 
ART. 
4.7 Chemical Stability Evaluation 
 The chemical stability of amorphous ART under two different storage 
conditions was examined by using HPLC after 1-week and 3-months of 
storage. Samples of ART/AC (1:3 w/w), ART/AC (1:1 w/w) and ART/AC 
(4:1 w/w) were chosen for the chemical stability test with untreated ART and 
spray dried ART as controls. The untreated ART and spray dried ART could 
preserve more than 99% of drug without degradation after storage at 
40 °C/75% RH in open pans for 12-months (Table 4.4), attesting to the 
chemical stability of crystalline drugs under stressed condition. However, the 
co-spray dried samples show poor chemical stability under both the stressed 
(40 °C/75% RH) and mild (25 °C/18% RH) conditions (Table 4.5). The 
samples started to degrade drastically within the first-week upon storage and 
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completely degraded after 3-months; with particle agglomeration and 
formation of sticky samples was observed. The poor chemical stability of 
treated ART might have been attributed to the amorphization of ART and the 
catalytic activity of AC. With regards to the catalytic activity, it can be 
surmised that the AC which is widely used as a catalyst for the decomposition 
of hydrogen peroxide (Aguinaco et al., 2011, Rey et al., 2011) could have 
accelerated the degradation of ART by reacting with peroxide bridge in ART 
molecules. Therefore, apart from the strong adsorption capacity of AC, the 
degradation of ART could be another reason for poor dissolution of the treated 
ART. 
Table 4.4 Percentage of ART remained after stored at 40 ºC/75 %RH 
Sample % of ART after 12-months 
ART  99.4 ± 1.6 
Spray dried ART  98.8 ± 1.8 




Table 4.5 Percentages of ART remaining in co-spray dried ART/AC after storage 
under 2 different storage conditions for 1-week and 3-months 
Sample Storage conditions % of ART remaining 
1-week 3-month 
ART/AC (1:3 w/w) Desiccators 
(25 °C/18% RH) 
19.9 ± 0.1 0 
Open pan 
 (40 °C/75% RH) 
0 0 
ART/AC (1:1 w/w) Desiccators 
 (25 °C/18% RH) 
28.9 ± 0.8 0 
Open pan 
 (40 °C/75% RH) 
0 0 
ART/AC (4:1 w/w) Desiccators 
 (25 °C/18% RH) 
32.9 ± 1.4 0 
Open pan 
 (40 °C/75% RH) 
0 0 
Data represent mean ± S.D., n=3 
4.8 Conclusions 
 Confinement of ART into the pores of AC produced amorphous forms 
with reduced particle size. Co-spray drying of ART with AC at high drug 
loading (ART/AC > 1:1 w/w) led to the formation of partial crystalline ART 
with two different polymorphs. The amorphization or reduction in crystallinity 
and particle size reduction are the important factors that contributed to the 
enhancement in dissolution rate and supersaturation of ART. Although the 
untreated ART and spray dried ART remain chemically stable for 12-months 
of storage test, the formulated samples show poor chemical stability under 
stressed and moderate conditions within the first month of storage, which 
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might adversely affect the drug release of ART. The poor stability of 




Chapter 5 Nano-Confinement of ART in SBA-15 
 Activated carbon was replaced by ordered mesoporous silica, SBA-15 
as a carrier to enhance the biopharmaceutical properties of ART. On the other 
hand, non-porous silica was used as a carrier to investigate the confinement of 
ART molecules inside the pore channels of SBA-15 and not on the external 
surface. The solid dispersions were formulated via co-spray drying (Figure 
5.1) with drug loadings lesser than 50 wt% since crystalline particles were 
observed for ART/AC at drug loading above 50 wt%. Since the formulation of 
amorphous forms is the objective of this research, attention was devoted to 
samples with drug ratios below 50% w/w and samples with drug loading 
above 50% w/w were formulated as a control. Meanwhile, more storage 
conditions were used to test the stability of the formulated solid dispersions: 
desiccators (25 °C/18% RH), Activ-vial
®
 (25 °C), open pan (25 °C/75% RH), 
Activ-vial
® 
(40 °C) and open pan (40 °C/75% RH). Since the capability of 
SBA-15 to improve the physicochemical stability of different types of poorly 
water-soluble drugs has been reported previously, it was expected that the 
physicochemical stability of amorphous ART could be retained by SBA-15 
especially under moderate storage conditions. Additionally, the 





Figure 5.1 Schematic diagram of formulation of ART/SBA-15 solid dispersion via 
co-spray drying. 
5.1 Changes to Pore Structure after Drug Loading  
 Figure 5.2 and Figure 5.3 display the nitrogen adsorption-desorption 
isotherms and pore size distributions of SBA-15 and co-spray dried 
ART/SBA-15 samples, respectively. Table 5.1 lists the average pore size (d), 
Brunauer-Emmett-Teller (BET) specific surface area (SBET) and total pore 
volume (Vpore) of the samples. According to the International Union of Pure 
and Applied Chemistry (IUPAC) classification, SBA-15 and drug-loaded 
samples illustrate the typical type IV adsorption isotherm containing the H1 
hysteresis loop in the range of P/P0 at 0.50–0.77, associated with mesoporous 
materials (Wu et al., 2012). Furthermore, based on Barrett-Joyner-Halenda 
(BJH) analysis, SBA-15 has a uniform pore size distribution with a mean pore 
size of approximately 8.7 nm. The total pore volume and BET surface area of 
SBA-15 are 1.16 cm
3
/g and 809.0 m
2
/g, respectively.  
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 Once co-spray dried with ART, the pore size of ART/SBA-15 
(1:3 w/w) reduced to 7.3 nm together with a decline in the amount of N2 
adsorbed. Correspondingly, the surface area and the total pore volume 
decreased to 370.7 m
2
/g and 0.63 cm
3
/g respectively. With the loading 
increased to 1:1 w/w, a further reduction was observed in these three 
parameters: the total pore volume declined to 0.20 cm
3
/g, the surface area 
reduced to 112.8 m
2
/g and the pore diameter shrank to 6.4 nm. The reduction 
of pore diameter, pore volume and surface area of SBA-15 indicate that most 
of the mesoporous channels were occupied with ART molecules through co-
spray drying. The narrowed hysteresis loop and the reduced amount of N2 
adsorbed suggest a limited size and number of pores after the encapsulation of 
ART. Moreover, the capillary condensation of the ART/SBA-15 samples 
shifted to lower relative pressures upon encapsulation of ART due to reduced 
pore size (Guo et al., 2013). Once the drug loading was increased to above 50 
wt% [ART/SBA-15 (3:1 w/w)], the pore volume, surface area and N2 
adsorption of co-spray dried samples shrank to almost non-porous materials as 





Figure 5.2 N2 adsorption-desorption isotherms of SBA-15 before and after co-spray 
drying with ART. 
 
 





Table 5.1 Pore volume, surface area and average pore size of SBA-15 before and 
after co-spray drying with ART 














370.7 ± 41.8 0.63 ± 0.04 7.34 ± 0.53  
ART/SBA-15 
(1:1 w/w) 
112.8 ± 24.5 0.20 ± 0.04 6.40 ± 0.32 
ART/SBA-15 
(3:1 w/w) 
36.6 ± 3.3  0.07± 0.01  4.60 ± 0.01  
Data represent mean ± S.D., n=3 
5.2 Drug Loading Efficiency 
 The encapsulation efficiency of SBA-15 was quantified by measuring 
the ART loading in the pore channels of SBA-15. ART-loaded samples 
weighing 5 mg were extracted with 50 mL of ethanol with stirring for 24 h, 
followed by filtration and analysis by HPLC. Table 5.2 outlines the drug 
loading efficiency of ART/SBA-15 samples at different drug ratios. The drug 
loading of ART/SBA-15 (1:3 w/w) and ART/SBA-15 (1:1 w/w) that represent 
the drug uptake by SBA-15 particles was 23.6 wt% and 48.8 wt% 
respectively. It is shown that more than 94% of ART in the designed 
formulation was loaded onto SBA-15. The obtained results are in agreement 
with results of thermal gravimetric analysis (TGA) (Figure 5.4). The high drug 
loading efficiency is mainly due to the high BET specific surface area and the 
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large pore volume of SBA-15, together with the efficiency of spray dying 
technique. 
In addition, the nano-confinement of ART inside the pore channels of 
SBA-15 can be investigated by correlating the drug loading and the pore 
volume reduction of SBA-15. The pore volume reduction is approximately 
equal to the theoretical volume of ART used for formulation. For example, the 
drug loading based on HPLC results indicates that in 1 g of ART/SBA-15 
(1:1) sample contained 0.488 g of ART and 0.512 g of SBA-15. Since the total 
pore volume of SBA-15 is 1.16 cm
3
/g, the available pore volume in 1 g of 
ART/SBA-15 (1:1) for ART inclusion was 1.16 × 0.512 = 0.59 cm
3
/g. 
Referring to the specific volume of ART (0.806 cm
3
/g), the total volume that 
was able to be occupied by ART was 0.488 × 0.806 = 0.39 cm
3
/g. Finally the 
calculated unoccupied pore volume of ART/SBA-15 (1:1) was 0.59 − 0.39 = 
0.20 cm
3
/g. This calculated unoccupied pore volume of the sample is the same 
as the BET result (Table 5.1) measured by N2 adsorption, indicating that most 
of the ART is inserted within the mesopores of SBA-15 and cause the 








Table 5.2 Drug loading of ART inside mesoporous silica 
Sample Theoretical drug 
loading [wt%] 
Drug Loading  





25 23.6 ± 1.2 94.4 ± 4.8 
ART/SBA-15 
(1:1 w/w) 
50 48.8 ± 1.1 97.6 ± 2.2 
Data represent mean ± S.D., n=3 
 
Figure 5.4 Thermograms of (a) untreated ART crystals, (b) ART/ SBA-15 (1:1 w/w) 




5.3 X-Ray Diffraction Analysis 
 The PXRD patterns of untreated ART, co-spray dried samples and 
physical mixtures are depicted in Figure 5.5. Intense PXRD peaks of untreated 
ART with 4 main characteristic peaks at 7.3°, 11.8°, 14.7° and 22.1° 
exemplify the typical reflections of the orthorhombic polymorphic form of 
ART as consistent with previous literature (Ambrogi et al., 2013). The co-
spray dried ART/SBA-15 samples with drug loadig lower than 50 wt.% 
display PXRD patterns without observable peaks attributable to the crystalline 
ART, indicating that no crystalline ART was detected by X-ray diffraction. 
The physical state of ART is fundamentally changed from the crystalline form 
to the amorphous after co-spray dried with SBA-15. However, PXRD peaks 
assigned to crystalline ART were detected for ART/SBA-15 (3:1 w/w) 
sample, indicating ART could be re-crystallized and remained on the external 
surface once the pore volume was fully occupied at drug loading above 50 
wt.%. Similarly, the physical mixtures of ART/SBA-15 also exhibited strong 
X-ray diffraction intensity with the same pattern of raw ART, since the 
physically mixed samples still exhibited completely crystalline forms. 
 The amorphization of ART is mainly due to the confinement of the 
drug within nano-sized pore channels of SBA-15 through capillary 
condensation and the subsequent rapid evaporation of the organic solvent 
during formulation (Planinšek et al., 2011), which prevent the nucleation and 
the formation of long-range ordered crystalline structures (Ambrogi et al., 
2013). It has been reported in the literature that pore diameters smaller than 
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20 nm are able to restrict the nucleation of drug molecules (Planinšek et al., 
2011, Shen et al., 2010). Since the pores of SBA-15 is in the range of 8–9 nm, 
those ART drug particles encapsulated within the pore channels are expected 
to be in the amorphous form.  
 
Figure 5.5 PXRD patterns of (a) ART/SBA-15 (1:3 w/w), (b) ART/ SBA-15 
(1:1 w/w), (c) ART/SBA-15 (3:1 w/w), (d) P.M.-ART/SBA-15 (1:3 w/w), (e) P.M.-
ART/SBA-15 (1:1 w/w) and (f) untreated ART crystals. 
5.4 Characterization by DSC 
 The physical state of all the samples was further investigated by DSC 
analysis, in which an endothermic melting peak can indicate crystallinity of 
the drug as suggested by Zhang et al. (2011). DSC thermograms of untreated 
ART, co-spray dried ART/SBA-15 and physical mixtures of ART/SBA-15 are 
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depicted in Figure 5.6. A single sharp endothermic peak is observed for the 
untreated ART at 153.4 °C, corresponding to the intrinsic melting point of the 
crystalline phase of ART, with an endothermic enthalpy of 73.0 J/g. In 
contrast, less intense and slightly broader melting peaks were observed in the 
thermogram for the physical mixtures of ART/SBA-15 at temperature lower 
than 153.4 °C. Once ART was co-spray dried with SBA-15, no endothermic 
peaks corresponding to drug melting were observed, confirming the absence 
of ART crystals. This result provides further evidence that ART in co-spray 
dried ART/SBA-15 dispersions are in amorphous the form, which is in 
agreement with the PXRD results.  
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Figure 5.6 DSC curves of (a) ART/SBA-15 (1:3 w/w), (b) ART/SBA-15 (1:1 w/w), 
(c) P.M.-ART/SBA-15 (1:3 w/w), (d) P.M.-ART/SBA-15 (1:1 w/w) and (e) untreated 
ART crystals. 
 
5.5 Morphology and Particle Size 
 Figure 5.7 shows the morphology and particle size of raw and spray 
dried ART, porous silica (SBA-15) and non-porous silica and co-spray dried 
samples. The crystalline nature of ART could be discerned from the untreated 
and spray dried ART [Figure 5.7(a) and (b)], in which both the particles are in 
an orthorhombic form with prism and rod-like shapes (Chan et al., 1997). Both 
the raw ART and spray dried ART exhibit particle size in the range of 50-1000 
μm and 0.5-10 μm, respectively. Meanwhile, SBA-15 appears as aggregates of 
141 
 
spherical and spheroid shaped particles [Figure 5.7(c)] with a narrow particle 
size distribution (average size about 0.5–1 µm). It is noted that both the co-
spray dried ART/SBA-15 (1:3 w/w) and ART/SBA-15 (1:1 w/w) exhibit the 
similar morphology as SBA-15 and no superficial drug crystals were observed 
[Figure 5.7(d) and (e)]. The retained morphologies and absence of additional 
particles on the external surfaces of the samples suggest that most of the ART 
particles are well-dispersed and encapsulated within the pore channels of the 
carrier. During co-spray drying, the presence of the SBA-15 particles prevent 
the nucleation and formation of large ART crystals, whereby the dissolved 
ART in liquid dispersion was quickly entrapped inside the pore channnels of 
SBA-15 through capillary condensation. These ART particles remain in 
amorphous the form within the confined pores of SBA-15 after the organic 
solvent was removed by rapid evaporation via spray drying (Zhao et al., 
2012a). However, when the ratio of ART/SBA-15 increased to 3:1 w/w 
[Figure 5.7(f)], changes in the morphologies can be seen with additional 
particles with smooth edges were observed on the surface. With such extents 
of drug loading, the amount of ART exceeded the capacity of total pore 
volume of SBA-15 and part of ART remained on the external surface of SBA-
15 to form surface particles after being co-spray dried.  
On the other hand, ART was co-spray dried with non-porous silica at 
different drug loadings as a comparison in order to provide additional 
evidence to support that artemisinin could be confined within the pore 
channels of SBA-15. The total pore volume and specific surface area of non-
porous silica are 0.012 cm
3
/g and 6.39 m
2
/g, respectively, which are very low 
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as compared with SBA-15. The morphologies and physical states of co-spray 
dried ART/non-porous silica have been shown in Figures 5.7 and 5.8, 
respectively. Apparently, the non-porous silica appeared to be in a uniform 
spherical form with particle size in the range of 0.3-0.6 µm. The sample of 
ART/non-porous-silica (1:9 w/w) shows morphology similar to that of raw 
non-porous silica. When the ART/non-porous-silica ratio was increased to 1:3 
w/w and 1:1 w/w, changes in the morphologies with the presence of smooth 
edges and crystalline particles corresponding to ART crystals can be clearly 
observed. The results indicated that crystalline ART particles could be formed 
on the external surface of non-porous silica during co-spray drying as the drug 
carrier lacks pore channels to accommodate the drug molecules. These ART 
particles were not observed on the external surfaces of SBA-15 even after co-
spray drying at the high ART/SBA-15 ratio of 1:1 w/w.  
Additionally, it was found that the presence of crystalline particles can 
be detected by PXRD (Figure 5.8) for the co-spray dried ART/non-porous 
silica (1:9 w/w) samples. Samples with 1:3 w/w and 1:1 w/w of drug-to-carrier 
weight ratios showed even stronger X-ray diffraction intensity with the same 
pattern of raw ART (Figure 5.8). These results indicate that, even as low as 10 
wt% of ART on surface on non-porous silica, ART could be re-crystallized 
and remained on the external surface of non-porous silica after being co-spray 
dried. In comparison, co-spray dried ART/SBA-15 showed amorphous PXRD 
patterns even at a high drug loading of 50 wt% (Figure 5.5), indicating that the 
ART molecules encapsulated inside the pore channels of SBA-15 after co-




Figure 5.7 SEM images of (a) untreated ART, (b) spray dried ART, (c) SBA-15, (d) 
ART/SBA-15 (1:3 w/w), (e) ART/SBA-15 (1:1 w/w), (f) ART/SBA-15 (3:1 w/w) (g) 
non-porous silica, (h) ART/non-porous silica (1:9 w/w), (i) ART/non-porous silica 





Figure 5.8 PXRD patterns of (a) ART/non-porous silica (1:9 w/w), (b) ART/non-
porous silica (1:3 w/w) and (c) ART/non-porous silica (1:1 w/w) 
5.6  Internal Pore Structure 
 TEM was used to reveal the internal mesoporous structural features of 
SBA-15 before and after loading as can be inspected in Figure 5.9. TEM 
images of SBA-15 clearly illustrate that the mean pore diameter of the 
cylindrical pore channels of mesoporous silica was uniform at approximately 
8.7 nm, which is in agreement with the N2 adsorption-desorption analysis. 
Moreover, the pore system of the SBA-15 is in a well-ordered hexagonal 
arrangement and straight lattice fringes were viewed along and perpendicular 
to the pore axis, confirming the existence of a two-dimensional hexagonal 






















structure of p6mm symmetry (Guo et al., 2013). The length of SBA-15 
particle is in the range from 0.5–1 µm (Figure 5.9a). Figure 5.9b and c 
illustrate the unchanged appearance of SBA-15 pore channels and pore walls 
after loading with ART particles. This verifies that the drug encapsulation did 
not change the appearance and the internal pore structures of SBA-15. In 
addition, TEM investigation also indicated that no particles were observed to 
accumulate at pore openings of SBA-15 at drug loading equal or below 50 
wt.%. This indicating that pore channels were not blocked by ART at the pore 
opening position to cause significant shrinkage of the pore volume after drug 
loading. As comparison, extra drug particles at outside of SBA-15 particles 
could be observed (indicated by red arrows) for sample with 75 wt.% drug 





Figure 5.9 TEM images with different orientations of (a) SBA-15, (b) ART/SBA-15 

















5.7 Dissolution Profile (Sink Condition) 
 The USP IV dissolution profiles are presented in Figure 5.10. The 
results indicate that the amount of drug released from co-spray dried 
ART/SBA-15 samples was much higher than other control samples of 
crystalline ART and ART/SBA-15 physical mixtures. Within the first 15 min 
of sampling time, the crystalline ART and the P.M.-ART/SBA-15 (1:1 w/w) 
and P.M.-ART/SBA-15 (1:3 w/w) achieved drug release of only 14.7%, 
26.7% and 13.9%, respectively. The final accumulated amount of drug 
released from crystalline ART was only 56.7% after 2 h and that from the two 
physical mixtures was even lesser than the crystalline ART. The strong 
adsorption capacity of SBA-15 which able to re-adsorb the dissolved drug 
might contribute to the lower drug release from physical mixtures of 
ART/SBA-15 compared with crystalline drug. In comparison, the drug release 
from co-spray dried solid dispersions are markedly superior: by 15 min, an 
initial burst release of 57.0% (p < 0.05) and 63.8% (p < 0.05) of ART from 
ART/SBA-15 (1:3 w/w) and ART/SBA-15 (1:1 w/w), respectively, was 
observed; by 2 h, 82.9% (p < 0.05) and 95.0% (p < 0.05) of ART had been 
released from ART/SBA-15 (1:3 w/w) and ART/SBA-15 (1:1 w/w), 
respectively.  
The dissolution studies for ART/SBA-15 based samples were 
conducted only for 2 hours even though not 100% of the drug released within 
2 hours of dissolution. Since the gastric emptying rate is about 15−20 min, the 
first 20 min of dissolution is important and needs to be considered for oral 
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drug delivery (FDA, 1997). It is unlikely that the slower dissolution rate of 
ART/SBA-15 samples was due to the recrystallization of the dissolved drug in 
the sample holder due to the minute amount of dissolution medium passing 
through the drug samples (refer Section 6.5). More likely the samples required 
time to diffuse through the pore channels as SBA-15 with 2D porous channels 
is not dissolved in medium. 
As comparison, the dissolution test was repeated using USP II (Figure 
5.11) in order to determine the complete release of the loaded drug. Within the 
first 15 min, the crystalline ART and the P.M.-ART/SBA-15 (1:1 w/w) and 
P.M.-ART/SBA-15 (1:3 w/w) achieved drug release of only 9.3%, 25.3% and 
31.1%, respectively. However, for the fco-spray dried samplesof ART/SBA-
15 (1:3 w/w) and ART/SBA-15 (1:1 w/w) show improved drug release: by 
15 min, an initial burst release of more than 90% (p < 0.05) was observed and 
by 2 h, 100% (p < 0.05) of ART had been released. Although the dissolution 
profiles obtained by using USP-II and USP-IV are not identical, the basic 
trend of difference among these samples is same. The ART co-spray dried 
with SBA-15 showed much higher dissolution rate than raw crystal ART or 
mixed with SBA-15.  
 Various mechanisms govern the rapid release of ART from SBA-15 
encapsulated products, the first of which is the physical changes of ART by 
nano-confinement as revealed by PXRD and DSC (Ambrogi et al., 2013, Li-
hong et al., 2013). Particles in the amorphous form are at the most energetic 
solid state and exhibit better dissolution and solubility compared with their 
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crystalline counterparts (Hancock and Parks, 2000, Hancock and Zografi, 
1997). Therefore, no additional energy is required to dissolve the disordered 
ART since these drug particles inherently exhibit greater molecular motion 
with reduced binding energy and intermolecular interactions (Zhao et al., 
2012a).  
 In addition, particle size reduction of the amorphous ART as 
determined by SEM images in Figure 5.7 also contributes to the dissolution 
enhancement. During co-spray drying, the ART drug particles are 
incorporated and homogeneously distributed inside the SBA-15 pore channels 
in amorphous forms with significantly reduced in particles size, which results 
in higher specific surface areas exposed to the dissolution medium compared 
with their crystalline counterpart. Thirdly, enhanced wettability of the solid 
dispersions due to the hydrophilic surface of silica carriers also leads to 
superior dissolution kinetics. The hydrophilicity of co-spray dried samples 
accelerate penetration rate of the water molecules into the capillaries of 
mesoporous silica and displace the ART molecules into the dissolution 
medium.  
 Finally, the enhanced drug release mechanism of ART from solid 
dispersions is also due to rapid desorption of drug molecules from pore 
channels of SBA-15, attributable to competitive interaction between water 
molecules and ART molecules because of the hydrophilicity of the silica pore 
walls (Ambrogi et al., 2013). Therefore, ART molecules bonded by weak van 
der Waal forces and hydrogen bonds are easily displaced by the influx of 
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water. Additionally, the mean pore diameter of SBA-15 which is in the 
mesoporous range of 8−9 nm and the short length of pore channels of SBA-15 
(0.5−1 µm) also could facilitate the drug release. The relatively shorter pore 
channels of SBA-15 as publicized by the SEM and TEM images could further 
minimize the diffusion resistance and contribute for faster release of ART. 
Compared to microporous materials with pore size smaller than 2 nm, SBA-15 
having considerably wider pores providing lesser steric hindrance to ART 
molecules to diffuse out of the pore channels, thus resulting in a greater 
amount of drug release (Van Speybroeck et al., 2009). The significance of 
pore diameter on dissolution kinetic was reported previously by Tarja Limnell 
et al. (2011a), who compared the performance of two mesoporous silica with 
different pore diameter (SBA-15 and MCM-41 with pore diameters of ~8 nm 
and ~2.5 nm, respectively). MCM-41, which has narrower pores than SBA-15, 
demonstrated slower release rate due to resistance that obstructs the diffusion 




Figure 5.10 Dissolution profiles of (a) P.M.-ART/SBA-15 (1:3 w/w), (b) P.M.-
ART/SBA-15 (1:1 w/w), (c) crystalline ART, (d) ART/SBA-15 (1:3 w/w) and (e) 






Figure 5.11 Dissolution profiles of (a) crystalline ART, (b) P.M.-ART/SBA-15 
(1:1 w/w), (c) P.M.-ART/SBA-15 (1:3 w/w), (d) co-spray dried ART/SBA-15 
(1:3 w/w) and (e) ART/SBA-15 (1:1 w/w) under sink condition using USP II. n=3, p 
< 0.05 versus free ART (this figure was not shown in the thesis). 
5.8 Dissolution Profile (Non-Sink Condition) 
 Figure 5.12 depicts the dissolution profiles of crystalline ART and co-
spray dried ART/SBA-15 samples. For crystalline ART, the amount dissolved 
in the first 5 min was 7.6 µg/mL and the concentration gradually increased 
throughout the experiment to 48.4 µg/mL in 2 h; nevertheless, equilibrium was 
not attained within the 2 h time period used in this study. For the co-spray 
dried ART/SBA-15 dispersions, an initial burst release was observed at the 
beginning of the dissolution and a supersaturation plateau was attained by 
60 min with a drug concentration of 101 µg/mL (p < 0.05). The 
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thermodynamic solubility of crystalline ART in water at 37 °C is reported to 
be 48 µg/mL (Ferreira et al., 2013), whereas the apparent solubility of the 
formulated amorphous ART in dispersion was enhanced by two fold 
[101 µg/mL (p < 0.05)] and the supersaturation could be sustained for 
120 min. 
 These results clearly indicate that the encapsulation of ART in 
mesoporous SBA-15 particles was able to circumvent the slow dissolution 
kinetics and low solubility of ART. Enhancing the apparent solubility is a vital 
step in improving the absorption and bioavailability of poorly water-soluble 
drugs. According to Fick's laws of diffusion, drug diffusion across the 
gastrointestinal epithelia can be improved by increasing the concentration 
gradient of the drug across the barriers (Van Speybroeck et al., 2010a). Hence, 
the enhanced apparent solubility of ART in this study would increase the 
availability of the drug across the gastrointestinal epithelia, thereby 
augmenting absorption and bioavailability.  
 Sustaining the enhanced supersaturation of drugs is a challenge faced 
in achieving optimal bioavailability. From a pharmaceutical perspective, 
besides improving the flux of drug across the intestinal membranes, 
supersaturation may also lead to rapid drug precipitation to energetically more 
favorable forms, which would affect the in vivo performance (Van Speybroeck 
et al., 2010a). This situation commonly necessitates precipitation inhibitors to 
delay the onset of crystallization and prolong the supersaturation. However, in 
in vitro aqueous solubility tests, the formulated co-spray dried ART/SBA-15 
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could sustain high supersaturation levels for at least 2 hours. Maintaining the 
supersaturation of ART is essential to ensure the dissolved drug to be absorbed 
across the intestinal lumen. Previous studies have also reported sustaining the 
supersaturation of itraconazole, but only for 30 min (Van Speybroeck et al., 
2010b).  
 The change in physical state (from the crystalline form to the 
amorphous), the pore architecture (a wider pore size and shorter pore 
channels), host-guest chemical interactions (weak van der Waal forces and 
hydrogen bonds) and the properties of loaded drug (reduced particles size and 
improved wettability) contribute to the improvement of the apparent solubility 
of ART. All these advantages in co-spray dried formulations allow a rapid 
penetration of the dissolution medium that ensure the breaking of the 
hydrogen bonds between ART molecules and SBA-15 silanol groups to 
achieve rapid dissolution and a high apparent solubility. The correlation 
between particles size and supersaturation of pharmaceutically active 
ingredients is well demonstrated by the Ostwald-Freunlich equation (Ostwald, 




Figure 5.12 Supersaturation of crystalline ART, ART/SBA-15 (1:3 w/w) and 
ART/SBA-15 (1:1 w/w) under non-sink condition using USP II. n=3, p < 0.05 versus 
free ART. 
5.9 Chemical Stability of Amorphous ART 
 Although the physical stability of formulated amorphous APIs has 
been investigated with different types of carriers, there is scarce literature on 
the chemical stability of APIs, especially with regard to ART. In order to 
address this gap, the chemical stability of amorphous ART under different 
storage conditions was examined. The chemical stabilities of co-spray dried 
ART/SBA-15 dispersions were analyzed by using HPLC after 3- and 6-
months of storage. The percentages of ART preservation as a function of 
storage time at different temperatures and relative humidity are tabulated in 
Table 5.3. As a control, untreated ART and spray dried crystalline ART could 
preserve more than 99% of ART without degradation after stressed storage 
tests at 40 °C/75% RH in open pans for 12-month (Table 4.4). Similarly, the 
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co-spray dried samples of ART/SBA-15 (1:3 w/w) and ART/SBA-15 
(1:1 w/w) stored in desiccators (25 °C/18% RH), Activ-vial
®
 at 25 °C and 40 
°C also displayed no or slight degradation of ART after 6-months of storage; 
more than 94% of ART was preserved in these samples. However, the samples 
in open pans at 25 °C/75% RH and 40 °C/75% RH started to degrade within 
the first-month of storage (data not shown) and ART degraded significantly 
after 6-months. In addition, it was observed that the ART/SBA-15 (1:3 w/w) 
exhibited a higher degradation rate than the ART/SBA-15 (1:1 w/w) samples. 
 In this study, 3 main factors that contribute to chemical degradation 
were investigated: storage temperature, relative humidity (% RH) and drug-
carrier ratio (Hailu and Bogner, 2011). It can be deduced that hydrolytic 
degradation is predominant during the storage, given that the relative humidity 
(% RH) plays an important role in chemical instability of amorphous ART 
than the storage temperature. All the samples stored at a high relative humidity 
(75% RH), regardless of the storage temperature, degraded more easily 
compared with those stored in Activ-vial
®
 and desiccators with a low 
humidity. The thermal stability of ART has been reported previously, as ART 
can remain stable without any decomposition even at its melting point (156–
157 °C) and it starts to breakdown only at 190 °C (Li and Zhou, 2010, Lin et 
al., 1985). Accordingly, it can be concluded that the storage temperature did 
not exhibit significant effects on the degradation of ART. 
 The drug-carrier ratio of ART/SBA-15 also influenced the degree of 
degradation of ART through its impact on the specific area and the pore 
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volume on moisture content. ART/SBA-15 (1:3 w/w) is observed to exhibit a 
higher degradation rate compared with ART/SBA-15 (1:1 w/w). The lower 
drug loading in ART/SBA-15 (1:3 w/w) implies a larger specific area and a 
greater pore volume of SBA-15 for adsorption and condensation of vapour. 
Subsequently, the greater degree of vapor condensation accelerates the 
degradation of the encapsulated ART and impairs its chemical stability. As 
shown in Table 5.3, a lower extent of drug loading is associated with a higher 
moisture content and all ART/SBA-15 (1:3 w/w) samples have a higher 
moisture content than ART/SBA-15 (1:1 w/w) samples. In addition, for 
samples stored at 75% RH, the moisture content increases with duration of 
storage. Conversely, the moisture content for samples stored at a lower 
humidity was observed to be as low as 2%. Thus, it is recommended that 
products of ART/SBA-15 be formulated with a high extent of drug loading to 
maximally fill pore structures and be stored under conditions of low humidity 




Table 5.3 Moisture content and amounts of ART remaining within ART/SBA-15 samples after storage under 5 different storage conditions 
for 3 and 6-months. 









Fresh  100.0 ± 1.5 100.0 ± 1.3 2.2 ± 0.1 1.7 ± 0.4 
3-months  Desiccators 
(25 °C/18% RH) 





97.1 ± 1.8 99.7 ± 1.3 2.24 ± 0.2 1.41 ± 0. 5 
Open pan 
(25 °C/75% RH) 





96.4 ± 3.6 98.5 ± 1.0 2.1 ± 0.4 1.9 ± 0.3 
Open pan 
(40 °C/75% RH) 
26.1 ± 0.1 59.8 ± 0.3 4.9 ± 0.9 2.6 ± 0.1 
6-months  Desiccators 
(25 °C/18% RH) 





97.5 ± 0.8 98.5 ± 0.9 2.1 ± 0.2 1.67 ± 0.4 
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 (25 °C/75% RH) 




 (40 °C) 
96.0 ± 4.1 94.3 ± 6.0 2.1 ± 0. 5 1.6 ± 0. 6 
Open pan 
 (40 °C/75% RH) 
0 27.9 ± 2.0 8.8 ± 0. 6 4.3 ± 0. 3 




5.10 Physical Stability of Amorphous ART  
 Despite the enhanced dissolution rate and supersaturation, amorphous 
drugs usually suffer from a poor thermodynamic stability as these drug 
particles tend to revert to the stable crystalline forms during transport and 
storage. Prolonging the physical stability of amorphous ART is one of the 
important considerations to preserve the enhanced physicochemical properties 
(Wang et al., 2013). Therefore, the physical stability of ART/SBA-15 
formulations upon storage was investigated under three different storage 
conditions for up to 6-months. Those three conditions with a lower % RH in 
which amorphous ART/SBA-15 exhibited good chemical stability were used: 
desiccators (25 °C/18% RH), Activ-vial
®
 (25 °C) and Activ-vial
® 
(40 °C). The 
solid states of these samples were analyzed by PXRD and the results are 
displayed in Figure 5.13 (A) and (B). As aforementioned, the freshly co-spray 
dried solid dispersions exhibited typical amorphous characteristics. After 
storage, these ART/SBA-15 samples still exhibited flat patterns without 
evidence of PXRD peaks corresponding to crystalline ART. This indicates that 
the amorphous ART entrapped in the pore channels of SBA-15 remained 
physically unchanged during storage as no crystalline ART could be detected 
by PXRD after 6-months. It is accordingly suggested that SBA-15 confers a 
strong re-crystallization inhibition effect that stabilizes ART in the amorphous 
form during long-term storage periods. 
 SBA-15 confers physical stability upon amorphous ART via three 
mechanisms: the size-constraint effect on nucleation and crystal growth (Shen 
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et al., 2011, Shen et al., 2010); the thickness and rigidity of pore walls 
(Rengarajan et al., 2008); and the formation of hydrogen bonds through 
surface silanol groups (Watanabe et al., 2001, Watanabe et al., 2002). As 
regards the size-constraint effect of mesoporous silica, it has been reported 
that the nucleation will only take place if the ratio of pore diameter to drug 
molecular size exceeds 20 (Sliwinska-Bartkowiak et al., 2001, Qian and 
Bogner, 2012). The small and uniform pore size of SBA-15 in the range of 
only 8–9 nm is highly effective in inhibiting the nucleation of ART crystals by 
restricting molecular transport and re-arrangement. In addition, the thicker and 
rigid pore walls of SBA-15, as depicted by the TEM images, are able to 
separate the fine amorphous particles effectively and change the nucleation 
mechanism that can prevent the re-crystallization process. For example, those 
drug molecules entrapped in the pore channels of SBA-15 need to nucleate 
homogeneously since the rigid and non-nucleating pore walls will further 
delay the re-crystallization and crystal growth of amorphous particles 
(Rengarajan et al., 2008). Moreover, those confined ART molecules can form 
hydrogen bonds with the silanol groups on interfacial surface. The 
immobilization of drug molecules on the surfaces of SBA-15 could further 
prevent the movement and re-crystallization of ART. The importance of 
hydrogen bonding between drug and carrier in stabilizing the amorphous drug 
has been reported by Limnell et al. (2011a). According to the authors, SBA-15 
is able to afford stability to amorphous indomethacin more effectively than 
MCM-41, due to the presence of larger number of silanol groups per unit area 
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Figure 5.13 PXRD patterns of (A) ART/SBA-15 (1:3 w/w) and (B) ART/SBA-15 
(1:1 w/w) that (a) freshly co-spray dried and after storage for 6-months in (b) 
desiccators (at 25 °C/18% RH), (c) Activ-vial® (at 25 °C) (d), Activ-vial® (at 40 °C) 
and (e) untreated ART crystals (fresh). 
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5.11 Dissolution after Storage using USP II 
 Those samples that exhibited adequate physical and chemical stability 
after 6-months of storage were subjected to dissolution tests (by using USP II) 
in order to assess the extent to which SBA-15 particles preserve the improved 
drug release of ART. Freshly co-spray dried samples were used as controls 
and the results are displayed in Figure 5.14. Approximately 90% (p < 0.05) of 
ART could be released to the dissolution medium in 2 h of dissolution. There 
are no significant changes in the drug release profile of the stored samples as 
compared with the freshly prepared samples. The long-term stability of 
amorphous ART in the dispersions and the hydrothermal stability of SBA-15 
with unchanged pore structures mainly contribute to the improved and 






Figure 5.14 Dissolution profiles (USP II) of ART from co-spray dried (A) ART/SBA-
15 (1:3 w/w) and (B) ART/SBA-15 (1:1 w/w) after storage at 3 different conditions 




5.12 In vitro Evaluation of Cytotoxicity  
 Cell viability is one of the most essential tools to evaluate the 
biocompatibility of oral drug delivery formulations. Therefore, in this study, 
the biocompatibility of the pure SBA-15 and equivalent concentrations of the 
free and encapsulated ART were quantified by assessing the effect of these 
samples on the survival rate of Caco-2 cells. Caco-2 cells were chosen as an in 
vitro model due to their morphological and physiological similarity to 
intestinal epithelial cells. Figure 5.15 presents the viability of Caco-2 cells 
after 24 h exposures to SBA-15 (0.25, 0.50, 1.0, 2.0 and 4.0 mg/mL), ART 
and ART/SBA-15 (25, 50, 100 and 200 µg/mL). The maximum concentration 
of the samples was limited to 200 µg/mL due to concerns with the formation 
of ART micro-crystals as observed with samples containing 400 µg/mL 
equivalent of ART as shown in Figure 5.16. 
 As seen in Figure 5.15, untreated ART, SBA-15 and formulated 
ART/SBA-15 samples exhibited neither harmful nor dose-dependent effects 
on the Caco-2 cells over the tested concentration range. Even at the highest 
concentration of samples, the cell survival rate remained above 90%, 
confirming little particle interference on cell integrity and negligible 
cytotoxicity. More importantly, no noticeable IC50 values were observed for 
any of the samples at any concentration after 24 h exposure. Several studies 
have reported the non-toxic nature of SBA-15 compared with other members 
of mesoporous silica such as MCM-41. It has also been reported that the entry 
of small and spherical particles into cells through endocytosis may be 
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responsible for cytotoxicity (Wang et al., 2013). Accordingly, it may be 
deduced that the non-toxic nature of SBA-15 in this study may be attributed to 
the inability of large particles to penetrate cell membranes. ART has likewise 
been reported to be safe for normal cells, despite its toxicity to various 






Figure 5.15 Caco-2 cell viability after 24 h incubation with (A) SBA-15 and (B) 
untreated ART and ART/SBA-15 solid dispersions at 37 ºC, as a function of the 





Figure 5.16 Optical microscopy of Caco-2 cells and ART. 
5.13 Conclusion 
 SBA-15 particles with outstanding features such as high surface areas, 
large pore volumes, uniform pore size, short pore channels and hydrophilicity, 
were used as a drug vehicle for poorly soluble ART to enhance its 
biopharmaceutical properties via co-spray drying. Spatial confinement of 
amorphous ART within the pore channels of SBA-15 mainly contributed to 
the remarkably enhanced dissolution kinetics compared with the crystalline 
ART. The amorphous ART/SBA-15 achieved supersaturation of ART more 
than two-fold of the equilibrium solubility of ART, which can be sustained for 
2 h without addition of any precipitation inhibitors. The ART/SBA-15 samples 
exhibited excellent chemical stability regardless of storage temperature under 
low humidity conditions. However, ART/SBA-15 showed obvious 
degradation when stored under conditions of high relative humidity. In 
addition, the amorphous state of ART/SBA-15 samples exhibited excellent 
physical stability lasting for 6-months with preserved enhanced dissolution 
properties. Meanwhile, as evident from the cell survival data, SBA-15, 
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untreated ART and formulated ART/SBA-15 samples show low cytotoxicity 
on Caco-2 cell line suggesting the biocompatibility of the samples. As 
comparison, non-porous silica was used a carrier to support the concenpt of 
nano-confinement of most of the ART drug particles inside the pore channel 
of SBA-15. Characteristic results such as PXRD, N2 adsorption, SEM and 
TEM prove the encapsulation of most of the ART particles inside the pore 




Chapter 6 Encapsulation of ART in Functionalized Food 
Additives 
 In comparison with mesoporous carriers, the solubility of ART was 
enhanced by using water-soluble transglycosylated food additives, α-glucosyl 
hesperidin (Hsp-G) and α-glucosyl stevioside (Stevia-G), via co-spray drying. 
These two food additives have been chosen as potential drug carriers by virtue 
of their superior aqueous solubility, relative safety and cost-effectiveness. 
Additionally, Hsp-G has been reported to possess significant anti-
inflammatory, hypotensive and analgesic effects; Stevia-G has been used as a 
sweetener for patients with diabetes and as a sugar substitute for 
hypoglycemia patients for more than 20 years. These functionalized foods 
have become an important ingredient in daily diets and play a vital role in 
preventing diseases in countries that face serious aging problem such as Japan 
(Tozuka et al., 2010). Therefore in this study the performance of 
transglycosylated food additives including drug loading capacity, drug release 
enhancement and storage stability will be studied and compared with SBA-15. 
6.1 X-Ray Diffraction (XRD) 
 Initially, solid dispersions of ART/Hsp-G and ART/Stevia-G were 
formulated at two different ratios: 1:3 w/w and 1:10 w/w. However, the 
samples of 1:3 w/w exhibited a small PXRD peak at diffraction angles of 
11.3° (Figure 6.1), although the 1:10 w/w samples showed halo patterns, 
suggesting the presence of the amorphous drug form. Since the presence of 
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crystal seeds in the solid dispersions can induce re-crystallization of the 
amorphous form and cause poor physical stability, the ART/Hsp-G (1:3 w/w) 
and ART/Stevia-G (1:3 w/w) samples were excluded in further analysis. 
 Comparison of X-ray diffraction of untreated ART, Hsp-G and Stevia-
G, physical mixtures and co-spray dried solid dispersions with different 
vehicles are presented in  
Figure 6.2 6.2. X-ray diffractions of untreated ART and spray dried ART 
(without carriers) have been discussed in Sections 4.3 and 5.3. Meanwhile, 
both the untreated hydrophilic carriers exist in the X-ray amorphous form as 
typical broad and halo amorphous band shown by the PXRD. The physical 
mixtures of ART with Hsp-G (1:10 w/w) and Stevia-G (1:10 w/w) show that 
the drug retained its original characteristic peaks though with reduced relative 
intensities. However, for spray dried solid dispersions of ART/Hsp-G 
(1:10 w/w) and ART/Stevia-G (1:10 w/w), halo diffraction patterns without 
characteristic peaks associated with the ART were observed, indicating that 
ART was no longer present in the crystalline form but might have been 
dispersed in an amorphous or monomolecular state. The non-crystalline forms 
of ART upon formulation can be attributed to the formation of micelle-like 
structure of Hsp-G and Stevia-G by encapsulating the ART molecules in 
hydrophobic cores (Figure 6.3) during co-spray drying inhibited the formation 




Figure 6.1 PXRD patterns of (a) ART/Hsp-G (1:10 w/w), (b) ART/Stevia-G 
(1:10 w/w), (c) ART/Hsp-G (1:3 w/w) and (d) ART/Stevia-G (1:3 w/w). 
 
Figure 6.2 PXRD patterns of (a) ART/Hsp-G (1:10 w/w), (b) ART/Stevia-G 
(1:10 w/w), (c) Hsp-G, (d) Stevia-G, (e) physically mixed ART/Hsp-G (1:10 w/w), 
(f) physically mixed ART/Stevia-G (1:10 w/w), (g) spray dried ART and (h) 
untreated ART crystals. (Note: Intensity of PXRD peaks of (e), (f), (g) and (h) were 





Figure 6.3 Schematic representation of the resultant micelle-like structures of Hsp-G 
in ethanol-water mixture solution [adapted from (Tozuka et al., 2010)]. 
6.2 Differential Scanning Calorimetry (DSC) 
 The thermal analysis of all the samples was performed by differential 
scanning calorimetric (DSC) and the results were presented in Figure 6.4. The 
melting point of crystalline ART at 153.4 °C as reported in Sections 4.2 and 
5.4 was further corroborated by the results of hot stage microscope images 
(Figure 6.5). The melting point of the crystal as observed during hot stage 
microscopy was 153.4 °C, which is almost similar to the value obtained from 
the DSC peak (Figure 6.4) and the melting point of ART is size-dependent in 
that it varies from 153.0–157.8 °C. Meanwhile, no endothermic peak appeared 
for Hsp-G and Stevia-G, indicating their amorphous nature. In the 
thermograms of physical mixtures, the endothermic peaks of P.M.-ART/Hsp-
G (1:10 w/w) and P.M.-ART/Stevia-G (1:10 w/w) were less intense, slightly 
broad and shifted towards to lower temperature (151.7 °C and 152.7 °C, 
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respectively). Once ART was co-spray dried with Hsp-G and Stevia-G, no 
peak corresponding to drug melting was observed, confirming the absence of 
ART crystals in the formulated samples. ART was successfully converted into 
the amorphous form upon encapsulation with the excipients, as the physical 
state was further confirmed by the powder X-ray diffraction results, indicating 
an amorphous form of the drug after co-spray dried with food additives. 
 
Figure 6.4 DSC curves of (a) Hsp-G, (b) ART/Hsp-G (1:10 w/w), (c) Stevia-G, (d) 
ART/Stevia-G (1:10 w/w), (e) physically mixed ART/Hsp-G (1:10 w/w), (f) 





Figure 6.5 ART crystal images as observed from the microscope equipped with a hot 
stage. 
6.3 Determination of Drug Loading 
 The encapsulation efficiency was quantified by measuring the ART 
loading in Hsp-G and Stevia-G after co-spray drying. ART-loaded samples 
weighing 5 mg were extracted with 50 mL of ethanol/water (1:1 v/v) with 
stirring for 24 h, followed by filtration and analysis by HPLC. Table 6.1 
outlines the drug loading efficiency of ART/Hsp-G (1:10 w/w) and 
ART/Stevia-G (1:10 w/w) samples. The drug uptake by Hsp-G and Stevia-G 
particles was 8.04 wt% and 8.42 wt% respectively. It is shown that more than 
88.6% and 92.7% of ART in the designed formulation were respectively 
encapsulated by Hsp-G and Stevia-G. However, when compared with drug 
loading of SBA-15 (48.8 wt%), the drug loading by functionalized food 
additives is considerably inferior. For SBA-15, the larger specific surface area 
and pore volume afforded accommodation of such large quantity of drug, 
which was difficult to achieve in food additives. Moreover, crystalline forms 
can be detected when the drug loading increased to 25 wt% (Figure 6.1). 
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Therefore, with respect to drug loading, SBA-15 has a better capacity 
compared with Hsp-G and Stevia-G. 
Table 6.1 Drug loading of ART within Hsp-G and Stevia-G 
Sample Theoretical drug 
loading [wt%] 
Drug Loading  





9.09 8.04 ± 0.43 88.6 ± 4.74 
ART/Stevia-G 
(1:10 w/w) 
9.09 8.42 ± 0.13 92.7 ± 1.43 
Data represent mean ± S.D., n=3 
6.4 Scanning Electron Microscope (SEM)  
 The surface morphologies of all the samples were characterized by using 
SEM and the micrographs thus obtained were depicted in Figure 6.6 
Figure 6.6. Refer to Sections 4.4 and 5.5 for more details about the physical 
state, polymorph and particle size of raw ART and spray dried ART. Figure 
6.6(c) and (d) reveal that the morphology of Hsp-G and Stevia-G appeared to 
be in irregular shape with a relatively wide particle size distribution within a 
range of 0.7–75.6 µm for Hsp-G and 0.8–139.0 µm for Stevia-G. This 
morphology of the excipients has been reported previously (Uchiyama et al., 
2011a, Tozuka et al., 2010). On the other hand, the spray dried additives 
[Figure 6.6(e) and (f)] show changes in morphology, whereby mixtures of 
irregular particles and shrank spheres can be observed. Meanwhile, the 
morphology of Hsp-G and Stevia-G were completely changed to shrunken 
spheres after co-spray dried with ART with a reduced particle size in the range 
of 0.5–14.2 µm [Figure 6.6(g) and (h)]. The disappearance of crystalline 
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particles of ART clearly indicates the encapsulation of ART by Hsp-G and 
Stevia-G and the final product appeared to be in non-crystalline forms. For the 
physical mixtures [Figure 6.6(g) and (h)], the drug and carriers appeared to be 
separate particles without changes in morphology or interactions between 
them. Conversely, for physical mixtures of ART/SBA-15 (Figure 7.7), SBA-
15 appeared to adhere on the surface of ART due to interactions such as 




Figure 6.6 SEM images of (a) untreated ART crystal, (b) spray dried ART crystal, (c) 
Hsp-G, (d) Stevia-G, (e) spray dried Hsp-G, (f) spray dried Stevia-G, (g) ART/Hsp-G 
(1:10 w/w), (h) ART/Stevia-G (1:10 w/w), (i) physically mixed ART/Hsp-G 




6.5 Dissolution Measurement 
 In this section, the dissolution profiles of co-spray dried solid 
dispersions and P.M.-ART/Hsp-G (1:10 w/w) and P.M.-ART/Stevia-G 
(1:10 w/w) were characterized and the results are depicted in Figure 6.7. As 
expected, both the untreated ART and physical mixtures have shown poor 
drug release rate. In the first 15 min, approximately 14.7% of the ART was 
released and it achieved 56.7% after 2 h. In the meantime, 54.9% of and 
53.5% ART was dissolved after 2 h from P.M.-ART/Hsp-G (1:10 w/w) and 
P.M.-ART/Stevia-G (1:10 w/w), respectively. The poor dissolution of ART is 
mainly due to its crystalline and hydrophobic nature. Meanwhile, the lack of 
interaction between ART and Hsp-G and Stevia-G in the physical mixtures 
caused poor dissolution as untreated ART; hardly any differences were 
observed in the dissolution rate between untreated drug and physical mixtures. 
 It is found that the use of the hydrophilic Hsp-G and Stevia-G as 
carriers in solid dispersions for poorly water-soluble drugs produced a 
dramatic improvement in the dissolution rate of ART. As shown in Figure 
6.7(d) and (e), ART loaded into functionalized food additives exhibited an 
initial burst of more than 94% (p < 0.05) within 5 min, in comparison with 
4.0% for the untreated drug. The amounts of drug release in 5 min from 
ART/Hsp-G (1:10 w/w) and ART/Stevia-G (1:10 w/w) were 94.1% (p < 0.05) 
and 99.4% (p < 0.05), respectively and the final dissolved amounts of ART 
was 99% (p < 0.05) for both the samples at end of the dissolution. The 
possibility of the dissolved drug to re-crystallize in the sample holder due to 
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the minute amount of dissolution medium passing through the drug samples 
can be excluded for ART samples, since nearly 100% of ART dissolution was 
achieved in 5 min without any decrease in the measured dissolution.  
Compared with mesoporous silica (Chapter 5), functionalized food 
additives have a remarkable role in enhancing dissolution rate, as attested to 
by an initial burst of almost 100% drug release within 5 min of dissolution 
test. The dissolution enhancement of treated ART was attributed to 
amorphization of ART alongside with particle size reduction and improved 
wettability by the hydrophilic carriers. The hydrophilic carriers could be 
rapidly wetted by water so that the drug molecules are surrounded with water, 
allowing fast drug dissolution. The impact of particle size reduction should be 






Figure 6.7 Dissolution profiles of (a) physically mixed ART/Stevia-G (1:10 w/w), (b) 
physically mixed ART/Hsp-G (1:10 w/w), (c) untreated ART, (d) ART/Stevia-G 
(1:10 w/w) and (e) ART/Hsp-G (1:10 w/w) using USP IV (sink condition). n=3, p < 
0.05 versus free ART. 
6.6 Solubility Measurement 
 Figure 6.8 shows the supersaturation of raw and formulated ART 
samples. The results indicated that the untreated ART possessed a very low 
aqueous solubility of 48.4 μg/mL, as was consistent with the reported 
literature (Ferreira et al., 2013). The supersaturation of the formulated solid 
dispersions was two-fold that of raw ART, i.e. the final solubility of 
ART/Hsp-G (1:10 w/w) and ART/Stevia-G (1:10 w/w) were 102.6 μg/mL (p < 
0.05) and 95.6 μg/mL (p < 0.05), respectively. Both the formulated samples 
achieved a burst release with more than 98 μg/mL (p < 0.05) of drug dissolved 
within the first 5 min; in contrast, a release of only 8.5 μg/mL was observed 
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for raw ART during the same period. The maximum concentration was 
achieved at the 15
th
 min of test, when the values of supersaturation achieved 
102.9 μg/mL (p < 0.05) and 100.5 μg/mL (p < 0.05) for ART/Hsp-G 
(1:10 w/w) and ART/Stevia-G (1:10 w/w), respectively. The slight decrease in 
the solubility of ART/Stevia-G (1:10 w/w) at the end of the experiment 
compared with the initial 15 min might have been due to precipitation or re-
crystallization of ART upon attainment of supersaturation.  
 The poor solubility of untreated ART is mainly owing to its stable and 
crystalline nature with a large crystal size as reported by Chan et al. (1997). 
According to them, ART exists in orthorhombic and triclinic forms, the former 
being more stable and less soluble than the latter. The formulation of solid 
dispersions of ART/Hsp-G and ART/Stevia-G afforded amorphous samples 
with rapid dissolution property which augmented the supersaturation of ART 
in the dissolution media. Binding energy between ART molecules become 
weaker upon conversion to the amorphous state, thereby necessitating no 
additional energy to break down the molecular structure during dissolution. 
Moreover, the particles size of drug loaded samples was reduced significantly, 
which can enlarge the contact area between the drug and the dissolution 





Figure 6.8 Supersaturation of (A) 200 mg of ART in solid dispersion of (a) untreated 
ART, (b) ART/Stevia-G (1:10 w/w) and (c) ART/Hsp-G (1:10 w/w). n=3, p < 0.05 
versus free ART. 
6.7 Chemical Stability Evaluation  
 The chemical stability of ART/Hsp-G (1:10 w/w) and ART/Stevia-G 
(1:10 w/w) samples was investigated for 6-months at 5 different storage 
conditions: desiccators (25 °C/18% RH), Activ-vial (25 °C/0% RH), open pan 
(25 °C/75% RH), Activ-vial (40 °C/0% RH) and open pan (40 °C/75% RH). 
Samples kept at higher temperatures including Activ-vial (40 °C/0% RH) and 
open pan (40 °C/75% RH) agglomerated to form hard lumps within two to 
three-weeks of storage as presented in Figure 6.9. High storage temperatures, 
moisture content and the presence of amorphous ART might induce the 
agglomeration and hardening of the food additive samples. Almost the same 
results were observed for ART/AC solid dispersions (agglomeration and 
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formation of sticky samples) after 3-months of storage under stressed 
conditions (Section 4.7). In contrast, previously, Tozuka et al. (2010) have 
conducted a similar type study on the physical stability of naringenin/Hsp-G 
(1:10 w/w) by storing the samples at 60 ºC for 3-months in a closed container; 
the samples showed a good physical stability throughout the storage. 
 The results of the chemical stability of the samples as a function of 
storage time at the remaining three conditions are presented in Table 6.2. Both 
the ART/Hsp-G (1:10 w/w) and ART/Stevia-G (1:10 w/w) exhibited excellent 
chemical stability with more than 95.8% of ART preserved for 6-months, at 
the end of which approximately 97.4–99.5% of ART could be preserved for 
ART/Hsp-G (1:10 w/w) and 95.8–99.8% for ART/Stevia-G (1:10 w/w). No 
appreciable changes in drug content were observed form 3-months to 6-
months of storage under these three storage conditions. It was found that 
moderate conditions are suitable for the food additives to preserve the 
chemical stability of ART. Besides that, the good chemical stability of treated 
ART in open pan (25 ºC/75% RH) might also be attributed to the re-




Figure 6.9 Physical appearances of (a) ART/Hsp-G (1:10 w/w) and (b) ART/Stevia-G 
(1:10 w/w) samples: (i) freshly co-spray dried and (ii) after 3-weeks of storage in 
open pan at 40 °C/75% RH. 
 
Table 6.2 Percentage of ART remaining in solid dispersions without degradation after 
storage under 3 different storage conditions for 6-months. 
Sample  Storage 
conditions  
% of ART remain 
3-month 6-month 
ART/Hsp-G 
(1:10 w/w)  
Desiccators 
 (25 °C/18% RH) 
99.5 ± 0.3 98.1 ± 0.5 
Activ-vial 
 (25 °C/0% RH) 
99.3 ± 1.0 97.4 ± 0.6 
Open pan 
 (25 °C/75% RH) 
98.0 ± 0.9 98.4 ± 1.0 
ART/Stevia-G 
(1:10 w/w)  
Desiccators 
 (25 °C/18% RH) 
99.1 ± 0.8 97.8 ± 0.9 
Activ-vial 
 (25 °C/0% RH) 
99.8 ± 0.7 95.8 ± 2.4 
Open pan 
 (25 °C/75% RH) 
97.6 ± 0.8 98.4 ± 0.5 
Data represent mean ± S.D., n=3 
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6.8 Physical Stability Evaluation and Drug Release after Storage 
 Based on Figure 6.10 and Figure 6.11, all the co-spray dried samples 
show halo patterns throughout the storage periods, with the exception of the 
samples stored in the open pan at 25 °C/75% RH, for which a PXRD peak 
corresponding to crystalline ART was observed after 6-months (Figure 6.11). 
The reappearance of micron size ART crystals can be observed through SEM 
images as depicted in Figure 6.12 (yellow arrows). For the as prepared fresh 
samples, the halo patterns of ART/Hsp-G (1:10 w/w) and ART/Stevia-G 
(1:10 w/w) indicate the presence of amorphous ART incorporated within Hsp-
G and Stevia-G. Molecular-level mixing and hydrophobic-hydrophilic 
interactions between ART and food additives in co-spray dried samples could 
inhibit the re-crystallization of ART by restricting the mobility of the 
encapsulated drug molecules. However, the samples stored in the open pans at 
25 °C/75% RH were unstable and started to re-crystallize in 6-months 
duration. The re-crystallization of ART can be interpreted as a consequences 
of the plasticizing of food additives under a humid condition (75% RH), which 
allow elevated mobility of the amorphous ART molecules to trigger the onset 
of drug nucleation and to induce crystallization, as suggested by Zhang et al. 
(2014). Therefore, dry and low-temperature conditions would be 
recommended for solid dispersions formulated with transglycosylated food 
additives. 
 Nevertheless, all the samples stored under moderate conditions still 
showed almost the same and rapid dissolution profile as freshly spray dried 
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samples (Figure 6.13). This is due to the long term physicochemical stability 
of the samples at moderate conditions. More than 87–100% (p < 0.05) of ART 
could be released to the dissolution medium. Similar results were observed for 
the samples kept at 25 °C/75% RH, even though partially formulated ART 
was re-crystallized (Figure 6.12). The unchanged dissolution properties of the 
samples might have been due to several factors: (1) the percentage of 
crystalline ART formed is still very low (as represented by the intensity of the 
PXRD peaks) and the rest of the samples are in amorphous form; (2) the 
particles size of the re-crystallized ART is still in the range of 10 µm (similar 
size as spray dried ART); and (3) the presence of extremely water-soluble 




Figure 6.10 PXRD patterns of (A) ART/Hsp-G (1:10 w/w) and (B) ART/Stevia-G 
(1:10 w/w) after storage for 3-months: (a) fresh , (b) desiccators (25 °C/18% RH), (c) 






Figure 6.11 PXRD patterns of (A) ART/Hsp-G (1:10 w/w) and (B) ART/Stevia-G 
(1:10 w/w) after storage for 6-months: (a) fresh, (b) desiccators (25 °C/18% RH), (c) 






Figure 6.12 SEM images of (a) ART/Hsp-G (1:10 w/w) and (b) ART/Stevia-G 






Figure 6.13 Dissolution profiles of ART from co-spray dried (A) ART/Hsp-G 
(1:10 w/w) and (B) ART/Stevia-G (1:10 w/w) after 6-months of storage. n=3, 




 The formulation of solid dispersions of ART with transglycosylated 
food additives, α-glucosyl hesperidin (Hsp-G) and α-glucosyl stevioside 
(Stevia-G), via co-spray drying offers several advantages and disadvantages as 
compared with SBA-15 (Chapter 5). Similar to SBA-15, amorphization of 
ART could be accomplished with Hsp-G and Stevia-G by encapsulating the 
drug in micro-particles, though the loading capacity of the food additives 
(9.1 wt%) is inferior to that of SBA-15 (50 wt%). Both the Hsp-G and Stevia-
G show a superior dissolution rate as a burst release of 100% of drug was 
achieved within 5 min, with the supersaturation enhanced by 2-fold. With 
regard to storage, dry conditions with a low temperature are suitable for solid 
dispersions of ART and food additives considering that elevated temperatures 
will cause drastic changes in the physical appearance of the samples and 




Chapter 7 Formulation of Amorphous form of Combination 
of ART and MFQ using SBA-15  
 ACTs are recommended worldwide to combat malaria and have a high 
potential to reduce drug resistance. However, few studies have been reported 
regarding the solubility and bioavailability enhancement of antimalarial drugs 
in combination therapies. In this study, the solubility of two poorly water-
soluble antimalarial drugs used in ACTs, ART and MFQ, was enhanced by 
encapsulating them in SBA-15 via co-spray drying. SBA-15, which showed a 
superior performance as compared with activated carbon and functionalized 
food additives, was chosen as the drug carrier for ACT formulation. 
Comparison between all the results obtained for all the carriers from previous 
chapters are summarized in Table 7.1. The storage conditions for stability 
study were based on the parameters that provide excellent storage stability to 




Table 7.1 Comparison of the results obtained from Chapters 4, 5 and 6 
Biopharmaceutical 
properties 
ART  ART/AC 







Physical state  C A  A A 
Drug Loading 
(wt%)  
− 50% 50% 9.1% 
Dissolution (after 
30 min)  
23.1% 61.7% 76.6% 100% 
Supersaturation 
(µg/mL)  
48 90 103 96 
Physical stability  − −   
Chemical stability      
C: crystalline 
A: amorphous 
    
7.1 Structural Characterization and Degree of Drug Loading  
 The corresponding adsorption-desorption isotherms and pore size 
distributions of SBA-15 are respectively shown in Figure 7.1 
Figure 7.1 and 7.2 whereas structural information about SBA-15 measured by 
the N2 adsorption is summarized in Table 7.2. Mesoporous silica with 
extraordinary features such as large specific surface area, pore volume and 
wide pore size distributions are able to bond and store both the drug molecules 
with more than 47.9 wt% of drug loading (16.5 wt% of ART and 31.4 wt% of 
MFQ) (Table 7.3). There were two observations after drug loading: sharp 
decreases in the BET surface area and total pore volume, which implies the 
incorporation of ART and MFQ into the pores of the carrier due to capillary 
forces; and the narrowing of the hysteresis loop, which suggests limited 
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number of pores and pore size. Despite the reduction in the amount of 
adsorbed nitrogen, the shape of the hysteresis loop remained unchanged, 
indicating the unchanged pore channels of SBA-15 after the co-spray drying, a 
fact that is in agreement with the TEM analysis (Section 7.4). The tail in the 
pore size distribution of SBA-15 at small pore diameters corresponds to traces 
of 12% of micropores, which vanished upon loading due to either filling or 
obstruction by the presence of drug particles. A significant reduction in 
nitrogen adsorption, surface area and pore volume were also observed for the 
physical mixtures due to the presence of non-porous APIs in the mixtures 
[Figure 7.1 (B) and Figure 7.2 (B)]. In order to maximize the drug release, the 
APIs loaded onto the mesoporous carrier need to be in an amorphous state. 
Therefore, the physical state of ART and MFQ formulated with SBA-15 was 




Figure 7.1 N2 adsorption-desorption isotherms of SBA-15 before and after (A) co-




Figure 7.2 Pore size distributions of SBA-15 before and after (A) co-spray drying and 
(B) physical mixing with ART and MFQ. 
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Table 7.2 Pore volume, surface area and average pore size of SBA-15 before and 
after co-spray dried with ART and MFQ 










SBA-15  809.0 ± 26.3  1.16 ± 0.04  8.70 ± 0.32  
ART/SBA-15 
(1:1 w/w)  
112.8 ± 24.5  0.20 ± 0.04  6.40 ± 0.32  
MFQ/SBA-15 
(1:1 w/w)  
188.3 ± 34.9  0.33 ± 0.07  6.80 ± 0.19  
ART/MFQ/SBA-15 
(1:2:3 w/w/w)  
123.6 ± 10.1  0.21 ± 0.10  6.34 ± 0.40  
P.M.-ART/SBA-15 
(1:1 w/w)  
251.20 ± 75.5  0.35 ± 0.30  7.32 ± 0.32  
P.M.-MFQ/SBA-15 
(1:1 w/w)  
297.4 ± 85.9  0.43 ± 0.32  6.51 ± 0.96 
P.M.-ART/MFQ/SBA-
15 (1:2:3 w/w/w)  
255.6 ± 61.1  0.31 ± 0.38  6.19 ± 0.40  
Data represent mean ± S.D., n=3 
Table 7.3 Drug loading of ART and MFQ within mesoporous silica 
Sample  Theoretical drug  
loading [wt%]  
Drug Loading  
 [wt%]  
Drug Loading 
efficiency [%]  
ART/SBA-15 
(1:1 w/w)  
50 48.8 ± 1.1  97.6 ± 2.2  
MFQ/SBA-15 
(1:1 w/w)  





 16.5 ± 0.9 
a





 31.4 ± 1.8 
b




refers to ART, 
b
 refers to MFQ 
Data represent mean ± S.D., n=3 
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7.2 Physical Characterization 
 The physical-state of untreated drugs and freshly spray dried and 
physically mixed samples were analyzed with PXRD and the results are 
shown in Figure 7.3 and 7.4. Untreated ART was crystalline in nature as 
indicated by the highly intense PXRD peaks mostly between 7.0° and 25.0°, as 
discussed in Sections 4.3 and 5.3. The untreated MFQ shows PXRD peaks 
with relatively reduced intensity as compared with ART. Characteristic peaks 
at diffraction angles (2θ) of 10.9°, 11.3°, 14.1°, 15.3°, 21.2°, 23.2°, 25.0°, 
25.3° indicate the crystalline nature of MFQ, which is most similar to the form 
D polymorph of the drug (Kitamura et al., 1994).  
 It can be observed that MFQ alone could be transformed into 
amorphous form upon spray drying; however, this was not possible for ART 
even when different processing routes (including spray drying) were applied 
(Figure 7.4(f) and Figure 7.5). Neither appearance of new peaks nor 
disappearance of existing peaks was detected for the spray dried ART. The 
locations of all PXRD peaks are almost identical, whereas the relative 
intensity of the peaks varies as compared with raw ART, indicating the 
decrease in the crystallinity of the drug. However, co-spray drying of ART and 
MFQ was able to produce amorphous ART due to co-amorphization. 
Nevertheless, a weak peak at 10.6° could be detected after one-week storage in 
desiccators at 25 °C/18% RH, suggesting the re-appearance of traces of 
crystalline drugs [Figure 7.6(a)]. This indicates that the amorphous ART/MFQ 
is physically unstable and has the propensity re-crystallize upon one-week of 
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storage. The re-crystallization of the sample is mainly attributed to the re-
crystallization of ART since the PXRD peak corresponds to the characteristic 
peak of ART. Conversely, amorphous MFQ remains physically unchanged 
during the same storage period [Figure 7.6(a)]. 
 
Figure 7.3 PXRD patterns of (a) ART/MFQ/SBA-15 (1:2:3 w/w/w), (b) MFQ/SBA-





Figure 7.4 PXRD patterns of (a) spray dried MFQ, (b) co-spray dried ART/MFQ 
(1:2 w/w), (c) P.M.-MFQ/SBA-15 (1:1 w/w), (d) P.M.-ART/MFQ/SBA-15 
(1:2:3 w/w/w), (e) P.M.-ART/SBA-15 (1:1 w/w), (f) spray dried ART and (g) P.M.-
ART/MFQ (1:2 w/w). 
 For the P.M.-ART/MFQ (1:2 w/w), the diffraction pattern showed 
sharp and specific peaks from the original crystalline forms (Figure 7.4), with 
the main diffraction angles (2θ) at 10.9°, 11.3°, 14.1° and 15.3° attributed to 
the crystalline MFQ and those at 7.4°, 10.0°, 11.9°, 14.7°, 20.1°, 20.7° and 
22.1° to the crystalline ART. The presence of both the characteristic peaks of 
MFQ and ART with unchanged peak intensity reflects the unchanged 
crystallinity with no strong interactions between the drugs in the physical 
mixtures. Conversely, for the physical mixtures of drug/SBA-15, the PXRD 
pattern exhibited the reflections relative to crystalline drugs with reduced 
intensity compared with untreated drugs and with P.M.-ART/MFQ (1:2 w/w). 
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 On the other hand, all the spray dried solid dispersions of ART, MFQ 
and ART/MFQ with SBA-15 exhibit flat PXRD patterns. The characteristic 
peaks of ART and MFQ disappeared completely after incorporation into 
mesoporous silica, implying a non-crystalline or amorphous state of the 
confined drugs. Pore size of carriers (Zhao et al., 2012b), drug-carrier 
interactions (Takeuchi et al., 1987) and rapid evaporation of the solvent 
(Planinšek et al., 2011) during formulation appear to be responsible for the 
formation of amorphous particles. Sufficient space is required for the drug 
molecules to arrange themselves into an ordered structure and exist in the 
crystalline state. However, mesoporous silica with a narrow pore size 
distribution in the range of a few nanometers is effective in preventing the 
formation of crystals due to space confinement. Additionally, the drug 
molecules have less time to arrange into a crystal lattice due to the rapid 
evaporation of ethanol during spray drying, thereby predisposing the 
molecules into forming a disordered structure instead of an ordered one. Also, 
the tendency is high for the hydroxyl groups of drug molecules to form 
hydrogen bonds with the silanol groups of SBA-15. This enables thorough 
dispersion of drug molecules in the pore channels. Similarly, various studies 
such as those by Takeuchi et al. (2004, 1987) and Watanabe et al. (2001, 2002, 
2003) have elucidated the interactions between drug molecules and silanol 




Figure 7.5 PXRD patterns of (a) melt quenched ART, (b) cryo milled ART and (c) 
ball milled ART. 
  
Figure 7.6 PXRD patterns of (a) co-spray dried ART/MFQ (1:2 w/w) and (b) spray 




 SEM was employed to characterize the morphology of unprocessed 
and processed ART and MFQ as shown in Figure 7.7. The morphologies of 
untreated ART, spray dried ART and SBA-15 [Figure 7.7(b), (e) and (j)] have 
been discussed in Section 5.5. Figure 7.7(a) depicts the typical crystal habits 
of MFQ, which appears as a needle-shaped structure resembling the 
morphology of the polymorph form D. The form D is thermodynamically 
more stable than others at 37°C (Kitamura et al., 1994). The length of the 
MFQ crystals is in the range of 10–250 µm and the crystals are much smaller 
and thinner compared with untreated ART [Figure 7.7(b)]. The P.M.-
ART/MFQ [Figure 7.7(c)] clearly illustrates the size difference of these two 
drugs. It can be observed that ART and MFQ exist as two separate particles in 
the physical mixture and only adhere to each other presumably due to the 
presence of weak forces such as electrostatic forces and van der Waals. 
 In contrast to the unchanged morphology of ART after spray drying 
[Figure 7.7(e)], the morphology of spray dried MFQ [Figure 7.7(d)] was 
completely changed to irregular and shrunken spherical particles, as attributed 
to the drug amorphization. The particles size was reduced to less than 5 µm, 
which was even smaller than the spray dried ART. The amorphization of MFQ 
was further supported by PXRD results (Figure 7.4). Importantly, the 
amorphization of MFQ could be achieved by spray drying without the 
presence of any carriers, which is difficult to achieve for ART. However, the 
co-amorphization of ART/MFQ was able to change the morphology of ART 
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together with MFQ without any trace of crystalline particles [Figure 7.7(f)]. 
The amorphous ART/MFQ particles are perfectly spherically-shaped with 
particle size less than 5 µm. The amorphization of ART might be 
accomplished due to the mixing at the molecular level and the presence of 
interactions, presumably hydrogen bonding between ART and MFQ. 
 The physical mixtures [Figure 7.7(g), (h) and (i)] showed a blend of 
drugs and SBA-15. The presence of both the carrier and the drugs can be seen 
since there are no significant changes to the crystalline morphology of the 
drugs. This also suggests that there is a lack of strong interactions between the 
drug and carrier particles in the physical mixtures. However, the SBA-15 
particles adhered to the surface of ART and MFQ crystals may be due to 
electrostatic and van der Waals forces. 
 Meanwhile, the co-spray dried solid dispersions of drug/carriers are 
found to have conglomerated [Figure 7.7(k), (l) and (m)] and the morphology 
and the particles size of the samples are similar to SBA-15 particles [Figure 
7.7(j)], which in the range of 0.5−1 µm. Moreover, the formulated solid 
dispersion particles are smaller and more homogeneous in size and 
morphology compared with the untreated drugs and the physical mixtures. 
Hardly any drug crystals were noticed on the surface of SBA-15 as most of the 
drug particles were dispersed and absorbed in the pore channels of SBA-15 in 
an amorphous form. The presence of SBA-15 micron particles during co-spray 
drying was able to inhibit the ART particle aggregation and crystal growth. On 
the other hand, the presence of extra particles on the surface of SBA-15 
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occurred by increasing the drug loading to 86 wt%. As illustrated in  Figure 
7.7(n), non-uniform particles can be observed on the surface of co-spray dried 
ART/MFQ/SBA-15 (2:4:1 w/w/w), due to the drug loading exceeding the 




Figure 7.7 SEM images of (a) MFQ, (b) ART, (c) P.M.-ART/MFQ (1:2 w/w), (d) 
spray dried MFQ, (e) spray dried ART, (f) co-spray dried ART/MFQ (1:2 w/w), (g) 
P.M.-MFQ/SBA-15 (1:1 w/w), (h) P.M.-ART/SBA-15 (1:1 w/w), (i) P.M.-
ART/MFQ/SBA-15 (1:2:3 w/w/w), (j) SBA-15, (k) MFQ/SBA-15 (1:1 w/w), (l) 
ART/SBA-15 (1:1 w/w), (m) ART/MFQ/SBA-15 (1:2:3 w/w/w) and (n) 
ART/MFQ/SBA-15 (2:4:1 w/w/w). 
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7.4 Transmission Electron Micrograph (TEM) 
 The structural features of the SBA-15 were examined by TEM and the 
results are presented in Figure 7.8. The TEM micrographs revealed the 
spherical and spheroid shape of SBA-15 micron-particles with a particle size 
of 0.5–1 µm [Figure 7.8(a)]; in agreement with the shape determined through 
SEM measurements [Figure 7.7(j)]. At higher magnifications, the ordered 
cylindrical pore channels of SBA-15 can be observed with an estimated 
uniform pore size in the range of 8–9 nm (in agreement with N2 adsorption 
results) and thick pore walls. The thick pore walls and well-ordered pore 
channels are able to afford homogeneous drug distribution and restrict drug re-
crystallization. In addition, the wider pore size and shorter pore channels are 
advantageous for the adsorption and desorption of drug molecules with 
minimum diffusion resistance, which is beneficial for dissolution and 
solubility enhancement (refer to Section 0). Please refer to Section 0 for more 
details about the internal pore structure of SBA-15. The unchanged pore 
channels and pore walls of SBA-15 after co-spray drying with ART and MFQ 
particles underscore the rigidity and unchanged internal pore structure of 








Figure 7.8 TEM images of SBA-15 at scale of (a) 500 nm and (b) 100 nm and (c) 
ART/SBA-15 (1:1 w/w), (d) MFQ/SBA-15 (1:1 w/w) and (d) ART/MFQ/SBA-15 
(1:2:3 w/w/w). 
7.5 Chemical and Physical Stability Evaluation  
 The physicochemical stability of ART/MFQ/SBA-15 (1:2:3 w/w/w) 
upon storage was investigated for 6-months in desiccators (25 °C/18% RH) 
and Activ-vial
®
 (25 °C). These two conditions were chosen based on the 
previous screening studies on ART and MFQ. ART appears to be stable at low 
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humidity conditions despite the storage temperature as discussed in Section 





(40 °C), which were used to investigate the chemical 
stability of MFQ/SBA-15 (1:1 w/w). The results are summarized in Table 7.4. 
The amorphous form of MFQ co-spray dried with SBA-15 exhibited good 
chemical stability against degradation in desiccators (25 °C/18% RH) and 
Activ-vial
® 
(25 °C) with preservation of more than 98.0% of MFQ throughout 
the storage period. However, an obvious decrease was observed in the 
percentage of MFQ (86.4%) in Activ-vial
® 
(40 °C), suggesting that high 
temperatures are not suitable for MFQ storage; hence, this particular condition 
was excluded for the ART/MFQ combination stability study. The results of 
physicochemical stability of ART/SBA-15 and MFQ/SBA-15 were 
summarized in Table 7.5. 
 The results of chemical stability of ART/MFQ/SBA-15 (1:2:3 w/w/w) 
solid dispersion are summarized in Table 7.6. The percentage of ART and 
MFQ in solid dispersions stored in desiccators (25 °C/18% RH) and Activ-
vial
®
 (25 °C) remains almost unchanged without degradation after 6-months. 
Approximately 97–98% of drugs in desiccators (25 °C/18% RH) and 99% in 
Activ-vial
®
 (25 °C) were preserved, indicating that the process of spray drying 
and used storage conditions and storage periods did not affect the chemical 
stability of the drugs. 
 The solid dispersions also exhibited excellent physical stability as the 
samples retained their amorphous forms throughout the storage periods 
212 
 
without any traces of crystals. All the stored samples showed the halo PXRD 
pattern, as freshly co-spray dried samples, without the presence of PXRD 
peaks assigned to the crystalline ART or MFQ after 6-months (Figure 7.9). 
The ability of SBA-15 to inhibit re-crystallization through the size-constraint 
effect (Shen et al., 2011, Shen et al., 2010), thickness and rigidity of pore 
walls (Rengarajan et al., 2008) and interaction with silanol groups (Watanabe 
et al., 2001, Watanabe et al., 2002) not only play an important role in 
producing amorphous forms but also stabilizing the amorphous forms during 
long-term storage periods. Please refer to Section 5.10 for more details. In 
addition, the hydrothermal stability of SBA-15 also contributes to the 
maintenance of the dispersed state of amorphous drug molecules, since the 
stability of solid dispersions is also expected to be a function of the stability of 
the carrier (Mellaerts et al., 2010, Cassiers et al., 2002).  
Table 7.4 Amounts of MFQ remaining within MFQ/SBA-15 (1:1 w/w) samples after 
storage under 3 different storage conditions for 3 and 6-months. 
Storage conditions Percentage of remaining MFQ 
3-months 6-months 
Desiccators 
 (25 °C/18% RH) 









94.5 ± 3.5 86.4 ± 7.1 




Table 7.5 Summary of the results of chemical stability of ART and MFQ 
Condition  Samples 
ART/SBA-15 (1:1 w/w) MFQ/SBA-15 (1:1 w/w) 
Desiccators  




 (25 °C)    
Open pan 




 (40 °C)   
Open pan 
 (40 °C/75% RH)  
 − 
   
Table 7.6 Amounts of ART and MFQ remaining in ART/MFQ/SBA-15 
(1:2:3 w/w/w) samples after storage at 2 different storage conditions for 3 and 6-
months. 
Storage conditions  Percentage of drug 
3-month 6-month 
Desiccators  
 (25 °C/18% RH)  
97.7 ± 2.1
a










 (25 °C)  99.8 ± 0.3
a
















Figure 7.9 PXRD patterns of ART/MFQ/SBA-15 (1:2:3 w/w/w) after storage for 6-
months: (a) fresh, (b) desiccators (25 °C/18% RH), (c) Activ-vial
®
 (25 °C) and (d) 
P.M.-ART/MFQ (1:2 w/w). 
7.6 In vitro Drug Release  
 Figure 7.10, 7.11 and 7.12 illustrate the in vitro drug release profiles of 
solid dispersions of ART and MFQ with SBA-15 at various conditions using 
1× phosphate buffered saline (PBS) as a dissolution medium. Figure 7.10 and 
Figure 7.11 depict the drug release under sink condition using USP IV and 
non-sink condition using USP II, respectively, to study the dissolution rate and 
supersaturation of the drugs, respectively. Shown in Figure 7.12 is the effect 
of aging on the dissolution rate, as the drug release of the samples was 
analyzed after 6-months of storage using USP II. The drug release behaviors 
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of all the formulated samples were compared with that of the co-spray dried 
ART/MFQ (1:2 w/w) and P.M.-ART/MFQ (1:2 w/w). 
 As shown in Figure 7.10, the P.M.-ART/MFQ (1:2 w/w) achieved only 
marginal dissolution rates: the amount of drugs dissolved in the first 15 min 
were only 10.1% of ART and 21.1% of MFQ and in 2 h were only 26.8% of 
ART and 54.6% of MFQ. This finding indicates the poor dissolution of the 
untreated drugs due to their hydrophobic and crystalline nature. In contrast, 
the co-spray dried ART/MFQ (1:2 w/w) sample exhibited an improved 
dissolution rates compared with the untreated drugs: the amount of drugs 
dissolved in the first 15 min were 24.5% of ART and 37.7% of MFQ and in 
2 h were 75.4% (p < 0.05) of ART and 89.6% (p < 0.05) of MFQ. A markedly 
superior drug release is observed for co-formulated ART/MFQ/SBA-15 
(1:2:3 w/w/w) sample: by 15 min, initial burst release of 76.0% (p < 0.05) of 
ART and 87.3% (p < 0.05) of MFQ was observed; by 2 h, 100% (p < 0.05) of 
ART and MFQ had been released. 
 Figure 7.11 shows the supersaturation of untreated ART of 
48.4 µg/mL, which is similar to the value reported by Ferreira et al. (2013). 
For crystalline MFQ, no equilibrium was observed within the 2 h dissolution 
period and the amount of MFQ dissolved after 2 h was 90.2 µg/mL. However, 
the apparent solubility of the drugs from mesoporous silica formulation was 
significantly higher than that of untreated drugs. Co-formulated ART achieved 
a supersaturation of 124.8 µg/mL (p < 0.05), which could be sustained for 
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120 min whereas the MFQ showed an apparent solubility of 282.1 µg/mL (p < 
0.05) with no attainment of equilibrium after 2 h. 
 The enhanced dissolution rate and apparent solubility of ART and 
MFQ (both BCS class II drugs) by nano-confinement are expected to improve 
their absorption in the gastrointestinal tract and thereby improve their 
bioavailability. Several factors contribute to the dissolution and 
supersaturation enhancement: (1) a lack of crystallinity due to amorphization, 
(2) augmented surface area of the drug via particle size reduction, (3) host-
guest interactions such as weak van der Waal forces and hydrogen bonds, (4) 
enhanced wettability caused by hydrophilic carrier and (5) pore architecture 
such as pore size and length of pore channels.  
 Two processes are involved in drug release from the pores of the 
carrier into the dissolution medium: first, penetration of water molecules to 
dissolve the entrapped drugs; and second, diffusion of the dissolved drugs 
through the pore channel into the dissolution medium. Factors such as the 
hydrophilicity of carriers and host-guest interactions facilitate the rapid 
penetration of dissolution medium influx through the pore channels to break 
the hydrogen bonds between drug molecules and silanol groups to displace 
them drug molecules. The rapid displacement of drug molecules by the 
dissolution medium attributes to the competitive interaction between water 




 The dissolution and the apparent solubility are enhanced by their 
amorphous forms with reduced particles size. Drugs incorporated into the 
pores channels of SBA-15 within the nanometer range will be in the 
amorphous form (Figure 7.3) and the formation of the highly ordered 
crystalline forms may be restricted by the confined space of the nanopores. 
This culminates in a reduction in the lattice energy of the drug molecules 
compared with the crystalline forms, thereby dramatically increasing the 
apparent solubility and dissolution rate of the drugs. The effects of 
amorphization and particle size reduction on the drug release were further 
reflected by the dissolution enhancement of the co-spray dried ART/MFQ 
(1:2 w/w) sample.  
 Finally, the relatively wider pore size and shorter pore channels 
accelerate the diffusion of the dissolved drug by minimizing the diffusion 
distance and the pore restriction. The mean pore diameter of SBA-15 is in the 
range of 8–9 nm (Table 7.1) and the length of the pore channels is in the range 
of 0.5–1 µm (Figure 7.7 and Figure 7.8). The considerably wider pore opening 
and shorter pore channels of SBA-15 provide lesser steric hindrance to ART 
and MFQ molecules to diffuse out of the pore channels, thus resulting in a 
rapid desorption of a greater amount of drug molecules without any 




Figure 7.10 Dissolution profiles (under sink condition using USP IV) of ( ) 
P.M.-ART/MFQ (1:2 w/w), ( ) co-spray dried ART/MFQ (1:2 w/w) and ( ) 
ART/MFQ/SBA-15 (1:2:3 w/w/w). The dotted lines with hollow markers refer to 




Figure 7.11 Supersaturation (under non-sink condition using USP II) of ( ) 
P.M.-ART/MFQ (1:2 w/w) and ( ) ART/MFQ/SBA-15 (1:2:3 w/w/w). The 
dotted lines with hollow markers refer to ART and the solid lines with solid markers 




 Depicted in Figure 7.12 are the in vitro dissolution rate profiles of the 
ART/MFQ/SBA-15 (1:2:3 w/w/w) sample after 6-months of storage with 
fresh P.M.-ART/MFQ (1:2 w/w) sample as a control. An initial burst release 
of the drugs is observed for almost all the samples with approximately 91.1–
97.6% (p < 0.05) of drugs released to the dissolution medium in 2 h upon 
dissolution. In addition, there are significant differences in the drug release 
profiles of the stored samples as compared with the untreated drugs because 
only 35.6% of ART and 59.7% of MFQ were dissolved at the end of the assay. 
The long-term stability of amorphous ART and MFQ in the solid dispersions 
and the hydrothermal stability of SBA-15 with unchanged pore structures 
contribute to an excellent shelf life with preserved dissolution behavior of 






Figure 7.12 Dissolution profiles (under sink condition using USP II) of ( ) fresh 
P.M.-ART/MFQ (1:2 w/w) and ART/MFQ/SBA-15 (1:2:3 w/w/w) stored in ( ) 
desiccators (25 °C/18% RH) and ( ) Activ-vial
®
 (25 °C) after storage for 6-
months. The dotted lines with hollow markers refer to ART and the solid lines with 
solid markers refer to MFQ. n=3, p < 0.05 versus free drugs. 
7.7 Conclusion 
 The results have revealed that it is technically feasible to generate X-
ray amorphous ART and MFQ combinative solid dispersions using 
mesoporous carriers via co-spray drying. The significance of the mesoporous 
carriers is reflected by the fact that the amorphous ART could be stabilized by 
the presence of SBA-15. Although amorphous ART/MFQ could be achieved 
without any excipients, this amorphous form has been found to be physically 
unstable and would revert to the crystalline form within one week of storage in 
desiccators (Figure 7.6). 
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 The remarkably enhanced dissolution kinetics of amorphous 
ART/SBA-15 and MFQ/SBA-15 compared with the crystalline counterpart 
and its physical mixtures are attributed to the advantageous structural 
properties and hydrophilicity of SBA-15. Moreover, the particle size reduction 
and amorphization of ART and MFQ due to spatial confinement in the pore 
structure of SBA-15 also contributed to the enhanced dissolution. The 
elucidation of the physicochemical stability of ART and MFQ is vital to 
prolonging the shelf life of the formulated amorphous antimalarial drugs with 
preserved drug release profile. Given the excellent chemical and physical 
stability of co-spray dried ART/MFQ/SBA-15 at moderate and dry storage 
conditions for 6-months, it is accordingly recommended that the solid 
dispersions of combination of these two drugs be stored at low humidity and 




Chapter 8 Overall Conclusions 
 The aim of this research is to examine the feasibility of porous and 
biocompatible excipients in enhancing the biopharmaceutical properties of 
BCS class II antimalarial drugs, ART and MFQ. Based on our knowledge, 
studies on the stability of formulated ART have been rarely reported despite 
the abundance of studies on in vitro drug release. Additionally, mesoporous 
carriers and functionalized food additives have not been used in generating 
solid dispersions of antimalarial drugs. Most importantly, combinations of 
ART and MFQ have never been studied before. Our results have revealed that 
it is technically feasible to generate amorphous solid dispersions of ART using 
mesoporous carriers and functionalized food additives via co-spray drying. 
The significance of the carriers in amorphization of ART is reflected by the 
fact that the drug was unable to amorphize by spray drying in their absence. 
Co-spray drying of MFQ and ART nonetheless was able to produce 
amorphous ART without any excipients, albeit this amorphous form was 
physically unstable and reverted to the crystalline form within one-week of 
storage even in desiccators.  
 The application of mesoporous carriers and functionalized food 
additives, coupled with spray drying, to enhance the solubility of poorly 
water-soluble ART and MFQ may impart numerous advantages. SBA-15 with 
a large drug loading capacity will diminish materials and energy consumption 
by minimizing wastage of raw materials. Meanwhile, Hsp-G and Stevia-G are 
extremely water-soluble, safe and cost-effective materials. Moreover, the 
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single-step co-spray drying of ART and MFQ with excipients will translate 
into a reduced number of energy-intensive secondary manufacturing steps 
such as milling, micronization and blending. Additionally, the elucidation of 
the physical and chemical stability of ART and MFQ with suitable storage 
conditions will enable the prolongation of the shelf-life of the amorphous 
drugs. 
 Initially, activated carbon (AC) was selected as the mesoporous carrier 
for ART since AC is an industrially available, cost-effective porous material at 
a large scale and has been widely used in medical applications. ART/AC at 5 
different weight ratios were prepared through co-spray drying: ART/AC 
(1:3 w/w), ART/AC (1:1 w/w), ART/AC (2:1 w/w), ART/AC (3:1 w/w) and 
ART/AC (4:1 w/w). Solid dispersions with drug loading up to 80 wt% were 
formulated in order to study the encapsulation capacity of AC to form 
amorphous forms. It was expected that AC would be able to form amorphous 
solid dispersions even at higher drug loading due to its large pore volume and 
specific surface area with strong adsorption capacity. However, only co-spray 
drying of ART/AC samples below 50 wt% drug loading (ART/AC ≤ 1:1 w/w) 
result in amorphous ART; at high drug loading (ART/AC > 1:1 w/w), 
formation of partially crystalline ART in orthorhombic and triclinic forms 
could be observed. Nonetheless, formulation of both the amorphous and 
partially crystalline forms contributed to the enhancement in dissolution rate 
and supersaturation of ART. Although the supersaturation of the treated ART 
was enhanced 2-fold compared with untreated ART, the drug release profile of 
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treated ART was affected by the strong adsorption capacity and catalytic 
activity of AC. 
 Mesoporous silica (SBA-15) with outstanding features such as high 
specific surface area, large pore volume, uniform pore size, short pore 
channels and hydrophilic nature was chosen as a drug vehicle to replace AC. 
Amorphization and particles size reduction of ART via spatial confinement 
contributes to the remarkable dissolution kinetics and supersaturation. The 
dissolution rates of the formulated ART/SBA-15 are significantly improved 
than that of the untreated drug and the supersaturation is enhanced by 2-fold of 
the equilibrium solubility of crystalline drug. Strikingly, the enhanced 
supersaturation could be sustained for 120 min without addition of any 
precipitation inhibitors. The ART/SBA-15 samples exhibited excellent 
chemical stability in desiccators (25 °C/18% RH), Activ-vial
®
 (25 °C) and 
Activ-vial
® 
(40 °C), indicating that the degradation of ART could be prevented 
under low humidity conditions under the storage temperature of 25°C and 40 
°C. In addition, the amorphous state of ART/SBA-15 samples also exhibited 
excellent physical stability for 6-months with preserved enhanced dissolution 
properties of ART. Therefore, the conditions of desiccators (25 °C/18% RH), 
Activ-vial
®
 (25 °C) and Activ-vial
® 
(40 °C) were used for further analysis. 
Finally, the low cytotoxicity effect of untreated ART, SBA-15 and formulated 
ART/SBA-15 on Caco-2 cells after 24 hours incubation proves the 
biocompatibility of SBA-15 and ART. 
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Additionally, the investigation of non-porous silica as a control and 
characteristic studies such as SEM, TEM, PXRD and N2 adsorption clearly 
demonstrate that most of the ART drug particles entrapped inside the pore 
channel of SBA-15 and not on the external surfaces. SBA-15 able to appear in 
amorphous form even at high drug loading of 50 wt.% as compared with non-
porous silica which is unable to accommodate even 10 wt.% of ART in 
amorphous forms. However, ART/SBA-15 only appeared to be in crystalline 
form with additional particles on the external surface once the pore volume 
was fully occupied at drug loading of 75 wt.%. Based on these results, a 
conclusion that most of the ART molecules are entrapped in the pore channels 
of SBA-15 can be drawn. 
 On the other hand, the performance of inorganic and water-insoluble 
material (SBA-15) as a drug carrier was compared with that of the water-
soluble carriers, α-glucosyl hesperidin (Hsp-G) and α-glucosyl stevioside 
(Stevia-G). Relative to SBA-15, both the food additives exhibited 
extraordinary dissolution profiles, for which 100% of drug release was 
achieved within 5 min mainly due to the amorphization of the ART and 
extreme aqueous solubility of the carriers. Meanwhile, the enhanced 
supersaturation of ART from Hsp-G and Stevia-G was almost two-fold as 
achieved by the solid dispersion of SBA-15, although a slight decrease in 
supersaturation could be observed after 2 h. However, the drug loading 
achieved through ART/Hsp-G and ART/Stevia-G was very low (9.1 wt%) and 
solid dispersions at 25 wt% of drug loading formed crystalline samples. In 
addition, only dry and low-temperature conditions were suitable for the 
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storage of these samples given that formation of micro-crystals at 25 °C/75% 
RH and changes in the physical state in Activ-vial
®
 (40 °C) and open pan (40 




ART/AC  ART/SBA-15  ART/Hsp-G & 
ART/Stevia-G  






high high low 
Dissolution (after 
30 min) 
61.7% 76.6% 100% 
Supersaturation 
(µg/mL) 
90 103 96 
Storage  
stability 
poor good good 
 Therefore, based on the previous screening study as summarized in the 
table above, SBA-15 was chosen as the carrier for the formulation of ART and 
MFQ combination. Storage test was conducted under two storage conditions 
with desiccators (25 °C/18% RH) and Activ-vial
®
 (25 °C); Activ-vial
® 
(40 °C) 
was excluded since it caused degradation of MFQ/SBA-15 solid dispersions. 
As expected, it was technically feasible to formulate amorphous solid 
dispersions of combination of ART and MFQ using SBA-15 at weight ratio of 
1:1 (w/w) via co-spray drying. The formulated solid dispersions exhibited 
superior performance in drug loading efficiency, drug release and storage 
stability for ART and MFQ drugs. Based on the obtained results, it is 
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recommended that the formulated solid dispersions of ART/MFQ/SBA-15 be 
stored at low humidity and low temperature to prolong the shelf-life of the 
dosage forms. Extensive studies on ART and ART/MFQ could provide a 
practical reference in understanding the physicochemical stability of these two 





Chapter 9 Recommendations and Future Work  
 Notwithstanding the advantages of the formulation of solid dispersions 
with mesoporous silica and functionalized food additives in enhancing the 
biopharmaceutical properties of poorly water-soluble drugs, some limitations 
remain that need to be addressed. For example, although the bioavailability of 
BCS class II drugs is expected to be enhanced through solubility enhancement, 
the caveat is that the acceptable methods to quantify the bioavailability and 
therapeutic effect of the drugs are through in vivo studies. Therefore, it would 
be recommended that in vitro cellular studies (such cell permeability) and in 
vivo experiments be conducted to completely evaluate the bioavailability 
enhancement of formulated antimalarial drugs. In vivo studies such as 
pharmacokinetics analysis, biodistribution analysis through imaging and 
antimalarial efficacy studies are recommended to evaluate the bioavailability 
of formulated solid dispersions. 
 Apart from that, additional works are required in order to furnish more 
data for validation and to corroborate the claim in our research. Below are 
some recommendations for future work. 
1. To compare the efficiency of spray drying with that of other 
formulation techniques. Although spray drying has been found to been 
a remarkable technique to formulate antimalarial drugs in solid 
dispersions, other techniques such freeze drying, ball milling, hot melt 
extrusion and supercritical fluid technique are appealing in this 
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context. Therefore, it is recommended that comparison be made 
between all such formulation techniques. 
2. To evaluate the effects of nano-confinement of SBA-15 on other 
antimalarial drug combinations such as artemisinin-naphthoquine or 
artesunate-mefloquine, which are available in the market and widely 
used in ACTs. The performance of the formulated samples can be 
compared with that of the commercialized products of either fixed-
dose combination tablets or co-blistered tablets. 
3. To evaluate the co-formulations of ART/MFQ/SBA-15 solid 
dispersions with functionalized food additives. Since both the Hsp-G 
and Stevia-G have the ability to act as a drug carrier and sugar 
substitute, these two materials can be exploited. They not only able to 
enhance the biopharmaceutical properties of ART and MFQ but also to 
suppress the bitterness of the formulated dosage forms and increase 
their palatability and, in turn, patient compliance. There are two 
different approaches to co-formulate the samples: co-spray drying both 
the drugs (ART and MFQ) and both the carriers (SBA-15 and Hsp-G 
or Stevia-G) together; or coating the formulated solid dispersions of 
ART/MFQ/SBA-15 with Hsp-G or Stevia-G. 
4. To elucidate the effects of MFQ in co-amorphization with other 
antimalarial drugs. It has been shown in this research that MFQ has the 
ability to form co-amorphous samples when co-spray dried with ART. 




5. To identify the feasibility and biocompatibility of all the formulations 
by extending the in vitro cytotoxicity studies to food additives and 
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